

Cancer Incidence in Belgium 2010

Special issue
Cancer in Children
and Adolescents



Cancer Incidence in Belgium 2010

Special issue
**Cancer in Children
and Adolescents**



© 2013 Belgian Cancer Registry
Stichting Kankerregister - Fondation Registre du Cancer – Stiftung Krebsregister

Editorial team:

Belgian Cancer Registry: Kris Henau, Nancy Van Damme, Frédéric Calay,
Mia Slabbaert, Linda Thibaut, Julie Francart, Karen Vos, Katia Emmerechts,
Liesbet Van Eycken

BSPHO: Yves Benoit, An Van Damme, Christophe Chantrain, Anne Uyttebroeck

Responsible editor: Liesbet Van Eycken, Koningsstraat 215, 1210 Brussels

Design: www.magelaan.be

D/2013/11.846/1

Use of data

The information in this publication may be used freely on condition of correct quotation of the source and reference.

Recommended reference:

Cancer in Children and Adolescents, Belgian Cancer Registry, Brussels, 2013

Additional information can be requested at:

Tel. 0032-2-250 10 10

Fax 0032-2-250 10 11

e-mail: info@kankerregister.org info@registreducancer.org

This publication was realized with the specific financial support of



The Belgian Cancer Registry receives financial support of:



Met steun van de
Vlaamse overheid



BRUSSELS
HOOFDSTEDELIJK
GEWEST



CONTENTS

Abbreviations	4
Foreword	5
Methodology	6
Notification and submission to the Cancer Registry	7
Quality of incidence data	8
Calculation of incidence, mortality and survival	10
Childhood cancer in Belgium	12
I-XII All cancers	13
I Leukaemias, myeloproliferative and myelodysplastic diseases	18
II Lymphomas and reticuloendothelial neoplasms	22
III Central nervous system tumours (CNS) and miscellaneous intracranial and intraspinal neoplasms	27
IV Sympathetic nervous system tumours	32
V Retinoblastoma	34
VI Renal tumours	35
VII Hepatic tumours	37
VIII Bone tumours	38
IX Soft tissue sarcoma	42
X Germ cell, trophoblastic and other gonadal neoplasms	46
XI Carcinomas and other malignant epithelial neoplasms	51
Cancer in Infants	59
Reference list	60
Appendix	63
Appendix 1: Notifications by source type in children and in adolescents, Belgium 2004-2009	64
Appendix 2: Cancer incidence in children and adolescents, Belgium 2004-2009	68
Cancer in Belgium, 2010	87

ABBREVIATIONS

ALL	Acute lymphoid leukaemia
AML	Acute myeloid leukaemia
BSPHO	Belgian Society of Paediatric Haematology Oncology
CBSS	Crossroads Bank for Social Security
CNS	Central nervous system
GCT	Germ cell tumours
GCTOG	Germ cell tumours, trophoblastic and other gonadal neoplasms
ICCC-3	International Classification of Childhood Cancer (3 rd edition)
ICD10	International Classification of Diseases (10 th edition)
ICD-O3	International Classification of Diseases for Oncology (3 rd edition)
MOC	Multidisciplinary Oncological Consult
NHL	Non-Hodgkin lymphoma
NNSS	National Number for Social Security
Non-RMS	Non-rhabdomyosarcoma
PNET	Primitive neuroectodermal tumours
RMS	Rhabdomyosarcoma
SNS	Sympathetic nervous system
STS	Soft tissue sarcomas
WSR	World Standardised incidence Rates

The special issue 'Cancer in Children and Adolescents' in this publication is the result of a fruitful collaboration between the Belgian Cancer Registry and the Belgian Society of Paediatric Haematology Oncology (BSPHO). With the introduction of the Cancer Plan of Minister Onkelinx in 2008, initiatives were taken to establish a national coordination cell for clinical and scientific research in paediatric haemato- oncology under the umbrella of the BSPHO. The foundation of this national cell has favored the setup of a supplementary childhood cancer registration network with all the 8 Belgian paediatric haemato- oncology centres besides the classic cancer registration including the pathology and clinical registration pathways. The specific data has been collected from the incidence year 2004 onwards. Incidence and survival data for children and adolescents are presented for Belgium (5 years) and for Flanders (10 years).

In addition, the cancer incidence tables 2010 for all ages are printed for Belgium and for the three regions. The incidence data are regularly updated and can be found on the website of the Belgian Cancer Registry (<http://www.kankerregister.org/Statistieken> <http://www.registreducancer.org/Statistiques>).

A publication is also an outstanding moment to sincerely thank all the physicians, pathologists and data managers in the hospitals for their intensive commitment and sustained efforts in registration.

A special issue is devoted to this subject because cancer in children and adolescents strongly differs from the adult malignancies. It is, all the more than in adults, an emotionally loaded subject and the cover was chosen for this reason. Children and adolescents stand for future, initiatives, dreams, hope... and every new cancer diagnosis can make a young life as sensitive as a bubble.

Each year about 320 children (<15 years) and 180 adolescents (15-19 years) face the diagnosis and treatment of cancer. Malignant diseases are rare under the age of 20 years when compared to adults, where cancer accounts for more than 99% of the total cancer burden. Every year, approximately 70 patients younger than 20 years die from cancer.

Since the nineteen sixties, mortality rates have dramatically declined for most childhood cancers. This decrease in mortality reflects an improved cancer survival rate for children. Survival increased for all childhood cancers, but by varying amounts and at different points in time. The progress is not only linked to more effective drugs. Most of these improvements can be attributed to the accurate use of already existing drugs and effective combinations of them, to better insights in the natural behavior of the disease, to better diagnostic methods, to better surgery and radiotherapy and to a better identification of prognostic factors.

We hope that this work can be an asset for your daily practice and for further collaborations in order to strengthen scientific population based cancer research.

Brussels, February 2013

Anne Uyttebroeck
President BSPHO




Liesbet Van Eycken
Director BCR



NOTIFICATION AND SUBMISSION TO THE CANCER REGISTRY

New legislation initiatives since 2003 and the foundation of the Belgian Cancer Registry in 2005, forced a breakthrough in the Belgian cancer registration. Especially the Royal Decree on the oncological care programs in 2003 with the reimbursement of the multidisciplinary oncological consult (MOC) and the creation of the specific law on the Cancer Registry in 2006 provided a firm legal basis for cancer registration in Belgium.⁽¹⁾⁽²⁾ This legislation makes cancer registration compulsory for the oncological care programs and for the laboratories for pathological anatomy. Furthermore, the law authorizes the use of the national number for social security (NNSS) as the unique identifier of the patient. The NNSS favours linkage with other medical and/or administrative data. Furthermore, through linkage with the Crossroads Bank for Social Security (CBSS), the NNSS enables the Registry to perform active follow up on vital status and date of death of the patients.

A complete description of the data registration and data collection related to hospitals and pathology laboratories was reported in the publication 'Cancer Incidence in Belgium, 2008'⁽³⁾. As of the year of incidence 2004, Belgian cancer incidence data are available. The general data flow (Figure 1) relies on all information (notifications) coming from the oncological care programs (clinical network) and all pathological anatomy laboratories (pathology network).



MOC: Multidisciplinary Oncological Consult
CBSS: Crossroads Bank for Social Security

In 2009, a specific collaboration has been setup with all the 8 Belgian paediatric centres for haemato-oncology. Data has been collected from the incidence year 2004 onwards (Table 1).

Table 1 Overview paediatric centres for haemato-oncology in Belgium

Universitair Ziekenhuis Gent
ZNA Koningin Paola Kinderziekenhuis, Antwerpen
Universitair Ziekenhuis Leuven
Universitair Ziekenhuis Brussel
Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles
Cliniques Universitaires Saint-Luc, Bruxelles
CHR de la Citadelle, Liège
CHC Les Cliniques Saint-Joseph Montegnée, Liège

Quality of incidence data

Completeness of the cancer registry (degree of coverage)

Completeness is the extent to which all incident cancers in the Belgian population are included in the Cancer Registry. Incidence rates will be close to their true value if maximum completeness in case finding procedures can be achieved.


The number of notifications and data sources per tumour is a raw indicator of completeness. The higher the average, the more complete the registration process. Linkage of data from different sources and source types leads to information that is more complete, precise and reliable.

Number of notifications from paediatric centres for haemato-oncology

In Belgium, between 2004 and 2009, a total number of 2,973 cancers are diagnosed in children and adolescents (0-19 years). The registration for these tumours originated from 7,741 notificationsⁱ (on average 2.6 notifications per tumour [range 1-8]). In 35% of the cases, a notification was received from three different pathways (clinical oncology + pathological + paediatric centre). Due to the lower number of adolescent cancers diagnosed by paediatric centres (Figure 2), the average number of notifications in this age group is lower (2.2) when compared to children in the age group 0-14 years (2.8).

Sixty percent of the 2,973 cancers recorded in children and adolescents was registered by a paediatric centre for haemato-oncology. Especially under the age of 12 years, the contribution of the paediatric centres is substantial. In this age group, a notification from a paediatric centre is received in almost 90 percent of the diagnoses. The notification of the other 10% (registration by multidisciplinary consult, registration by pathology only, ...) are mostly brain tumours, epithelial neoplasms, lymphomas and leukaemias. But this does not automatically imply that the paediatric centres for haematology-oncology were not involved in the diagnostic and therapeutic setting for the patient. After the age of 16 years, notifications from paediatric centres are rare but this is in line with age groups treated in paediatric centres.

ⁱ Only unique notifications from 1 source were included. If the same source registered the same diagnosis more than once, this is counted as 1 notification.

Figure 2 Notifications of paediatric centres for haemato-oncology by age at diagnosis, Belgium 2004-2009

Number of notifications from paediatric centres for haemato-oncology by tumour type

Under the age of 15 years, more than 90% of all leukaemias (I), neuroblastomas (IV), retinoblastomas (V), renal (VI), hepatic (VII) and bone tumours (VIII) are registered by a paediatric centre (Table 2). Lymphomas (II), soft tissue sarcomas (IX) and germ cell tumours (X) are notified in more than 80% of all cases by a paediatric centre. For brain tumours (III), this is only 75%. Epithelial neoplasms (XI) are less frequently registered by a paediatric centre. The majority of these tumour types are registered by pathology laboratories (Appendix 1) and are not notified by any other source type. Special attention should be made for the clinical registration of these cases.

Table 2 Notifications from paediatric centres for haemato-oncology by tumour type, Belgium 2004-2009

ICCC-3 Classification	0-14 years			15-19 years			0-19 years		
	Total	Paediatric notification		Total	Paediatric notification		Total	Paediatric notification	
	N	N	%	N	N	%	N	N	%
I-XII All tumours	1,913	1,604	83.8%	1,060	157	14.8%	2,973	1,761	59.2%
I Leukaemias, myeloproliferative and myelodysplastic diseases	500	480	96.0%	125	32	25.6%	625	512	81.9%
II Lymphomas and reticuloendothelial neoplasms	238	211	88.7%	264	32	12.1%	502	243	48.4%
III CNS and miscellaneous intracranial and intraspinal neoplasms	475	356	74.9%	146	25	17.1%	621	381	61.4%
IV Neuroblastomas and other peripheral nervous cell tumours	128	124	96.9%	2	-	-	130	124	95.4%
V Retinoblastomas	64	59	92.2%	-	-	-	64	59	92.2%
VI Renal Tumours	102	97	95.1%	6	3	50.0%	108	100	92.6%
VII Hepatic tumours	11	10	90.9%	1	-	-	12	10	83.3%
VIII Malignant bone tumours	99	90	90.9%	77	30	39.0%	176	120	68.2%
IX Soft tissue and other extraosseous sarcomas	105	90	85.7%	83	17	20.5%	188	107	56.9%
X Germ cell tumours, trophoblastic tumours and neoplasms of gonads	59	48	81.4%	112	11	9.8%	171	59	34.5%
XI Other malignant epithelial neoplasms and malignant melanomas	127	38	29.9%	239	7	2.9%	366	45	12.3%
XII Other and unspecified malignant neoplasms	5	1	20.0%	5	-	-	10	1	10.0%


Number of notifications by data source

A total of 926 tumours (48%) diagnosed in children (0-14 years of age) are notified by the three main source types (paediatric centres, laboratories for pathological anatomy/clinical biology and hospitals/health insurance companies) (Figure 3).

In total, 1,610 (84%) of all diagnoses are delivered by more than one source type.

The remaining 303 tumours are only registered by one source type of which 83 tumours (4.3%) are notified by a paediatric centre only. These tumours mainly concern brain tumours (N=28), leukaemias (N=17) and lymphomas (N=10). Leukaemias are not expected to be reported by the pathological pathway. Another important part of these tumours are only diagnosed on clinical basis and not confirmed microscopically. The 147 diagnoses (7.7%) only received from a laboratory were submitted to an individual and thorough quality control to confirm the diagnoses. This specific control included a review of the written protocols and if necessary, the pathologist was contacted for additional information about the diagnosis. For 73 tumours (3.8%) only a registration from an oncological care program was received. Also here this mainly concerns brain tumours (N=35) and leukaemias (N=12). But, this does not automatically imply that the paediatric centres for hematology-oncology were not involved.

Figure 3 Notifications for childhood cancer by source type, Belgium 2004-2009



Calculation of incidence, mortality and survival

Description of the dataset

The incidence data presented in this report are based on the cancer records for Belgian residents that were available at the Cancer Registry in January 2012.

For reporting purposes, these tumours are classified according to the International Classification of Childhood Cancer (ICCC-3)⁽⁴⁾.

Mortality statistics, used in the first chapter, are represented in the ICD-10 classification⁽⁵⁾.

Population data were obtained from the Directorate-General Statistics Belgium⁽⁶⁾.

The different chapters included in this document are based on the main tumour types as described in the ICCC-3 classification. For every tumour type, general incidence and survival results are presented. When possible, a more detailed analysis by age group, histology or primary site (ICD-O3⁽⁷⁾) is carried out. Additionally, a separate chapter is dedicated on cancer in infants (<1 year). As cancer is a rare disease in children and adolescents, analyses are based on small numbers. Therefore, the data collected over six years are grouped for the calculation of Belgian incidence and survival data. The incidence rates for both sexes are presented separately whenever possible. Otherwise, data for boys and girls are aggregated.

Incidence and survival rates always include children and adolescents, unless otherwise specified. Results about children only include diagnoses in the age group 0-14 years of age. Adolescent diagnoses are tumours registered in patients of 15-19 years of age. Cancer in infants represent diagnoses for patients younger than 1 year of age.

Incidence and mortality

Incidence is the number of new cases occurring in a given time period in a specific population. It provides a direct estimate of the probability or risk of illness, and can be expressed in different ways:

- The crude incidence rate is calculated by dividing the number of new cases observed during a given time period by the corresponding number of people in the population at risk. The crude rate is expressed as the number of new cases per 1,000,000 persons per year.
- The age-specific incidence rate is the number of newly diagnosed cases in a particular 5-year age group over a specified time period and expressed per 1,000,000 persons per year.
- The age-standardised incidence rate is a weighted average of the individual age-specific rates using an external standard population. It is the incidence that would be observed if the population had the age structure of the standard population (European or World Standard Population). Since age has a powerful influence on the risk of cancer, this standardisation is necessary when comparing several populations that differ with respect to their age structure. In this publication, the World Standard Population is used for standardisation and consequently World Standardised incidence Rates (WSR) are reported. These are expressed as the number of new cases per 1,000,000 persons per year.
- Male/Female (M/F) ratios are calculated by dividing the corresponding age standardised incidence rates (WSR).

According to international guidelines, incidence rates for children and adolescents are expressed per 1,000,000 person years. In adults, incidence rates are expressed per 100,000 person years. The same principles are applied to calculate mortality data.

Trends in incidence

Only six consecutive years of incidence data are available for Belgium. Moreover, cancer in children is very rare. Analysis of trends and the interpretation of results is complicated by the low number of yearly diagnoses, leading to important annual fluctuation in incidence rates. For the Flemish Region, the Belgian Cancer Registry disposes of 11 years of incidence data. Incidence rates were aggregated over five year and are presented as three moving averages (1999-2003, 2002-2006, and 2005-2009).

Survival

The Belgian Cancer Registry performs active follow up on vital status for all patients. Data on vital status is obtained from the Crossroads Bank for Social Security (CBSS)⁽⁸⁾, by means of the national number for social security (NNSS).

For this publication, patients are followed up until 01/01/2012. Between 2004 and 2009 a total of 83 patients are lost to follow up (2.8%). A total of 64 patients, out of the 83 patients, are lost to follow up due to a missing national number. These patients are excluded from survival analysis. The remaining 19 patients are censored on the last date the patients were known to be alive. These patients are included in the survival analysis.

Observed survival rates are calculated and presented as Kaplan Meier⁽⁹⁾ survival curves. Published tables in appendix with 5 or 10 year survival rates are accompanied with 95% confidence intervals, which are calculated using the Rothman method.⁽¹⁰⁾ Calculation of survival rates is only performed for the first tumour known at the registry. Consequently, the absolute numbers used in the survival analyses will be slightly different from those reported within the framework of incidence rates. When determining the tumour sequence, all tumours following the ICC-3 classification are included. Since cancer in children and adolescents is rare, these survival analyses are often based on a very low number of patients. When the numbers of patients at risk dropped to less than 10 cases, the survival data are not presented.

For Belgium, 5-year survival rates are calculated for all patients diagnosed between 2004 and 2009. Occasionally, 10-year survival rates for the Flemish Region (diagnoses 1999-2009) are presented.

Incidence

Cancer is a rare disease in children. Compared to the total cancer burden in Belgium, childhood cancer comprises less than 1%. Every year, about 320 children (0-14 years) and 175 adolescents (15-19 years) are diagnosed with cancer (Table 3). All sites combined, more diagnoses are registered in boys (55%) than in girls (45%), corresponding with a male/female ratio of 1.35.


Table 3 Cancer in children and adolescents by sex, Belgium 2004-2009

	Age group 0-14				Age group 15-19				Age group 0-19			
	Boys		Girls		Boys		Girls		Boys		Girls	
	N	WSR	N	WSR	N	WSR	N	WSR	N	WSR	N	WSR
2004	181	205.0	133	158.4	87	278.9	76	254.1	268	221.7	209	180.0
2005	191	214.4	159	187.2	88	278.3	86	283.8	279	228.8	245	208.9
2006	164	183.3	154	177.6	98	303.3	79	255.3	262	210.3	233	195.1
2007	151	168.4	134	155.7	100	304.6	86	272.9	251	199.1	220	182.1
2008	168	184.6	144	165.8	101	303.4	77	241.0	269	211.4	221	182.7
2009	198	219.1	136	154.6	101	302.8	81	252.7	299	238.0	217	176.7

WSR: age-standardised rate, using the World Standard Population (N/1,000,000 person years)

Age specific incidence rates (Figure 4) are higher for the youngest and oldest age groups when compared to children between 5 and 10 year. Although incidence rates for children between 0-4 years and those aged 15-19 years are similar, major differences in tumour types can be observed between these age groups.

Figure 4 Cancer in children and adolescents: age specific incidence rates by sex, Belgium 2004-2009



Leukaemias, brain tumours, lymphomas and carcinomas are the most frequent malignancies in children and adolescents (Figure 5, Figure 6). However, their importance varies by age group. In the age group 0-4 years, leukaemias comprise 31% of all tumour diagnoses. The highest incidence rates are observed at the age of 2-3 years (Figure 7). After this age, the incidence of leukaemia decreases. In adolescents, only 12% of all cancer diagnoses are leukaemias. Lymphomas (25%) and carcinomas (23%) are the most common tumours in adolescents (Figure 6) and are less common at younger age (4% and 1% respectively in the age group 0-4 years).

Figure 5 Cancer in children and adolescents: new diagnoses by tumour type and age group, Belgium 2004-2009








Figure 6 Cancer in children and adolescents by tumour type, Belgium 2004-2009



The highest incidence rates for neuroblastomas and other peripheral nerve cell tumours (IV), retinoblastomas (V), renal tumours (VI) and hepatic tumours (VII) are found in infants (age <1 year). These tumours are seldom diagnosed in patients older than 9 years of age. Germ cell tumours (X) and soft tissue sarcomas (IX) are frequently diagnosed in very young children and in adolescents. They are less frequent in children in the age group 5-15 years.

Bone tumours (VIII) are less frequent under the age of 10 years. Their incidence rates are the highest between the age of 10 to 19 years.

Figure 7 Cancer in children and adolescents: age specific incidence rates by tumour type, Belgium 2004-2009



Trends

Analyses from the ACCIS-project ⁽¹¹⁾ showed an annual increase of 1.1% in childhood cancer incidence in Europe. Due to the low number of new diagnoses, it is not yet possible to draw reliable conclusions on trends for the Belgian cancer incidence data. Incidence rates between 1999 and 2009 remain stable in the Flemish Region (Figure 8).

Figure 8 Cancer in children and adolescents: incidence and mortality* (WSR), Flemish Region 1999-2009





Figure 9 Cancer in children and adolescents: mortality (WSR) by sex, Belgium 1960-2009



(aggregated 5 years mortality data (WSR) from WHO 1960-1999 ^{(12) (13)}, Belgium 2004, 2005, 2006, 2008 and Flemish Region 2000-2003, 2007, 2009) ^{(14) (15) (16) (6)}.


Since the nineteen sixties (Figure 9), mortality rates have dramatically declined for most childhood cancers. This decrease in mortality reflects an improved cancer survival rate for children. Survival has increased for all childhood cancers since the late 1960s, but by varying amounts and at different points in time. These improvements are not linked to more effective drugs alone. Most of these improvements are linked to the accurate use of already existing drugs (effective combinations), to the knowledge of natural behaviour of the disease, to better diagnostic methods, to better surgery and radiotherapy and to a better identification of prognostic factors. One example of a major improvement in childhood cancer care is improved efficacy of chemotherapeutic agents for acute lymphocytic leukaemia ⁽¹⁷⁾.

ii Incidence and mortality are reported in different classification systems. Incidence is reported by means of the ICC-3 classification⁽⁴⁾, while mortality data is classified according to the ICD10 classification⁽⁵⁾. The ICC-3 classification includes some benign and borderline malignancies that are not included in the mortality statistics.

Survival


Children and adolescents with cancer have a relatively good prognosis (Figure 10 and Figure 11). Five-year survival rates for girls (87%) are slightly higher than for boys (84%). In children, 5-year survival rates for boys and girls are almost the same, while in adolescents the rates for girls are higher than for boys. Survival rates in the Flemish Region seem to improve slightly in the last decade (Figure 12) from 83% to 85%.

Figure 10 Cancer in children (0-14 year): observed survival by sex, Belgium 2004-2009




N at risk						
Boys	1023	954	904	718	564	431
Girls	830	773	734	603	476	367

Figure 11 Cancer in adolescents (15-19 year): observed survival by sex, Belgium 2004-2009



N at risk						
Boys	545	516	485	385	296	216
Girls	458	441	428	345	274	198

Figure 12 Cancer in children and adolescents: observed survival, Flemish Region 1999-2003, 2002-2006, 2005-2009



N at risk											
1999-2003	1213	1121	1060	1023	1011	1004	996	989	980	772	585
2002-2006	1279	1185	1125	1098	1080	1071	828	601	386	183	
2005-2009	1275	1200	1137	889	664	464	224				

I LEUKAEMIAS, MYELOPROLIFERATIVE AND MYELODYSPLASTIC DISEASES

Incidence


Leukaemia(I) is the most frequent cancer in children. Between 2004 and 2009 a total number of 625 new diagnoses are registered in children (N = 500) and adolescents (N = 125) in Belgium (Table 4). More boys are diagnosed with leukaemia than girls (M/F ratio = 1.3).

The relative frequency of leukaemia (Figure 13) to the total childhood cancer burden varies with age. It increases from 10% at birth to 40% around the age of 2-3 year. Afterwards the relative proportion of leukaemia decreases with increasing age to about 10% for adolescents.

Table 4 New diagnoses of leukaemia, Belgium 2004-2009

Boys		Total	0-14	15-19
I	Leukaemia	362	290	72
Ia	Lymphoid leukaemia	273	236	37
Ib	Acute myeloid leukaemia	51	31	20
Ic-le	Leukaemia other	38	23	15
Girls		Total	0-14	15-19
I	Leukaemia	263	210	53
Ia	Lymphoid leukaemia	189	162	27
Ib	Acute myeloid leukaemia	53	37	16
Ic-le	Leukaemia other	21	11	10

Figure 13 Relative frequency of leukaemia by age at diagnosis, Belgium 2004-2009



The most frequent subtype, **acute lymphoid leukaemiaⁱⁱⁱ (ALL: Ia)**, represents 74% of the total number of leukaemia cases. Higher incidence rates are observed in boys (M/F ratio = 1.4).

In infants ALL(Ia) represents 50% of all leukaemia diagnoses. The incidence rates (Figure 15) increase dramatically to reach a peak incidence at the age of 2-3 years, where the rates are 5 times higher than in infants. This peak is fully due to the peak age of the precursor-B ALL. Between the ages of 3 to 9 years, incidence rates decrease rapidly and reach the rates observed in infants. In this age group (1-9 years) ALL(Ia) represents 80% or more of all leukaemia diagnoses. From the age of 10 years onwards, the incidence rates for ALL(Ia) remain fairly stable. The relative proportion of ALL(Ia) decreases to 73% in the age group 10-14 years of age and 51% in adolescents (Figure 13).

ⁱⁱⁱ Since the subgroup lymphoid leukaemia (Ia) consisted solely of diagnoses of acute lymphoid leukaemia, the abbreviation ALL was used to denote subgroup Ia.

The distinctive shape of the age-specific incidence curve for ALL can be well-described by a mathematical model which assumes that childhood ALL results from two genetic events required for full malignant transformation with the first of these events occurring in utero ^{(18) (19) (20)}.

The 2nd most frequent subtype, **acute myeloid leukaemia (AML: Ib)**, accounts for 17% of the leukaemia diagnoses. Incidence rates in boys and girls are comparable (M/F ratio = 0.9). The highest proportion of AML (Figure 14) is observed in infants (42%) and in adolescents (29%). In the other age groups AML accounts for 10 to 16% of all leukaemia diagnoses.

The remaining **leukaemia subtypes (Ic-e)** are rare and represents less than 10% of all new leukaemia diagnoses in children.

Figure 14 Leukaemia by age group, Belgium 2004-2009






Figure 15 Age specific incidence rates for ALL (Ia) and AML (Ib), Belgium 2004-2009



Trends

When comparing incidence data from the Flemish Region over time, the incidence rate (WSR) of leukaemia remains fairly stable (Figure 16). In adolescents, a small decrease in ALL(Ia) and an increase in AML(Ib) can be observed. A detailed trend analysis is currently not available due to the low number of diagnoses.


Figure 16 Leukaemia in children and adolescents: age standardised incidence (WSR), Flemish Region 1999-2003, 2002-2006, 2005-2009.



Survival

The prognosis for leukaemia is greatly dependent on the leukaemia subtype. In the Flemish Region, the 10-years survival rate for ALL (Ia) is 81% (Figure 17). The 10-years survival rate for AML (Ib) is considerably lower (61%). The main decrease in the survival rates for both subtypes is observed in the first three years after diagnosis. After three years the survival rates are 86% for ALL and 63% for AML. Thereafter the rates remain fairly stable.

Figure 17 Leukaemia in children and adolescents: observed survival for ALL (Ia) and AML (Ib), Flemish Region 1999-2009




N at risk

ALL (Ia)	432	410	384	340	299	265	224	191	154	123	94
AML (Ib)	99	82	69	57	51	46	39	31	28	22	16

The 5-year survival rates in Belgium for ALL (Figure 18) are very comparable between boys (86%) and girls (87%). For AML (Figure 19), boys seem to have a worse prognosis than girls (respectively 51% and 63% 5-year survival rates).


Figure 18 ALL (Ia): observed survival by sex, Belgium 2004-2009



N at risk

Boys	267	251	238	186	141	108
Girls	187	176	167	141	115	89


Figure 19 AML (Ib): observed survival by sex, Belgium 2004-2009



N at risk

Boys	49	38	30	23	20	17
Girls	53	42	37	30	22	14

Survival of ALL (Ia) varies considerably with age (Figure 20). Infants have the worst prognosis. Five year survival rates are not presented due to the low number of patients at risk. However of the 12 infants diagnosed with ALL in Belgium between 2004 and 2009, 5 died within the first six months after diagnosis. Prognosis for adolescents (68%) is worse than for children between 1 and 4 years of age (88%) and children in the age group 5-9 years (93%). These observations are consistent with international findings.^{(18) (19)} A possible explanation for the difference in prognosis between the age groups is a difference in biological subtype.^{(20) (21) (22) (23) (24)} The prognosis for the different age groups for AML (Ib) is more comparable (Figure 21).



N at risk							N at risk						
< 1 y	12	7	5	3	3	3	< 1 y	10	7	6	4	4	3
1-4 y	193	185	184	155	129	97	1-4 y	24	17	14	13	8	5
5-14 y	187	179	170	135	101	80	5-14 y	34	30	25	19	16	13
15-19 y	62	56	47	35	25	18	15-19 y	34	26	23	18	15	11

II LYMPHOMAS AND RETICULOENDOTHELIAL NEOPLASMS


Incidence

Between 2004 and 2009, a total number of 502 new diagnoses of lymphoma(II) (Table 5) are registered in children (N = 238) and adolescents (N = 264) in Belgium. More boys are registered than girls (M/F ratio = 1.3), a difference mainly observed in children (M/F ratio = 1.6). The male/female ratio in adolescents is 1.1. More boys are registered at childhood than in adolescence, while for girls this is the opposite.

Table 5 New diagnoses of lymphoma, Belgium 2004-2009

Boys		Total	0-14	15-19
II	Lymphomas	292	150	142
IIa	Hodgkin	143	56	87
IIb	Non-Hodgkin	84	41	43
IIc	Burkitt	47	38	9
IId-e	Other lymphoma	18	15	3
Girls		Total	0-14	15-19
II	Lymphomas	210	88	122
IIa	Hodgkin	120	34	86
IIb	Non-Hodgkin	60	26	34
IIc	Burkitt	16	15	1
IId-e	Other lymphoma	14	13	1

Figure 22 Relative frequency of lymphoma by age at diagnosis, Belgium 2004-2009



Lymphomas(II) are the 3rd most frequent type of childhood cancer (17%). The percentage of lymphoma diagnoses increases with age (Figure 22). In children younger than 5 years, the proportion of lymphoma varies between 3% and 6%. Between the ages of 5 and 14 years, the proportion remains around 20%. Lymphoma is the most frequent tumour type in adolescents, accounting for 25% of all tumours.

Figure 23 Lymphoma: age specific incidence, Belgium 2004-2009





Figure 24 Lymphoma by age group, Belgium 2004-2009



With more than half of all new lymphoma diagnoses in children and adolescents, **Hodgkin lymphoma (IIa)** is the most frequent lymphoma-subtype (Figure 23 and Figure 24). Although rare in children younger than 10 years of age, it represents one of the most common malignancies in adolescents.

The most common subtype of Hodgkin lymphoma (IIa) is nodular sclerosis (Figure 25). This histological subtype represents 56% of all diagnoses under the age of 10, increasing to 70% in adolescents.

Under the age of 5 years, only 3 children are diagnosed with Hodgkin lymphoma. In children between 5 and 14 years of age, a male predominance can be observed that disappears in adolescence (Figure 26). The male/female ratios are 1.9, 1.6 and 1.0 for the age groups 5-9 years, 10-14 years and 15-19 years respectively. Especially in the mixed cellularity subtype (Figure 28), a higher incidence in boys can be observed (M/F ratio = 2.9, 2.4 and 0.7 in the age group 5-9, 10-14 and 15-19 years respectively). For nodular sclerosis, the rates between boys and girls are more comparable (Figure 27). These observations are consistent with international epidemiological features of Hodgkin lymphoma.⁽²⁵⁾

Figure 25 Hodgkin lymphoma by age group, Belgium 2004-2009




Figure 26 Hodgkin lymphoma: age specific incidence rates by sex, Belgium 2004-2009




Figure 27 Hodgkin lymphoma – nodular sclerosis subtype: age specific incidence rates by sex, Belgium 2004-2009





Figure 28 Hodgkin lymphoma – mixed cellularity subtype: age specific incidence rates by sex, Belgium 2004-2009



Non-Hodgkin lymphomas (NHL; IIb), the 2nd most frequent lymphoma subtype, represent 29% of the total number of lymphoma diagnoses in children and adolescents. The overall incidence rates of NHL (IIb) remain relatively stable until the age of 15 years (Figure 23). After the age of 15, an increase in age specific incidence rate is observed.

The relative contribution of NHL (IIb) remains rather stable (20-25%) in every age group (Figure 24). However, NHL represent a heterogeneous group of malignant tumours and between the age groups differences can be observed in NHL-subtype (Figure 29). The main subgroups, precursor cell lymphomas (IIb1), mature B-cell lymphomas (IIb2) and mature T- and NK-cell lymphomas (IIb3) are evenly distributed under the age of 5 years. In the age group 5-9 years, precursor cell lymphomas (IIb1) and mature T- and NK-cell lymphomas (IIb3) are the most common subtypes. In the age group 10-19 years the most common histological subtype is mature B-cell lymphoma (IIb2).

Between the sexes (Figure 30), higher incidence rates can be observed for boys for precursor cell (IIb1) and mature B-cell lymphomas (IIb2). The incidence rates for T- and NK-cell lymphomas (IIb3) are equal in both sexes.

Figure 29 Non-Hodgkin lymphoma by age group, Belgium 2004-2009





Figure 30 Non-Hodgkin lymphoma: age standardised incidence (WSR) by histology and sex, Belgium 2004-2009




Burkitt lymphomas (IIc) represent the 3rd group with 13% of the total lymphoma incidence. They show a marked predominance around the age group of 5-9 years (Figure 23). In the first years of life and after the age of 15 years, the incidence rates are low. The incidence rate in boys is almost three times higher than in girls (M/F ratio = 2.7).

The remaining **lymphoma subtypes (II d-e)** are rare (32 cases) and represent less than 10% of all new lymphoma diagnoses in children. The majority (26 cases) of these lymphoma diagnoses are malignant histiocytosis (II d). This subtype is most frequently diagnosed in infants. In other age groups the incidence rates are very low. The remaining 6 cases are lymphoma NOS (II e).

Trends

International trends show that incidence rates for lymphomas (all subtypes) increase faster in adolescents than in children. ⁽²⁶⁾ When comparing the incidence rates in the Flemish Region over time (Figure 31), a lower incidence rate for Hodgkin (IIa) and non-Hodgkin lymphoma (IIb) can be observed for adolescents in the period 1999-2003 when compared to the other time periods. In childhood lymphoma however, the incidence rates rather seem to decline slightly.





Survival

The 5-year survival rates for the different lymphoma subtypes in children (0-14 year) are slightly higher than in adolescents (Figure 32 and Figure 33). The 5-year survival rates for Hodgkin and non-Hodgkin lymphoma are 99% and 90% in children. In adolescents they are 97% and 86% respectively.

Burkitt lymphoma (IIc) is rarely seen in adolescents and the number of cases are too low for a survival analysis. In children, Burkitt lymphoma have a 5-year survival rate of 94%.

Figure 32 Lymphoma: observed survival in children, Belgium 2004-2009

Figure 33 Lymphoma: observed survival in adolescents, Belgium 2004-2009



N at risk

Hodgkin (IIa)	90	89	88	76	63	54
Non-Hodgkin (IIb)	64	62	60	51	41	30
Burkitt (IIc)	52	49	49	43	28	24

N at risk

Hodgkin (IIa)	164	163	163	129	105	78
Non-Hodgkin (IIb)	76	71	68	60	46	36

III CENTRAL NERVOUS SYSTEM TUMOURS (CNS) AND MISCELLANEOUS INTRACRANIAL AND INTRASPINAL NEOPLASMS

Incidence


Tumours of the central nervous system (CNS) represent the 2nd most frequent tumour in children and adolescents (21%). In Belgium, 621 new diagnoses are registered between 2004 and 2009 (Table 6). Slightly more boys are diagnosed than girls (M/F ratio = 1.1).

CNS tumours occur quite frequently in all age groups. In very young children (age group 0-4 years), CNS tumours account for 23% of all tumour diagnoses. In children between 5 and 14 years of age (Figure 34), CNS tumours are the most frequent malignancy (26% of all tumour diagnoses).

Table 6 New diagnoses of CNS tumours, Belgium 2004-2009

Boys		Total	0-14	15-19
III	CNS tumours	332	251	81
IIIa	Ependymoma	33	25	8
IIIb	Astrocytoma	129	97	32
IIIc	PNET	49	44	5
IIId-f	CNS other	121	85	36
Girls		Total	0-14	15-19
III	CNS tumours	289	224	65
IIIa	Ependymoma	36	33	3
IIIb	Astrocytoma	136	107	29
IIIc	PNET	34	29	5
IIId-f	CNS other	83	55	28

Figure 34 Relative frequency of CNS tumours by age at diagnosis, Belgium 2004-2009



The CNS tumours represent a heterogeneous collection of malignancies with different histology, behaviour and prognosis. The distribution of the different histological subtypes differs by age group (Figure 35 and Figure 36).

Ependymomas (IIIa) are the most important CNS subtype at infancy. The incidence rates for this tumour decrease fast until the age of 4 (Figure 36). After the age of 4, ependymomas are very rare. Slightly more girls are diagnosed than boys (M/F ratio = 0.8). In very young children (0-4 year) the incidence rates in girls are almost twice as high as in boys (M/F ratio = 0.6). In patients between 5 and 19 years of age, more boys are diagnosed with ependymoma than girls (M/F ratio = 1.6).

The ependymoma group (IIIa) contains two subgroups, the 'real' ependymoma diagnoses (IIIa1) and choroid plexus tumours (IIIa2). When considering all age groups, two out of three diagnoses are 'real' ependymoma (IIIa1). The remaining neoplasms are choroid plexus tumours (IIIa2). The latter group is almost solely diagnosed at infancy and in the first years of life, while only half of the ependymoma (IIIa1) group is diagnosed in this age group (Table 7).

Astrocytomas (IIIb) are the most frequent CNS subtype (43%). In the age group 5-14 years they represent half of all the diagnosed CNS tumours. The incidence rates for girls are somewhat higher than for boys (all ages M/F ratio = 0.9).

Astrocytoma (IIIb) includes a wide variety of tumour types ranging from slowly growing pilocytic astrocytoma to aggressive glioblastoma. Table 7 contains a regrouping of these different tumour types according to the WHO grading system ⁽²⁷⁾. Half of all astrocytomas are diagnosed as grade I. They are most frequently diagnosed in the age group 5-9 years, where they encompass about 60% of the astrocytoma diagnoses. The number of grade II astrocytomas increases with age. In adolescents they are almost as frequent as grade I astrocytoma. Grade III astrocytomas are uncommon. Most diagnoses are found between the age of 5 and 14 years. Grade IV astrocytomas are mostly diagnosed after the age of 10 years. For 31 astrocytomas, a grade could not be assigned. These tumours are optic nerve gliomas (NOS), almost all diagnosed in the first years of life.

Figure 35 CNS tumours by age group, Belgium 2004-2009





Figure 36 CNS tumours: age specific incidence rates by histology, Belgium 2004-2009



Incidence rates for **primitive neuroectodermal tumours (IIIC)** decrease slightly with age. The majority of these malignancies are diagnosed in children younger than 5 years of age (Table 7). After the age of 10 year, incidence rates are very low (Figure 36). More boys are diagnosed with PNET (IIIC) than girls (M/F ratio = 1.4). Medulloblastomas (IIIC1) are the most common histological subtype. The other subtypes are very rare.

The remaining **CNS tumours (IIId-f)** represent a very diverse group of rare tumours (Table 7).


Table 7 CNS tumours: number of new diagnoses by age group, Belgium 2004-2009

ICCC-3 classification		0-4	5-9	10-14	15-19	0-19
III	CNS and miscellaneous intracranial and intraspinal neoplasms	190	136	149	146	621
IIIa	Ependymomas and choroid plexus tumours	42	6	10	11	69
IIIa1	Ependymomas	21	5	8	11	45
IIIa2	Choroid plexus tumours	21	1	2	0	24
IIIb	Astrocytomas	65	72	67	61	265
	WHO I	26	42	33	26	127
	WHO II	11	13	17	23	64
	WHO III	2	6	5	3	16
	WHO IV	3	5	10	9	27
	Grade unknown	23	6	2	0	31
IIIc	Intracranial and intraspinal embryonal tumours	34	20	19	10	83
IIIc1	Medulloblastomas	24	13	15	8	60
IIIc2	Primitive neuroectodermal tumours (PNET)	6	5	3	2	16
IIIc3	Medulloepitheliomas	0	0	0	0	0
IIIc4	Atypical teratoid/rhabdoid tumours	4	2	1	0	7
IIId	Other gliomas	21	16	23	9	69
IIId1	Oligodendrogliomas	7	2	6	4	19
IIId2	Mixed and unspecified gliomas	13	14	15	4	46
IIId3	Neuroepithelial glial tumours of uncertain origin	1	0	2	1	4
IIIe	Other specified intracranial and intraspinal neoplasms	20	21	21	45	107
IIIe1	Pituitary adenomas and carcinomas	0	2	6	9	17
IIIe2	Tumours of the sellar region (craniopharyngiomas)	3	14	5	3	25
IIIe3	Pineal parenchymal tumours	1	0	0	1	2
IIIe4	Neuronal and mixed neuronal-glial tumours	11	5	6	27	49
IIIe5	Meningiomas	5	0	4	5	14
IIIf	Unspecified intracranial and intraspinal neoplasms	8	1	9	10	28

Trends

In the last decade, an increase in the incidence rates in the Flemish Region can be observed (Figure 37). This increase is mainly observed in astrocytoma in children and in adolescents. According to international data ^{(28) (29)}, incidence rates for CNS tumours in children and adolescents annually increase with 1.7%.

Figure 37 CNS tumours: age standardised incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006 and 2005-2009



Survival

Prognosis for CNS tumours is largely dependent on the histological diagnosis. Of the main ICCC-3 subgroups, PNET (IIIc) have the worst prognosis with a 5-year survival rate of 61%. The WHO ⁽²⁷⁾ classifies these tumours as highly malignant (WHO IV).


Ependymomas (IIIa), astrocytomas (IIIb) and other gliomas (IIId) have comparable 5-year survival rates of 83%, 81% and 80% respectively (Figure 38). However, ependymomas (IIIa) and astrocytomas (IIIb) contain diagnoses with very different prognosis. Figure 39 and Figure 40 show the survival rates for respectively ependymoma and astrocytoma by WHO-grade ⁽²⁷⁾.

No deaths are observed for the 15 patients diagnosed with a WHO I ependymoma. WHO II ependymomas still have fairly high survival rates around 90%. The worst prognosis for ependymomas is observed for the WHO III cases with a 5-year survival rate of 67%.

Grade I astrocytomas also have a very good prognosis (95% 5-year survival). Survival for WHO II astrocytomas decreases to 81%. The prognosis for grade III-IV astrocytoma is the worst of all CNS tumours. After 2 years, the survival rate is only 31%.

The group of other and unspecified tumours (IIIe-f) consist mainly of tumours with a good prognosis. This category has a very high 5-year survival rate of 95% (Figure 38). A small subset of rare malignant tumours (mainly meningioma and pineoblastoma) in this category is the reason for the 5% loss of patients after 1 year.


Figure 38 CNS tumours: Observed survival by histology, Belgium 2004-2009



N at risk

IIIa	65	59	55	48	38	29
IIIb	253	226	211	166	125	96
IIIc	82	67	59	44	30	25
IIId	64	58	52	38	30	22
IIIe-f	128	122	122	88	71	50


Figure 39 Ependymoma: observed survival by WHO-classification, Belgium 2004-2009



N at risk

WHO I	15	15	14	12	11	8
WHO II	22	20	18	14	13	0
WHO III	28	22	20	16	14	10

Figure 40 Astrocytomas (IIIb): observed survival by WHO-classification, Belgium 2004-2009



N at risk

WHO I	121	119	117	93	64	48
WHO II	62	55	49	38	33	24
WHO III-IV	39	22	15	9	6	5

IV SYMPATHETIC NERVOUS SYSTEM TUMOURS

Incidence

In Belgium, 130 new diagnoses of sympathetic nervous system (SNS) tumours are registered in children and adolescents between 2004 and 2009 (Table 8). Slightly more boys are diagnosed than girls (M/F ratio = 1.3).

The majority (98%) are neuroblastomas (IVa) that occur almost exclusively in infants and very young children. In infants, this tumour is the most frequently diagnosed cancer (25%). Its occurrence decreases with age and becomes very rare in older children and adolescents (Figure 41 and Figure 42).

The adrenal gland is the most common primary localisation of the SNS tumours (Figure 43).

Table 8 New diagnoses of SNS tumours, Belgium 2004-2009

Boys		Total	0-14	15-19
IV	SNS tumours	74	73	1
IVa	Neuroblastoma	72	71	1
IVb	Other SNS tumours	2	2	0
Girls		Total	0-14	15-19
IV	SNS tumours	56	55	1
IVa	Neuroblastoma	55	54	1
IVb	Other SNS tumours	1	1	0

Figure 41 Relative frequency of SNS tumours by age at diagnosis, Belgium 2004-2009




Figure 42 SNS tumours: age specific incidence rates, Belgium 2009






Figure 43 SNS tumours: number of new diagnoses (N) by primary site, Belgium 2004-2009



Survival

Foetal neuroblastomas very often differentiate into benign neoplasms. In infants and young children, the number of patients needing therapy for an aggressive variant increases. In older children, neuroblastomas are very frequently aggressive malignancies.^{(30) (31)} Age, dichotomized at 18 months, is one important parameter in determining prognosis.⁽³²⁾ In the Flemish Region, 10-year survival rates (Figure 44) are very high for children up to 18 months of age (92%). For patients of 18 months of age and older, prognosis is much worse (50% 10-year survival rates).

Figure 44 SNS tumours: observed survival by age group, Flemish Region 1999-2009



N at risk

	0	1	2	3	4	5	6	7	8	9	10
Age < 18 months	50	47	47	41	36	36	32	26	20	15	13
Age ≥ 18 months	66	57	47	35	32	26	22	18	12	8	5

V RETINOBLASTOMA

Incidence

Retinoblastoma is a rare disease. In the period 2004-2009 a total of 64 new diagnoses are registered in Belgium, 39 in boys and 25 in girls (M/F ratio = 1.5). Almost all diagnoses occur under the age of 5 years (Figure 45 and Figure 46). The oldest patient was nine years of age at the time of diagnosis. At infancy retinoblastomas represent 11% of all tumour diagnoses.

Figure 45 Relative frequency of retinoblastoma by age at diagnosis, Belgium 2004-2009





Figure 46 Retinoblastoma: age specific incidence rates, Belgium 2004-2009



VI RENAL TUMOURS

Incidence

Renal tumours are a rare childhood malignancy. In Belgium, 108 new diagnoses are registered between 2004 and 2009 (Table 9), 55 in boys and 53 in girls (M/F ratio = 1.0). They represent less than 4% of all malignancies in children and adolescents. The majority (94%) of the renal tumours are nephroblastomas. Renal carcinoma, the most frequent type of adult renal cancer, seldom occurs in childhood.

Table 9 New diagnoses of renal tumours, Belgium 2004-2009

Boys		Total	0-14	15-19
VI	Renal Tumours	55	50	5
VIa	Nephroblastomas	51	47	4
VIb	Renal carcinomas	3	2	1
VIc	Unspecified renal tumours	1	1	0
Girls		Total	0-14	15-19
VI	Renal Tumours	53	52	1
VIa	Nephroblastomas	50	50	0
VIb	Renal carcinomas	2	1	1
VIc	Unspecified renal tumours	1	1	0

Most nephroblastoma diagnoses occur before the age of 6 years (Figure 47): they represent approximately 10% of all childhood cancer malignancies. The highest incidence rates are observed in the first years of life. After the age of 3 years, the incidence rates decline rapidly (Figure 48). After the age of 5 years, renal tumours are very rare.

Figure 47 Relative frequency of renal tumours by age at diagnosis, Belgium 2004-2009






Figure 48 Renal tumours: age specific incidence rates, Belgium 2004-2009



Survival

Renal tumours have a good prognosis (Figure 49). The 5 year survival rate in the Flemish Region is 94% and remains stable thereafter (92% 10 year survival rate).

Figure 49 Observed survival for renal tumours, Flemish Region 1999-2009.



N at risk

	0	1	2	3	4	5	6	7	8	9	10
Renal tumours	112	109	106	98	91	81	73	60	53	41	30

VII HEPATIC TUMOURS

Incidence


Hepatic tumours are an extremely rare disease. In children and adolescents they represent 0.4% of all malignancies. In Belgium, there are only 12 new diagnoses registered between 2004 and 2009, 6 boys and 6 girls. Among the hepatic tumours, there are 10 diagnoses of hepatoblastoma and 2 hepatocellular carcinoma (Table 10). The majority of the tumours are diagnosed in the first years of life (Figure 50).

Due to the low incidence rates, no further analyses are performed on hepatic tumours.

Table 10 New diagnoses of hepatic tumours, Belgium 2004-2009

Boys		Total	0-14	15-19
VII	Hepatic tumours	6	5	1
VIIa	Hepatoblastomas	5	5	0
VIIb	Hepatic carcinomas	1	0	1
Girls		Total	0-14	15-19
VII	Hepatic tumours	6	6	0
VIIa	Hepatoblastomas	5	5	0
VIIb	Hepatic carcinomas	1	1	0

Figure 50 Hepatic tumours: age specific incidence rates, Belgium 2004-2009



VIII BONE TUMOURS

Incidence

In Belgium, between 2004 and 2009, 176 new diagnoses of bone tumours are registered, which represent 6% of all cancer diagnoses in children and adolescents (Table 11). More boys are diagnosed than girls (M/F ratio = 1.3). The incidence rates for bone tumours between the sexes are more comparable in children (M/F ratio = 1.1) than in adolescents (M/F ratio = 1.5). Bone tumours are rare in children younger than 5 years of age. After the age of 5, the incidence rates (Figure 52) increase to reach a peak in late childhood (around 15 years of age). Afterwards, in adolescence, incidence rates seem to decline slightly. This trend is already observed in international studies.⁽³³⁾ In the age group 10-14 years bone tumours represent 10-15% of all childhood cancer diagnoses (Figure 51).

Table 11 New diagnoses of bone tumours, Belgium 2004-2009

Boys		Total	0-14	15-19
VIII	Bone tumours	100	53	47
VIIIa	Osteosarcomas	50	23	27
VIIIb	Chondrosarcomas	4	0	4
VIIIc	Ewing tumours	42	27	15
VIII d-e	Other bone tumours	4	3	1
Girls		Total	0-14	15-19
VIII	Bone tumours	76	46	30
VIIIa	Osteosarcomas	36	22	14
VIIIb	Chondrosarcomas	3	0	3
VIIIc	Ewing tumours	33	23	10
VIII d-e	Other bone tumours	4	1	3

Figure 51 Relative frequency of bone tumours by age at diagnosis, Belgium 2004-2009




Figure 52 Bone tumours: age specific incidence rates by histology, Belgium 2004-2009





Figure 53 Bone tumours by age group, Belgium 2004-2009




Ewing sarcoma (43%) and osteosarcoma (49%) are the predominant histological subtypes. The incidence rates for both tumours increased with age, but with a somewhat different age-pattern (Figure 53).

Bone tumours are very rare under the age of 5 years and almost all diagnoses are Ewing sarcomas (VIIIc). The highest incidence rate of Ewing sarcoma (VIIIc) is observed in the age group 10-14 years. Osteosarcomas (VIIIa) are rare under the age of 10 years. With the onset of adolescence, incidence rates increase and after the age of 10, they become the dominant bone tumour diagnosis.

Osteosarcoma (VIIIa) and Ewing sarcoma (VIIIc) also differ in site distribution (Figure 54). The long bones of the lower limbs are the predominant primary site for bone tumours (93 diagnoses). Three out of four tumours at this localisation are osteosarcoma (VIIIa). The most frequent primary site for Ewing sarcoma (VIIIc) is the central axis (spinal column-rib-sternum-pelvic bones-sacrum-coccyx), followed by the long bones of the lower limbs.


Figure 54 Bone tumours: incidence by primary site and histology, Belgium 2004-2009



Trends

International studies show little evidence of consistent changes in bone tumour incidence in children and adolescents.⁽³³⁾ In the Flemish Region, incidence rates in children seem to increase slightly in the last decade. In adolescents, lower incidence rates are observed between 2005 and 2009 when compared to the other time periods (Figure 55).

Figure 55 Bone tumours: age standardised incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006 and 2005-2009




Survival

The 5-year survival rates for children in Belgium by histology show no difference in prognosis between osteosarcoma (VIIIa) (73%) and Ewing sarcoma (VIIIc) (75%) (Figure 56). For adolescents (Figure 57), prognosis for Ewing sarcoma (VIIIc) seems less than for osteosarcoma (VIIIa). For osteosarcoma the 5-year survival rates are 70%, for Ewing sarcoma the numbers at risk are less than 10 and therefore no 5-year survival rate is calculated.

Prognosis for Ewing sarcoma (VIIIc) depends on the primary localisation (Figure 58): primary tumours of the central axis have a worse prognosis than tumours on other sites.


Figure 56 Bone tumours in children: observed survival by histology, Belgium 2004-2009



N at risk

Osteosarcoma (VIIIa)	44	42	36	30	24	16
Ewing sarcoma (VIIIc)	49	46	42	34	28	20


Figure 57 Bone tumours in adolescents: observed survival by histology, Belgium 2004-2009



N at risk

Osteosarcoma (VIIIa)	38	35	32	29	25	19
Ewing sarcoma (VIIIc)	24	23	19	13	9	6

Figure 58 Ewing sarcoma (VIIIc): observed survival by primary site, Belgium 2004-2009



N at risk

Central axis	29	27	21	15	11	9
Other localisations	44	42	40	32	26	17

IX SOFT TISSUE SARCOMA

Incidence

Soft tissue sarcomas (STS) are a heterogeneous group of neoplasms. These tumours represent 6% of all childhood and adolescent cancer diagnoses. The relative frequency of STS by age at diagnosis is evenly distributed around 6% (Figure 59). All STS combined; more boys are diagnosed than girls (M/F ratio = 1.3).

Soft tissue sarcomas are classified in 2 broad categories: rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma (Non-RMS).

Table 12 New diagnoses of soft tissue sarcoma, Belgium 2004-2009

Boys		Total	0-14	15-19
IX	Soft tissue sarcoma	106	66	40
IXa	Rhabdomyosarcoma	44	34	10
IXb-e	Non-rhabdomyosarcoma	62	32	30
Girls		Total	0-14	15-19
IX	Soft tissue sarcoma	82	39	43
IXa	Rhabdomyosarcoma	24	21	3
IXb-e	Non-rhabdomyosarcoma	58	18	40

Figure 59 Soft tissue sarcoma: relative frequency by age at diagnosis, Belgium 2004-2009






Figure 6o STS: age specific incidence rates by histology, Belgium 2004-2009

Figure 61 STS by age group, Belgium 2004-2009





Rhabdomyosarcoma (IXa) are the most important sarcoma in children under the age of 10 years (Figure 6o and Figure 61). Almost twice as many boys are registered with RMS than girls (M/F ratio = 1.7) (Table 12).

Two main histological types of rhabdomyosarcoma exist. Embryonal RMS is the most frequently diagnosed subtype (66% of RMS) and primarily targets infants and young children. Alveolar RMS (19% of RMS) becomes more frequent in older children and adolescents (Figure 62). The remaining 10 RMS diagnoses (15%), consists of 6 unspecified RMS, 1 pleomorphic RMS and 3 spindle cell RMS.

RMS occur at various sites in the body. The most common sites in our dataset are head and neck (29%) and the genito-urinary tract (28%). Embryonal RMS accounts for about 70% of the diagnoses for every site, with exception of the limbs (Figure 63). This result must be interpreted with care, since there are only 6 diagnoses of RMS registered at the limbs. However, this observation is comparable with results obtained in the ACCIS study.⁽³⁵⁾

Figure 62 Rhabdomyosarcoma by histology, Belgium 2004-2009

Figure 63 Rhabdomyosarcoma by primary site, Belgium 2004-2009



Non-rhabdomyosarcoma (IXb-e) are more frequently diagnosed after the age of 10 years (Figure 60). In adolescents, they account for 84% of all STS diagnoses. This group contains a wide variety of different histological subtypes (Table 13). The majority of the Non-RMS diagnoses are fibrohistiocytic tumours (23%), synovial sarcomas (15%) and fibrosarcomas (14%). The remaining subtypes each encompass less than 10% of the Non-RMS.


Table 13 Non-rhabdomyosarcoma by histology, Belgium 2004-2009

ICCC-3 Classification		Total	New diagnoses (N)				
	%		00-	05-	10-	15-	
IXb-e	Non-rhabdomyosarcomas	120	100,0%	13	7	30	70
IXb	Fibrosarcomas	17	14,2%	4	0	5	8
IXb1	Fibroblastic and myofibroblastic tumours	7	5,8%	3	0	2	2
IXb2	Nerve sheath tumours	10	8,3%	1	0	3	6
IXb3	Other fibromatous neoplasms	0	0,0%	0	0	0	0
IXc	Kaposi sarcomas	1	0,8%	0	0	1	0
IXd	Other specified soft tissue sarcomas	93	77,5%	9	6	22	56
IXd1	Ewing tumours and Askin tumours of soft tissue	12	10,0%	1	1	1	9
IXd2	PNET of soft tissue	1	0,8%	0	0	1	0
IXd3	Extrarenal rhabdoid tumours	0	0,0%	0	0	0	0
IXd4	Liposarcomas	4	3,3%	0	0	0	4
IXd5	Fibrohistiocytic tumours	28	23,3%	2	2	7	17
IXd6	Leiomyosarcomas	6	5,0%	0	0	2	4
IXd7	Synovial sarcomas	18	15,0%	1	1	5	11
IXd8	Blood vessel tumours	10	8,3%	4	0	0	6
IXd9	Osseous and chondromatous neoplasms of soft tissue	4	3,3%	0	0	3	1
IXd10	Alveolar soft parts sarcomas	2	1,7%	0	0	0	2
IXd11	Miscellaneous soft tissue sarcomas	8	6,7%	1	2	3	2

Trends

European data show an annual increase of 1.8% in the incidence of soft tissue sarcoma. ⁽³⁵⁾ However, in Western Europe this trend could not be observed. The observed incidence rates in the Flemish Region rather seem to decrease slightly (Figure 64), mainly in children. The low number of new diagnoses did not allow a more detailed trend analysis.

Figure 64 Soft tissue sarcoma: age standardized incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006, 2005-2009



Survival

Histology is considered as an important factor in prognosis. (34) In our data, little difference in survival is observed in RMS (82%) versus non-RMS diagnoses (76%)(Figure 65). Although based on small numbers, a larger difference in survival rates is observed within the different RMS subtypes, with higher survival rates for embryonal RMS than for other histological RMS subtypes (Figure 66). Alveolar RMS is mainly responsible for the lower survival rates. Of the 12 children with alveolar RMS included in the survival analysis in Belgium (2004-2009), 5 did not survive more than 2 years.

Figure 65 STS in children and adolescents: observed survival by histology, Belgium 2004-2009





Figure 66 RMS in children and adolescents: observed survival by histology, Belgium 2004-2009



N at risk

	0	1	2	3	4	5
RMS (IXa)	66	61	54	46	36	23
Non-RMS (IXb-e)	117	111	103	78	57	43

N at risk

	0	1	2	3	4	5
Embryonal RMS	45	43	40	36	31	22
Other RMS	21	19	15	11	6	2

Incidence


Germ cell tumours, trophoblastic and other gonadal neoplasms (GCTOG) represent 6% of all tumours in children and adolescents. The majority of the tumours are found in adolescents where they account for 11% of all tumour diagnoses.

In Belgium, 171 new diagnoses are registered between 2004 and 2009 (Table 14). Almost twice as many boys are diagnosed than girls (M/F ratio = 1.7). In adolescents the number of new diagnoses in boys is five-fold the number in girls, corresponding with a male/female ratio of 5.4. However, in children (M/F ratio = 0.5), the opposite is observed with two times more diagnoses in girls than in boys.

Table 14 New diagnoses of GCTOG, Belgium 2004-2009

Boys		Total	0-14	15-19
X	GCTOG	115	20	95
Xa	Intra-cranial / -spinal GCT	22	10	12
Xb	Extra-cranial / -gonadal GCT	6	5	1
Xc	Gonadal GCT	86	5	81
Xd	Gonadal carcinoma	0	0	0
Xe	Other and unspecified	1	0	1
Girls		Total	0-14	15-19
X	GCTOG	56	39	17
Xa	Intra-cranial / -spinal GCT	5	4	1
Xb	Extra-cranial / -gonadal GCT	21	20	1
Xc	Gonadal GCT	24	14	10
Xd	Gonadal carcinoma	4	0	4
Xe	Other and unspecified	2	1	1

Figure 67 GCTOG: relative frequency by age at diagnosis, Belgium 2004-2009



At infancy, GCTOG represent 8% of all cancer diagnoses (Figure 67). In children between the age of 1 and 13 year, the incidence rates are very low. Around the age of 14-15 year incidence rates increase rapidly with age, especially in boys (Figure 68).

Figure 68 GCTOG: age specific incidence rates by sex, Belgium 2004-2009






Figure 69 GCT: age specific incidence rates by primary site, Belgium 2004-2009



GCTOG are subdivided in five main groups according to the cells of origin (germ cells (Xa-c), trophoblastic cells (Xd) or other cells (Xe)). The germ cell tumours (GCT) are further separated by site of origin (gonads (Xc), central nervous system (Xa) or elsewhere (Xb)).

The majority (64%) of GCTOG tumours, occurring among children younger than 20 years of age, are gonadal germ cell tumours (Xc). However, when only children younger than 15 years of age are considered, non-gonadal germ cell tumours (Xa and Xb) are more common than gonadal (Xc) germ cell tumours (Table 14, Figure 69 and Figure 70).

Figure 70 GCTOG by age group, Belgium 2004-2009



Intracranial and intraspinal GCT (Xa) are more frequently diagnosed in older children and adolescents. In the age group 5-9 years GCTOG are very rare (9 diagnoses in Belgium between 2004 and 2009). In this age group, intracranial and intraspinal GCT (Xa), with 5 diagnoses in Belgium between 2004 and 2009, are the most frequent GCTOG subtype (Figure 70).

Almost all intra-cranial/-spinal GCT (Xa) are diagnosed in boys (81%). The male/female ratio is 4.1.

Intracranial GCT are frequently diagnosed in endocrine glands (Table 15). Six diagnoses are registered in the pituitary gland and eight in the pineal gland. The remaining 13 diagnoses are registered as primary brain tumours.

The most frequently diagnosed histological subtype (Figure 71) in boys and girls are germinomas (Xa1) (81%, both sexes combined). The remaining tumours are teratomas (Xa2) or mixed germ cell tumours (Xa6).

Table 15 Intracranial and intraspinal GCT (Xa) in children and adolescents by primary site, Belgium 2004-2009

Primary localisation	N
Cerebrum	2
Cerebral ventricle	3
Brain stem	1
Brain, NOS	7
Pituitary gland	6
Pineal gland	8

Extracranial and extragonadal GCT (Xb) are most frequently diagnosed in infants and very young children (Figure 70). Of the 27 diagnoses, 22 are registered in children younger than 3 years of age.

In contrast with the other GCT (Xa and Xc), where far more boys are diagnosed, the majority of extracranial and extragonadal GCT (Xb) are diagnosed in girls (M/F ratio = 0.3).


Extracranial and extragonadal GCT (Xb) are most frequently diagnosed in the pelvic region (67%). The most frequent histological subtypes are teratomas (Xb2) and yolk sac tumours (Xb4), respectively 44% and 30% when both sexes are combined (Figure 71).

Gonadal GCT (Xc) are by far the most frequent diagnosed GCTOG (64%). In adolescence, more boys (testicular GCT) are diagnosed than girls (ovarian GCT), while in childhood the opposite is observed (Table 14). The male/female ratio is 0.4 in children and 7.8 in adolescents.

The majority of testicular GCT (Figure 71) are of mixed origin (Xc6; 31%), embryonal carcinoma (Xc3; 24%) and teratoma (Xc2; 23%). 94% of gonadal GCT are diagnosed in adolescents. In children, only five testicular GCT are diagnosed, three yolk sac tumours and two immature teratomas.

Diagnoses of ovarian GCT (Figure 71) are predominantly teratoma (Xc2; 50%). Two out of three ovarian teratoma diagnoses occurred in children.

Figure 71 Germ cell tumours (Xa-c) by histology and sex, Belgium 2004-2009




Gonadal carcinomas (Xd) are a rare malignancy in children and adolescents. In Belgium, between 2004 and 2009, only 4 adolescent girls are diagnosed with an ovarian gonadal carcinoma.

The remaining GCTOG diagnoses, **other and unspecified malignant gonadal tumours (Xe)**, are very rare. Only three diagnoses of Sertoli-Leydig cell tumour are registered in this category in Belgium between 2004 and 2009.

Trends


When comparing the incidence data over time in the Flemish Region, an increase in age standardised incidence (WSR) can be observed. This increase can almost entirely be attributed to an increase in testicular cancer (Xc) in adolescents. The increase in incidence of adolescent testicular germ cell tumours is comparable to the increase in testicular cancer observed in young adult males.⁽³⁾ In children, incidence rates for GCTOG(X) seem to decrease slightly (Figure 72), but due to the low incidence rates, analyses on trends are not possible.

Figure 72 GCTOG in boys: age standardised incidence (WSR) by age group and primary localisation, Flemish Region 1999-2003, 2002-2006, 2005-2009



In girls, due to the low number of new diagnoses, trends for GCTOG(X) are not clear (Figure 73).

Figure 73 GCTOG in girls: age standardised incidence (WSR) by age group and primary localisation, Flemish Region 1999-2003, 2002-2006, 2005-2009



XI CARCINOMAS AND OTHER MALIGNANT EPITHELIAL NEOPLASMS


Incidence

Carcinomas are the most common histological cancer type in adults. Nevertheless, a variety of malignant epithelial neoplasms do occur in children and adolescents. In Belgium, between 2004 and 2009, 127 children and 239 adolescents are diagnosed with an malignant epithelial neoplasm. Almost two out of three carcinomas are diagnosed in girls (Table 16). For all tumour sites, with the exception of lung (XIf4), colon and rectum (XIf2) and nasopharyngeal carcinomas (XIc), incidence rates for girls are higher than for boys (Figure 74). All carcinomas combined, the male/female ratio is 0.6.

Table 16 New diagnoses of malignant epithelial neoplasms, Belgium 2004-2009

Boys		Total	0-14	15-19
XI	Malignant epithelial neoplasms	144	54	90
XIa	Adrenocortical carcinomas	1	1	0
XIb	Thyroid	21	6	15
XIc	Nasopharyngeal carcinomas	5	4	1
XId	Malignant melanomas	36	13	23
XIe	Skin (non melanoma)	19	6	13
XIf1	Salivary glands	3	3	0
XIf2	Colon and rectum	7	2	5
XIf3	Appendix	39	16	23
XIf4	Lung	8	2	6
XIf10-11	Other and unspecified	5	1	4
Girls		Total	0-14	15-19
XI	Malignant epithelial neoplasms	222	73	149
XIa	Adrenocortical carcinomas	1	0	1
XIb	Thyroid	41	12	29
XIc	Nasopharyngeal carcinomas	3	2	1
XId	Malignant melanomas	54	12	42
XIe	Skin (non melanoma)	38	20	18
XIf1	Salivary glands	9	4	5
XIf2	Colon and rectum	4	0	4
XIf3	Appendix	55	21	34
XIf4	Lung	6	1	5
XIf6	Breast	3	0	3
XIf7	Cervix uteri	1	0	1
XIf10-11	Other and unspecified	7	1	6

Figure 74 Malignant epithelial neoplasms: age standardised incidence (WSR) by primary localisation and sex, Belgium 2004-2009



This diverse group of malignant epithelial neoplasms is the 5th most frequent tumour in children and the 2nd most frequent in adolescents. In young children carcinomas are very rare. In late childhood, the incidence rates increase sharply with age. In adolescents, they account for 23% of all malignancies (Figure 75 and Figure 76).

Figure 75 Malignant epithelial neoplasms: relative frequency by age at diagnosis, Belgium 2004-2009






Figure 76 Malignant epithelial neoplasms: age specific incidence rates by sex, Belgium 2004-2009




The most frequent malignant epithelial neoplasms are endocrine tumours (carcinoids) of the **appendix (XIf3)**. This tumour is most commonly discovered by coincidence during routine appendectomy, where they are found in 0.3-0.9% of patients. ^{(36) (37)} Between 2004 and 2009, a total of 94 diagnoses are registered in Belgium, 39 in boys and 55 in girls (M/F ratio = 0.7). Carcinoids of the appendix (XIf3) are very rare in children younger than 10 years of age. In the age group 5-9 years of age, only 8 carcinoid tumours of the appendix (XIf3) are diagnosed, 6 boys and 2 girls (M/F ratio = 2.8). The incidence rates increase with age (Figure 77). After the age of 10 years, more girls are diagnosed than boys (M/F ratio is 0.5 for the age group 10-14 years and 0.6 in the age group 15-19 years).



Worldwide, registration practices for carcinoid tumours of the appendix vary between registries. This variation is considered a potential source of artifact when comparing data between regions. ⁽³⁷⁾ The Belgian Cancer Registry includes all carcinoids of the appendix, regardless of size. Recent updates in the ICD-O3 classification ⁽⁷⁾ published by the WHO ⁽³⁸⁾, include any carcinoid of the appendix in the list of malignant neoplasms.

An important parameter determining prognosis of carcinoids is the size of the tumour (Figure 78). Information on size is available in 67 cases (27 boys and 40 girls). The median size is 7mm (range 1.5mm – 22mm). In 76%, 21% and 3% of cases the diameter is $\leq 10\text{mm}$, $>10\text{mm}-20\text{mm}$ and $>20\text{mm}$ respectively. Tumours diagnosed in girls (median size = 7.5mm [range 1.5mm – 22mm]) are often larger than in boys (median size = 7mm [range 2mm – 15mm]). In girls 28% of the carcinoid diagnoses in girls are larger than 10mm, while in boys this is only 19%.



The 2nd most frequent malignant epithelial neoplasm is **malignant melanoma (X1d)**. For the period 2004-2009, a total of 90 cases of melanoma are diagnosed in Belgium (Table 16), 36 boys and 54 girls (M/F ratio = 0.7). In children, no difference is observed between the sexes (13 boys and 12 girls, M/F ratio = 1.1) (Figure 79). In adolescents the diagnosis of melanoma is made more frequently in girls (N = 42) than in boys (N=23) (M/F ratio = 0.5).

Figure 79 Malignant melanoma (X1d): age specific incidence by sex, Belgium 2004-2009






Figure 80 Malignant melanoma (X1d): distribution by primary site and sex, Belgium 2004-2009



In boys, melanoma more often occur on the trunk and the head, while in girls more melanoma are diagnosed on the upper and lower limbs (Figure 80). This preferential tumour localisation is comparable with the site distribution in adults.⁽³⁾

For the 90 melanoma diagnoses in Belgium, information on stage is available in 72 of the cases. For registrations between 2004 and 2009, stage is classified by means of the 6th edition of the UICC TNM.⁽⁴²⁾ After excision, the extent of melanoma can be classified by a pathological assessment of the primary tumour (pT-category). Figure 81 shows an overview of the distribution of cancers with a known pT-stage. The majority (68%) of the cases with known pathological T-value is pT1 in both sexes. The pT2, pT3 and pT4 melanoma diagnoses account for

respectively 17%, 11% and 7%. Between boys and girls a different stage distribution is observed (Figure 81). In boys 24% of the diagnoses are pT3-4, while in girls this is only 14%. Staging of the primary tumour (pT) in melanoma relies on information on the tumour thickness and ulceration. ⁽⁴⁰⁾ The exact tumor thickness, also known as Breslow index, is known in 56 of the melanoma diagnoses (22 boys and 34 girls) (Figure 82). The median Breslow index (both sexes) is 0.67mm (range 0.17-6.08mm). Melanoma diagnosed in boys are generally thicker in size (median Breslow index = 0.89mm [range 0.17-5mm]) than tumours in girls (median Breslow index = 0.58mm [range 0.22-6.08]).



The 3rd most frequent malignant epithelial neoplasms are **thyroid carcinomas (X1b)**. In Belgium, 62 new cases are diagnosed between 2004 and 2009 (Table 16). Two times more girls (N = 41) are diagnosed with thyroid cancer than boys (N = 21). In children under the age of 10 years, thyroid cancers are rare. From the age of 10 years, incidence rates increase rapidly in boys and girls (Figure 83).

Histologically, four main types of thyroid carcinoma are distinguished (Figure 84). Papillary carcinoma are the most frequent subtype (68%). Follicular carcinoma and medullary carcinoma account for respectively 22% and 8% of the thyroid cancers. In Belgium, anaplastic carcinoma, the fourth main thyroid carcinoma type, is not observed in children and adolescents between 2004 and 2009.

Figure 83 Thyroid cancer (X1b): age specific incidence rates by sex, Belgium 2004-2009





Figure 84 Thyroid cancer (X1b) by histology, Belgium 2004-2009



Non-melanoma skin cancers (IXe) are the 4th most frequent malignant epithelial neoplasm. Between 2004 and 2009, 57 new cases (19 boys and 38 girls) are registered (Table 16). Under the age of 10, non-melanoma skin cancers (IXe) are rare. Only 8 new diagnoses (3 boys and 5 girls, M/F ratio = 0.6) are observed. In older children (age 10-14 year), especially in girls, an increase in the incidence rates is observed (Figure 85). In total, 18 cases (3 boys and 15 girls, M/F ratio = 0.2) are registered in this age group. In adolescents, 31 new diagnoses (13 boys and 18 girls, M/F ratio = 0.7) are registered. The majority of the non-melanoma skin tumours (IXe) are basocellular carcinomas (81%). Squamous cell carcinoma account for 14% (Figure 86). These tumours were subjected to a profound quality assessment. For every skin carcinoma, the corresponding pathology report has been reevaluated to ensure correct diagnosis.

Figure 85 Non melanoma skin cancer (IXe): age specific incidence rates by sex, Belgium 2004-2009






Figure 86 Non melanoma skin cancer (IXe) by histology, Belgium 2004-2009




The remaining epithelial neoplasms are very rare and no detailed analysis is performed for these tumour sites.

Trends

In children the incidence rates for malignant epithelial neoplasms in the Flemish Region seem to decrease slightly in girls (Figure 87). The decrease in girls can be related to the lower incidence rates in thyroid cancer (XIb) and malignant melanoma (XIId) in the period 2005-2009. Non-melanoma skin cancer (XIE) increases in girls. In boys, an increase is observed for malignant melanoma (XIId).



The main trend for all malignant epithelial neoplasms (XI) in adolescents (Figure 88) is comparable with the trend observed in children. In girls the incidence rates for malignant epithelial neoplasms (XI) seem to decrease, while no trend is observed in boys. Thyroid cancer (XIb) increases in boys and girls.



Survival

Malignant epithelial neoplasms (XI) have a very good prognosis. In children, (Figure 89) the 5 year survival rates in boys (89%) are significantly lower than the rates observed in girls (99%). In adolescents (Figure 90), the prognosis for boys and girls is comparable with respectively 96% and 97% 5 year survival rates.

Figure 89 Malignant epithelial neoplasms in children: observed survival by sex, Belgium 2004-2009





Figure 90 Malignant epithelial neoplasms in adolescents: observed survival by sex, Belgium 2004-2009



N at risk

Boys	50	48	47	41	35	25
Girls	68	68	67	58	48	36

N at risk

Boys	82	80	80	63	50	34
Girls	142	140	139	111	88	64

Cancer in Infants

Between 2004 and 2009, 201 tumours are diagnosed in the first year of life. Cancer in infants represents 11% of all childhood (0-14 years) cancer diagnoses.

Neuroblastomas (IV; N=49) are the most frequent tumour type. They represent 24% of all tumours in infants. CNS tumours (III; N=40) are the 2nd most frequent cancer among infants, representing 20%. Leukaemia (I; N=24), retinoblastoma (V; N=23) and germ cell tumours (X; N=16) complete the five most frequently occurring tumours (Figure 91).

Figure 91 Infants: age specific incidence rates by histology, Belgium 2004-2009





Figure 92 Infants: new diagnoses by month of age at diagnosis, Belgium 2004-2009



About 1 out of every 5 cancer in infants is diagnosed in the first month of life. Some of these tumours are possibly already detected in utero (Figure 92).

Figure 93 All tumours: observed survival by age group, Belgium 2004-2009





Figure 94 Observed survival by histology and age group, Belgium 2004-2009



N at risk

Infants (<1 year)	191	169	10	130	104	83
Children and adolescents (1-19 year)	2665	2515	2388	1920	1505	1129


Overall survival for infants (82%) is slightly poorer than for children and adolescents (86%) (Figure 93). Prognosis is largely dependent on the histological subtype (Figure 94). Neuroblastoma had a very good prognosis in infants (96% 5 year survival), while for children and adolescents 5 year survival is 61%. For brain tumours, the survival rates are somewhat less favourable for infants when compared to other children and adolescents (respectively 69% and 82%). In leukaemia the survival rates for infants (44%) are far worse than for the other ages (83%).

- (1) Koninklijk Besluit houdende vaststelling van de normen waaraan het zorgprogramma voor oncologische basiszorg en het zorgprogramma voor oncologie moeten voldoen om te worden erkend. Belgisch Staatsblad, 21 maart 2003.
Arrêté Royal: Fixe les normes auxquelles les programmes de soins de base en oncologie et les programmes de soin en oncologie doivent répondre pour être agréés. Moniteur Belge, 21 mars 2003.
- (2) Wet houdende diverse bepalingen betreffende gezondheid van 13 december 2006, artikel 39. Belgisch Staatsblad, 22 december 2006.
Loi portant dispositions diverses en matière de santé du 13 décembre 2006, article 39. Moniteur Belge, 22 décembre 2006.
- (3) Cancer Incidence in Belgium, 2008. Belgian Cancer Registry, Brussels 2011.
- (4) Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer 2005, Vols. 103: 1457-1467.
- (5) WHO. International Classification of Diseases and health-related problems-10th revision. Second edition. Geneva: WHO, 2004.
- (6) http://statbel.fgov.be/nl/statistieken/cijfers/bevolking/sterfte_leven/oorzaken/index.jsp. Belgium: Directorate-general Statistics and Economic information.
- (7) International Classification of Diseases for Oncology (ICD-O3), third edition. Geneva: WHO, 2000.
- (8) <http://www.ksz-bcss.fgov.be/>. [Online] Crossroads Bank for Social Security (CBSS).
- (9) Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statist Ass 1958, 53: 457-481.
- (10) Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978, Vols. 31: 557-560.
- (11) Steliarova-Foucher E, Stiller Ch, Kaatsch P et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project). An epidemiological study. Lancet 2004, Vols. 364: 2097-2105.
- (12) World Health Organization, mortality database. [Online] WHO. [Cited: 25 March 2011.] <http://www.who.int/whosis/mort/download/en/index.html>.
- (13) United Nations, World Population Prospects, the 2008 revision <http://www.un.org/esa/population/unpop.htm>.
- (14) Statistiek van de doodsoorzaken [Online publicatie]. <http://www.zorg-en-gezondheid.be/Cijfers/Sterftcijfers/>. Brussel : Vlaams Agentschap Zorg en Gezondheid, afdeling informatie en ondersteuning, Team Gegevensverwerking en Resultaatsopvolging, 2011.
- (15) Bulletins statistiques de décès. Bruxelles : Observatoire de la Santé et du Social de Bruxelles, 2008.
- (16) Bulletins statistiques de décès. Ministère de la Communauté française : Direction générale de la Santé-Cellule des statistiques des naissances et des décès, 2008.
- (17) Pinkel D. Five year follow up of 'total therapy' of childhood lymphocytic leukaemia. JAMA 1971, Vols. 216: 648-652.
- (18) Coebergh JW, Reedijk AM, de Vries E et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, Vols. 42: 2019-2036.
- (19) Smith MA, Gloeckler Ries LA, Gurney JG, Ross JA. Leukemia. [book auth.] Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. Bethesda: MD, Pub. No. 99-4649, 1999.
- (20) Trueworthy R, Shuster J, Look T et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group Study. J Clin Oncol 1992, Vols. 10: 606-613.


- (21) Rubnitz JE, Downing JR, Pui CH et al. TELgene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. *J Clin Oncol* 1997, Vols. 15: 1150-1157.
- (22) Rubnitz JE, Link MP, Shuster JJ et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood* 1994, Vols. 84: 570-573.
- (23) Rubnitz JE, Shuster JJ, Land VJ et al. Casecontrol study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. *Blood* 1997, Vols. 89: 1143-1146.
- (24) Hilden JM, Frestedt JL, Moore RO et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). *Blood* 1995, Vols. 86: 3876-3882.
- (25) Clavel J, Steliarova-Foucher E, Berger C et al. Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the ACCIS project. *Eur J Cancer* 2006, Vols. 42: 2037-2049.
- (26) Izarzugaza MI, Steliarova-Foucher E, Martos C, Zivkovic S. Non-Hodgkin Lymphomas incidence and survival in European children and adolescents (1978-1997): report from the ACCIS project. *Eur J Cancer* 2006, Vols. 42: 2050-2063.
- (27) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System, Fourth Edition. Lyon: IARC, 2007.
- (28) Peris-Bonet R, Martínez-García C, Lacour B et al. Childhood central nervous system tumours. Incidence and survival in Europe (1978-1997): report from the ACCIS project. *Eur J Cancer* 2006, Vols. 42: 2064-2080.
- (29) Stiller CA, Desandes E, Danon SE et al. Cancer incidence and survival in European adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006, Vols. 42: 2006-2018.
- (30) Brodeur GM, Sawada T, Tsuchida Y, Voute P. Neuroblastoma. Elsevier science BV. 2000.
- (31) Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. *Nat Rev Cancer* 2003, Vols. 3: 203-216.
- (32) Evans AE, D'Angio GJ. Age at diagnosis and prognosis in children with neuroblastoma. *J Clin Oncol* 2005, Vols. 23: 6443-6444.
- (33) Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the ACCIS project. *Eur J Cancer* 2006, Vols. 42: 2124-2135.
- (34) Pastore G, Peris-Bonet R, Carli M et al. Childhood soft tissue sarcomas incidence and survival in European children (1978-97): report from ACCIS project. *Eur J Cancer* 2006, Vols. 42: 2136-2149.
- (35) In't Hof KH, van der Wal HC, Kazemier G, Lange J.F. Carcinoid Tumour of the Appendix: An Analysis of 1,485 Consecutive Emergency Appendectomies. *J Gastrointest Surg* 2008, Vols. 12: 1436-1438.
- (36) Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System, Fourth Edition. Lyon: IARC WHO Classification of Tumours, No 3, 2010.
- (37) Steliarova-Foucher E, Kaatsch P, Lacour B et al. Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978-1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006, Vols. 42: 1915-1951.
- (38) WHO. WHO Classifications of diseases (ICD). List of ICD-O-3 updates - Updates 2011. [Online] [Cited: 6 April 2012.] <http://www.who.int/entity/classifications/icd/updates/ICDO3Updates2011.pdf>.
- (39) Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, International Union Against Cancer 6th edition, Wiley-Liss, Geneva, 2002.

- (40) [Online] Union for International Cancer Control (UICC). [Cited: 6 April 2012.] <http://www.uicc.org/>.
- (41) Ford AM, Bennett CA, Price CM et al. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. *Proc Natl Acad Sci USA* 1998, Vols. 95: 4584-4588.
- (42) Gale KB, Ford AM, Repp R et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. *Proc Natl Acad Sci USA* 1997, Vols. 94: 13950-13954.
- (43) Jawad MU, Cheung MC, Min ES et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. *Cancer* 2009, Vols. 115: 3526-3536.
- (44) Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. *Br J Cancer* 1977, Vols. 35: 1-39.
- (45) Smith M, Chen T, Simon R. Age-specific incidence of acute lymphoblastic leukemia in U.S. children: in utero initiation model. *J Natl Cancer Inst* 1997, Vols. 89: 1542-1544.
- (46) Spix C, Pastore G, Sankila R et al. Neuroblastoma incidence and survival in European children (1978-1997): report from the ACCIS-project. *Eur J Cancer* 2006, Vols. 42: 2081-2091.


Appendix 1: Notifications by source type in children and in adolescents, Belgium 2004-2009




0-14 years




15-19 years




Retinoblastoma: notifications by source type (N=64)




Retinoblastoma: notifications by source type (N=0)



Renal Tumours: notifications by source type (N=102)




Renal Tumours: notifications by source type (N=6)




0-14 years

**Hepatic tumours:
notifications by source type (N=11)**




15-19 years


**Hepatic tumours:
notifications by source type (N=1)**




**Malignant bone tumours:
notifications by source type (N=99)**




**Malignant bone tumours:
notifications by source type (N=77)**




**Soft tissue and other extrasosseous sarcomas:
notifications by source type (N=105)**




**Soft tissue and other extrasosseous sarcomas:
notifications by source type (N=83)**




0-14 years




15-19 years



Other malignant epithelial neoplasms and malignant melanomas: notifications by source type (N=127)



Other malignant epithelial neoplasms and malignant melanomas: notifications by source type (N=239)



Belgium: Boys, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009

Belgium: Boys 2004-2009	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
VIII: Malignant bone tumours	100	-	-	1	-	1	2	-	4	1	5	6	7	3	11	10	8	16	2	11	10
VIIIa: Osteosarcomas	50	-	-	-	-	-	-	-	-	3	2	5	-	7	6	7	9	2	5	4	4
VIIIb: Chondrosarcomas	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-	2
VIIIc: Ewing tumours and related sarcomas of bone	42	2	-	1	-	2	-	3	1	2	3	2	3	4	4	-	6	-	6	3	3
VIII.d: Other specified malignant bone tumours	3	-	-	-	1	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	1
VIIIe: Unspecified malignant bone tumours	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
IX: Soft tissue and other extraosseous sarcomas	106	9	8	5	6	2	1	1	3	2	1	3	6	8	4	7	5	8	13	7	7
IXa: Rhabdomyosarcomas	44	6	7	3	5	1	1	1	1	1	2	1	1	1	3	3	3	2	1	1	1
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	10	2	1	-	-	-	-	-	-	-	-	2	-	1	2	-	1	-	-	-	1
IXc: Kaposi sarcomas	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IXd: Other specified soft tissue sarcomas	42	1	-	2	1	1	-	2	1	-	-	2	7	1	2	1	3	9	5	4	4
IXe: Unspecified soft tissue sarcomas	9	-	-	-	-	-	-	1	-	1	1	1	-	-	-	1	1	2	1	1	1
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	115	7	1	1	-	-	1	-	-	2	-	2	2	1	3	10	15	19	20	20	31
Xa: Intracranial and intraspinal germ cell tumours	22	1	-	-	-	-	1	-	-	2	-	2	1	1	2	5	2	1	-	-	4
Xb: Malignant extracranial and extragonadal germ cell tumours	6	3	-	1	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1
Xc: Malignant gonadal germ cell tumours	86	3	1	-	-	-	-	-	-	-	-	-	1	-	-	5	13	18	20	25	25
Xd: Gonadal carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xe: Other and unspecified malignant gonadal tumours	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
XI: Other malignant epithelial neoplasms and malignant melanomas	144	-	1	-	-	1	1	-	2	8	5	4	1	4	15	12	11	14	20	15	30
XIa: Adenocortical carcinomas	1	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-
XIb: Thyroid carcinomas	21	-	-	-	-	-	-	-	1	-	-	-	-	4	1	1	3	4	3	4	4
XIc: Nasopharyngeal carcinomas	5	-	-	-	-	-	-	-	-	1	-	-	1	1	1	-	-	-	-	-	1
XId: Malignant melanomas	36	-	1	-	-	1	-	1	2	1	1	-	1	1	4	5	4	3	2	9	9
XIe: Skin carcinomas	19	-	-	-	-	-	-	1	1	1	1	-	1	1	1	-	4	2	2	2	5
XIf: Other and unspecified carcinomas	62	-	-	-	-	-	1	-	4	3	1	1	1	1	8	5	5	3	11	8	11
XII: Other and unspecified malignant neoplasms	3	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
XIIa: Other specified malignant tumours	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XIIb: Other unspecified malignant tumours	2	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
I-XII: All tumours	1,628	108	90	105	92	65	50	51	57	59	50	59	60	48	80	79	97	114	114	113	137

Belgium: Boys, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)

Belgium: Boys 2004-2009	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
Tot	100	5.5	-	2.8	-	2.8	-	11.0	2.7	13.7	16.2	18.6	7.9	28.5	25.6	20.3	40.7	5.1	28.5	26.2
VIII: Malignant bone tumours	50	-	-	-	-	-	-	-	-	8.2	5.4	13.3	-	18.1	15.4	17.8	22.9	5.1	12.9	10.5
VIIIa: Osteosarcomas	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.5	2.5	-	-	5.2
VIIIb: Chondrosarcomas	42	5.5	-	2.8	-	5.6	-	8.3	2.7	5.5	8.1	5.3	7.9	10.4	10.2	-	15.3	-	15.5	7.8
VIIIc: Ewing tumours and related sarcomas of bone	3	-	-	-	-	-	-	-	-	-	2.7	-	-	-	-	-	-	-	-	2.6
VIIId: Other specified malignant bone tumours	1	-	-	-	-	-	-	2.8	-	-	-	-	-	-	-	-	-	-	-	-
VIIIe: Unspecified malignant bone tumours	106	24.6	22.0	19.9	16.7	5.6	2.8	8.3	5.5	2.7	8.1	16.0	21.0	10.4	17.9	12.7	20.3	33.2	18.1	18.3
IX: Soft tissue and other extraosseous sarcomas	44	16.4	19.3	8.3	13.9	2.8	2.8	-	2.7	2.7	5.4	2.7	2.6	2.6	7.7	7.6	7.6	5.1	2.6	2.6
IXa: Rhabdomyosarcomas	10	5.5	2.8	-	-	-	-	-	-	-	-	5.3	-	2.6	5.1	-	2.5	-	-	2.6
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	1	-	-	-	-	-	-	-	-	-	-	-	-	2.6	-	-	-	-	-	-
IXc: Kaposi sarcomas	42	2.7	-	5.5	2.8	2.8	-	5.5	2.7	-	-	5.3	18.4	2.6	5.1	2.5	7.6	23.0	12.9	10.5
IXd: Other specified soft tissue sarcomas	9	-	-	-	-	-	-	2.8	-	-	2.7	2.7	-	-	-	2.5	2.5	5.1	2.6	2.6
IXe: Unspecified soft tissue sarcomas	115	19.1	2.8	2.8	-	-	2.8	-	-	5.5	-	5.3	5.2	2.6	7.7	25.4	38.1	48.6	51.8	81.1
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	22	2.7	-	-	-	-	2.8	-	-	5.5	-	5.3	2.6	2.6	5.1	12.7	5.1	2.6	-	10.5
Xa: Intracranial and intraspinal germ cell tumours	6	8.2	-	2.8	-	-	-	-	-	-	-	-	-	-	2.6	-	-	-	-	2.6
Xb: Malignant extracranial and extragonadal germ cell tumours	86	8.2	2.8	-	-	-	-	-	-	-	-	-	2.6	-	-	12.7	33.1	46.0	51.8	65.4
Xc: Malignant gonadal germ cell tumours	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xd: Gonadal carcinomas	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xe: Other and unspecified malignant gonadal tumours	144	-	2.8	-	-	2.8	-	5.5	22.0	13.7	10.8	2.7	10.5	38.8	30.7	28.0	35.6	51.1	38.8	78.5
XI: Other malignant epithelial neoplasms and malignant melanomas	1	-	-	-	-	-	-	-	-	-	-	-	2.6	-	-	-	-	-	-	-
XIa: Adrenocortical carcinomas	21	-	-	-	-	-	-	-	2.7	-	-	-	-	10.4	2.6	2.5	7.6	10.2	7.8	10.5
XIb: Thyroid carcinomas	5	-	-	-	-	-	-	-	-	2.7	-	-	2.6	2.6	2.6	-	-	-	-	2.6
XIc: Nasopharyngeal carcinomas	36	-	2.8	-	-	2.8	-	2.8	5.5	2.7	2.7	-	2.6	2.6	10.2	12.7	10.2	7.7	5.2	23.5
XId: Malignant melanomas	19	-	-	-	-	-	-	2.8	2.7	2.7	2.7	-	-	2.6	2.6	-	10.2	5.1	5.2	13.1
XIe: Skin carcinomas	62	-	-	-	-	-	2.8	-	11.0	8.2	2.7	2.7	2.6	20.7	12.8	12.7	7.6	28.1	20.7	28.8
XIf: Other and unspecified carcinomas	3	5.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.5	-	-	-
XII: Other and unspecified malignant neoplasms	1	2.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XIIa: Other specified malignant tumours	2	2.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.5	-	-	-
XIIb: Other unspecified malignant tumours	1,628	294.6	247.6	291.0	256.1	181.8	139.8	141.7	157.2	162.0	136.8	159.7	159.8	207.1	202.3	246.6	289.9	291.5	292.7	358.5

Belgium: Girls, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009

Belgium: Girls 2004-2009	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
VIII: Malignant bone tumours	76	-	2	-	1	-	1	-	3	3	3	10	7	5	10	13	5	3	6	3
VIIIa: Osteosarcomas	36	-	-	-	-	-	-	1	-	2	2	6	4	3	4	6	2	1	4	1
VIIIb: Chondrosarcomas	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	1
VIIIc: Ewing tumours and related sarcomas of bone	33	-	2	-	1	-	1	-	3	1	1	4	3	1	6	6	1	1	2	-
VIII d: Other specified malignant bone tumours	2	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-
VIII e: Unspecified malignant bone tumours	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1
IX: Soft tissue and other extraosseous sarcomas	82	4	2	3	4	2	4	2	1	3	2	2	2	1	3	4	3	6	10	11
IXa: Rhabdomyosarcomas	24	-	2	2	4	2	3	2	-	2	2	1	1	-	-	1	1	-	-	1
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	7	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	2	1	1
IXc: Kaposi sarcomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IXd: Other specified soft tissue sarcomas	51	3	-	1	-	1	-	1	1	-	1	1	1	3	4	2	3	8	10	11
IXe: Unspecified soft tissue sarcomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	56	9	6	3	1	-	2	2	2	2	3	2	2	2	5	2	6	4	2	3
Xa: Intracranial and intraspinal germ cell tumours	5	-	-	-	-	-	-	1	1	-	1	-	-	-	1	-	1	-	-	-
Xb: Malignant extracranial and extragonadal germ cell tumours	21	9	6	3	1	-	1	-	-	-	-	-	-	-	-	-	-	-	-	1
Xc: Malignant gonadal germ cell tumours	24	-	-	-	-	-	1	1	1	-	2	1	2	2	4	2	4	2	1	1
Xd: Gonadal carcinomas	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1
Xe: Other and unspecified malignant gonadal tumours	2	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	-	-
XI: Other malignant epithelial neoplasms and malignant melanomas	222	1	-	-	2	1	2	2	2	5	7	9	10	14	16	29	18	28	36	38
XIa: Adrenocortical carcinomas	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-
XIb: Thyroid carcinomas	41	-	-	-	-	-	-	1	-	1	1	-	1	7	1	8	2	4	4	11
XIc: Nasopharyngeal carcinomas	3	-	-	-	-	-	-	1	-	-	-	1	-	-	-	1	-	-	-	-
XId: Malignant melanomas	54	-	-	1	1	-	1	-	1	3	1	1	1	-	3	3	5	8	14	12
XIe: Skin carcinomas	38	-	-	-	1	-	1	-	1	1	2	2	2	3	6	5	3	2	5	3
XIf: Other and unspecified carcinomas	85	1	-	-	-	1	-	-	1	2	1	5	6	4	6	12	7	14	13	12
XII: Other and unspecified malignant neoplasms	7	1	-	-	-	-	-	-	-	1	-	-	-	-	1	-	-	2	1	1
XIIa: Other specified malignant tumours	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	1	1
XIIb: Other unspecified malignant tumours	3	1	-	-	-	-	-	-	1	-	-	-	-	-	1	-	-	-	-	-
I-XII: All tumours	1,345	93	81	82	69	44	55	36	34	36	38	48	50	54	70	97	76	87	110	115

Belgium: Girls, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)

Belgium: Girls 2004-2009	Tot	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
VIII: Malignant bone tumours	76	-	5.8	-	2.9	-	2.9	-	2.9	8.6	8.6	8.5	27.9	19.2	13.5	26.8	34.6	13.3	8.0	16.2	8.1
VIIIa: Osteosarcomas	36	-	-	-	-	-	-	-	2.9	-	5.7	5.7	16.7	11.0	8.1	10.7	15.9	5.3	2.7	10.8	2.7
VIIIb: Chondrosarcomas	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7	-	2.7	-	2.7
VIIIc: Ewing tumours and related sarcomas of bone	33	-	5.8	-	2.9	-	2.9	-	-	8.6	2.9	2.8	11.1	8.2	2.7	16.1	15.9	2.7	2.7	5.4	-
VIIId: Other specified malignant bone tumours	2	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7	-	-	-	-	-	-
VIIIe: Unspecified malignant bone tumours	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7	-	2.7
IX: Soft tissue and other extraosseous sarcomas	82	11.5	5.8	8.7	11.7	5.8	11.7	5.8	2.9	8.6	5.7	5.7	5.6	2.7	8.1	10.7	8.0	16.0	26.8	29.7	35.1
IXa: Rhabdomyosarcomas	24	-	5.8	5.8	11.7	5.8	8.8	5.8	-	5.7	5.7	2.8	2.8	-	-	-	2.7	-	2.7	-	2.7
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	7	2.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.3	5.4	2.7
IXc: Kaposi sarcomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IXd: Other specified soft tissue sarcomas	51	8.6	-	2.9	-	-	2.9	-	2.9	2.9	-	2.8	2.8	2.7	8.1	10.7	5.3	8.0	21.4	27.0	29.7
IXe: Unspecified soft tissue sarcomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	56	25.8	17.3	8.7	2.9	-	5.8	5.7	5.7	5.7	-	8.5	5.6	5.5	5.4	13.4	5.3	16.0	10.7	5.4	8.1
Xa: Intracranial and intraspinal germ cell tumours	5	-	-	-	-	-	-	-	2.9	2.9	-	2.8	-	-	-	2.7	-	-	2.7	-	-
Xb: Malignant extracranial and extragonadal germ cell tumours	21	25.8	17.3	8.7	2.9	-	2.9	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7
Xc: Malignant gonadal germ cell tumours	24	-	-	-	-	-	2.9	2.9	2.9	2.9	-	5.7	2.8	5.5	5.4	10.7	5.3	10.6	5.4	2.7	2.7
Xd: Gonadal carcinomas	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7	2.7	2.7
Xe: Other and unspecified malignant gonadal tumours	2	-	-	-	-	-	-	-	-	-	-	-	2.8	-	-	-	-	-	-	2.7	-
XI: Other malignant epithelial neoplasms and malignant melanomas	222	2.9	-	-	5.8	2.9	5.8	5.8	5.7	5.7	14.3	19.8	25.1	27.4	37.9	42.9	77.1	47.9	75.0	97.1	102.7
XIa: Adrenocortical carcinomas	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.7	-	-
XIb: Thyroid carcinomas	41	-	-	-	-	-	-	-	2.9	-	2.9	2.8	-	2.7	19.0	2.7	21.3	5.3	10.7	10.8	29.7
XIc: Nasopharyngeal carcinomas	3	-	-	-	-	-	-	-	2.9	-	-	-	2.8	-	-	-	-	-	-	-	-
XId: Malignant melanomas	54	-	-	-	2.9	2.9	-	2.9	-	-	2.9	8.5	2.8	2.7	-	8.0	8.0	13.3	21.4	37.7	32.4
XIe: Skin carcinomas	38	-	-	-	2.9	2.9	-	2.9	-	2.9	2.9	5.7	5.6	5.5	8.1	16.1	13.3	8.0	5.4	13.5	8.1
XIf: Other and unspecified carcinomas	85	2.9	-	-	-	-	2.9	-	-	2.9	5.7	2.8	13.9	16.5	10.8	16.1	31.9	18.6	37.5	35.0	32.4
XII: Other and unspecified malignant neoplasms	7	2.9	-	-	-	-	-	-	-	-	2.9	-	-	-	-	2.7	-	-	5.4	2.7	2.7
XIIa: Other specified malignant tumours	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.4	2.7
XIIb: Other unspecified malignant tumours	3	2.9	-	-	-	-	-	-	-	-	2.9	-	-	-	-	2.7	-	-	-	-	-
I-XII: All tumours	1,345	266.2	233.3	237.7	201.0	128.5	160.5	104.4	97.7	103.1	108.7	135.8	139.3	148.1	189.6	187.7	257.9	202.3	232.9	296.6	310.7

Belgium: age-standardised incidence rates of cancer in children and adolescents, by tumour type and sex in 2004-2009 (N/1,000,000 person years)

Belgium: 2004-2009	Boys (0-14 years)						Girls (0-14 years)						Boys (0-19 years)						Girls (0-19 years)						
	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI
I: Leukaemias, myeloproliferative and myelodysplastic diseases	290	52.5	54.2	55.5	0.079	210	39.8	41.0	41.8	0.060	362	48.5	50.1	51.3	0.098	263	36.8	38.0	38.8	0.074	189	26.4	27.6	28.4	0.054
Ia: Lymphoid leukaemias	236	42.7	44.2	45.4	0.065	162	30.7	31.7	32.4	0.046	273	36.6	38.1	39.4	0.074	53	7.4	7.5	7.6	0.015	51	6.8	6.9	6.9	0.014
Ib: Acute myeloid leukaemias	31	5.6	5.8	6.0	0.008	37	7.0	7.1	7.3	0.011	14	1.9	1.8	1.7	0.004	11	1.5	1.4	1.3	0.003	11	1.5	1.4	1.5	0.003
Ic: Chronic myeloproliferative diseases	5	0.9	0.9	0.8	0.001	3	0.6	0.5	0.5	0.001	21	2.8	2.8	2.8	0.006	10	1.4	1.5	1.5	0.003	3	0.4	0.4	0.4	0.001
Id: Myelodysplastic syndromes and other myeloproliferative diseases	16	2.9	2.9	2.9	0.004	8	1.5	1.6	1.7	0.002	3	0.4	0.4	0.4	0.001	-	-	-	-	-	-	-	-	-	-
Ie: Unspecified and other specified leukaemias	2	0.4	0.4	0.4	0.001	88	16.7	16.3	15.9	0.025	292	39.1	37.5	36.2	0.077	210	29.4	28.1	27.0	0.057	150	27.2	26.2	25.5	0.040
Ii: Lymphomas and reticuloendothelial neoplasms	150	27.2	26.2	25.5	0.040	88	16.7	16.3	15.9	0.025	292	39.1	37.5	36.2	0.077	210	29.4	28.1	27.0	0.057	150	27.2	26.2	25.5	0.040
Iia: Hodgkin lymphomas	56	10.1	9.5	9.0	0.015	34	6.4	6.1	5.8	0.009	143	19.2	18.0	17.0	0.037	120	16.8	15.7	14.8	0.033	56	10.1	9.5	9.0	0.015
Iib: Non-Hodgkin lymphomas	41	7.4	7.2	7.1	0.011	26	4.9	4.8	4.7	0.007	84	11.2	10.8	10.5	0.022	60	8.4	8.0	7.7	0.016	41	7.4	7.2	7.1	0.011
Iic: Burkitt lymphomas	38	6.9	6.7	6.6	0.010	15	2.8	2.8	2.8	0.004	47	6.3	6.2	6.1	0.013	16	2.2	2.3	2.3	0.005	38	6.9	6.7	6.6	0.010
Iid: Miscellaneous lymphoreticular neoplasms	12	2.2	2.3	2.4	0.003	11	2.1	2.2	2.3	0.003	15	2.0	2.1	2.2	0.004	11	1.5	1.7	1.8	0.003	12	2.2	2.3	2.4	0.003
Iie: Unspecified lymphomas	3	0.5	0.5	0.5	0.001	2	0.4	0.3	0.3	0.001	3	0.4	0.4	0.4	0.001	3	0.4	0.4	0.4	0.001	3	0.5	0.5	0.5	0.001
Ili: CNS and miscellaneous intracranial and intraspinal neoplasms	251	45.5	46.1	46.5	0.068	224	42.4	42.8	43.0	0.064	332	44.5	45.0	45.4	0.089	289	40.4	40.9	41.2	0.081	251	45.5	46.1	46.5	0.068
Ilii: Astrocytomas	25	4.5	4.8	4.9	0.007	33	6.2	6.7	7.0	0.009	33	4.4	4.6	4.7	0.009	36	5.0	5.5	5.8	0.010	25	4.5	4.8	4.9	0.007
Iliic: Intracranial and intraspinal embryonal tumours	97	17.6	17.7	17.9	0.026	107	20.3	20.1	19.9	0.030	129	17.3	17.4	17.6	0.035	136	19.0	19.0	18.9	0.038	97	17.6	17.7	17.9	0.026
Iliid: Other gliomas	44	8.0	8.2	8.3	0.012	29	5.5	5.6	5.7	0.008	49	6.6	6.8	7.0	0.013	34	4.8	4.9	5.0	0.010	44	8.0	8.2	8.3	0.012
Iliie: Other specified intracranial and intraspinal neoplasms	33	6.0	5.9	5.8	0.009	27	5.1	5.2	5.3	0.008	36	4.8	4.8	4.8	0.010	33	4.6	4.7	4.8	0.009	33	6.0	5.9	5.8	0.009
Iliif: Unspecified intracranial and intraspinal neoplasms	41	7.4	7.5	7.5	0.011	21	4.0	3.9	3.9	0.006	69	9.2	9.1	9.1	0.018	38	5.3	5.2	5.1	0.011	41	7.4	7.5	7.5	0.011
Iv: Neuroblastomas and other peripheral nervous cell tumours	11	2.0	2.1	2.1	0.003	7	1.3	1.3	1.2	0.002	16	2.1	2.2	2.2	0.004	12	1.7	1.6	1.6	0.003	11	2.0	2.1	2.1	0.003
IvA: Neuroblastomas and ganglioneuroblastomas	73	13.2	14.4	15.3	0.020	55	10.4	11.4	12.0	0.016	74	9.9	11.1	11.9	0.020	56	7.8	8.8	9.4	0.016	73	13.2	14.4	15.3	0.020
IvB: Other peripheral nervous cell tumours	71	12.9	14.1	14.9	0.020	54	10.2	11.2	11.8	0.016	72	9.6	10.8	11.7	0.020	55	7.7	8.6	9.3	0.016	71	12.9	14.1	14.9	0.020
V: Retinoblastomas	2	0.4	0.3	0.3	0.001	1	0.2	0.2	0.2	0.000	2	0.3	0.3	0.3	0.001	1	0.1	0.2	0.2	0.000	2	0.4	0.3	0.3	0.001
Vi: Renal Tumours	39	7.1	7.8	8.3	0.011	25	4.7	5.3	5.6	0.007	39	5.2	5.9	6.4	0.011	25	3.5	4.0	4.3	0.007	39	7.1	7.8	8.3	0.011
Via: Nephroblastomas and other nonepithelial renal tumours	50	9.1	9.7	10.1	0.014	52	9.8	10.5	10.9	0.015	55	7.4	8.0	8.4	0.015	53	7.4	8.1	8.6	0.015	50	9.1	9.7	10.1	0.014
Vib: Renal carcinomas	47	8.5	9.1	9.6	0.013	50	9.5	10.1	10.5	0.014	51	6.8	7.4	7.9	0.014	50	7.0	7.7	8.1	0.014	47	8.5	9.1	9.6	0.013
Vic: Unspecified malignant renal tumours	2	0.4	0.3	0.3	0.001	1	0.2	0.2	0.2	0.000	3	0.4	0.4	0.4	0.001	2	0.3	0.3	0.2	0.001	2	0.4	0.3	0.3	0.001
Vii: Hepatic tumours	1	0.2	0.2	0.2	0.000	1	0.2	0.2	0.2	0.000	1	0.1	0.2	0.2	0.000	1	0.1	0.2	0.2	0.000	1	0.2	0.2	0.2	0.000
ViiA: Hepatoblastomas	5	0.9	1.0	1.0	0.001	6	1.1	1.3	1.3	0.002	6	0.8	0.9	0.9	0.002	6	0.8	1.0	1.0	0.002	5	0.9	1.0	1.0	0.001
ViiB: Hepatic carcinomas	5	0.9	1.0	1.0	0.001	5	0.9	1.1	1.1	0.001	5	0.7	0.7	0.8	0.001	5	0.7	0.8	0.9	0.001	5	0.9	1.0	1.0	0.001
ViiC: Unspecified malignant hepatic tumours	-	-	-	-	-	1	0.2	0.2	0.2	0.000	1	0.1	0.1	0.1	0.000	1	0.1	0.2	0.2	0.000	-	-	-	-	-

Belgium: age-standardised incidence rates of cancer in children and adolescents, by tumour type and sex in 2004-2009 (N/1,000,000 person years)

Belgium: 2004-2009	Boys (0-14 years)						Girls (0-14 years)						Boys (0-19 years)						Girls (0-19 years)						
	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI	Tot	CR	ESR	WSR	CRI
	VIII: Malignant bone tumours	53	9.6	9.1	8.6	0.014	46	8.7	8.2	7.7	0.013	100	13.4	12.7	12.1	0.026	76	10.6	10.1	9.6	0.021	36	5.0	4.7	4.5
VIIIa: Osteosarcomas	23	4.2	3.9	3.6	0.006	22	4.2	3.9	3.6	0.006	50	6.7	6.3	5.9	0.013	36	5.0	4.7	4.5	0.010	4	0.5	0.5	0.5	0.001
VIIIb: Chondrosarcomas	-	-	-	-	-	-	-	-	-	-	4	0.5	0.5	0.5	0.001	3	0.4	0.4	0.4	0.001	33	4.6	4.5	4.3	0.009
VIIIc: Ewing tumours and related sarcomas of bone	27	4.9	4.7	4.5	0.007	23	4.4	4.2	4.0	0.006	42	5.6	5.4	5.2	0.011	33	4.6	4.5	4.3	0.009	2	0.3	0.3	0.2	0.001
VIIIId: Other specified malignant bone tumours	2	0.4	0.4	0.4	0.001	1	0.2	0.2	0.2	0.000	3	0.4	0.4	0.4	0.001	2	0.3	0.3	0.2	0.001	1	0.1	0.1	0.1	0.000
VIIIe: Unspecified malignant bone tumours	1	0.2	0.2	0.2	0.000	-	-	-	-	-	1	0.1	0.1	0.1	0.000	2	0.3	0.3	0.2	0.001	106	14.2	14.2	14.0	0.028
IX: Soft tissue and other extraosseous sarcomas	66	12.0	12.1	12.1	0.018	39	7.4	7.5	7.5	0.011	115	15.4	14.6	13.8	0.030	82	11.5	11.2	11.0	0.023	44	5.9	6.1	6.3	0.012
IXa: Rhabdomyosarcomas	34	6.2	6.5	6.6	0.009	21	4.0	4.1	4.2	0.006	22	2.9	2.8	2.7	0.006	24	3.4	3.5	3.6	0.007	10	1.3	1.3	1.3	0.003
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	8	1.4	1.4	1.4	0.002	1	0.2	0.2	0.2	0.000	1	0.1	0.1	0.1	0.000	7	1.0	0.9	0.9	0.002	1	0.1	0.1	0.1	0.000
IXc: Kaposi sarcomas	1	0.2	0.2	0.2	0.000	-	-	-	-	-	1	0.1	0.1	0.1	0.000	-	-	-	-	-	42	5.6	5.4	5.2	0.011
IXd: Other specified soft tissue sarcomas	20	3.6	3.5	3.4	0.005	17	3.2	3.1	3.1	0.005	4	0.8	0.9	0.9	0.002	21	2.9	3.3	3.6	0.006	9	1.2	1.1	1.1	0.002
IXe: Unspecified soft tissue sarcomas	3	0.5	0.5	0.5	0.001	-	-	-	-	-	1	0.1	0.1	0.1	0.000	2	0.3	0.3	0.2	0.001	115	15.4	14.6	13.8	0.030
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	20	3.6	3.7	3.7	0.005	39	7.4	7.5	7.6	0.011	115	15.4	14.6	13.8	0.030	56	7.8	7.9	7.9	0.016	10	1.8	1.7	1.7	0.003
Xa: Intracranial and intraspinal germ cell tumours	5	0.9	1.0	1.0	0.001	20	3.8	4.2	4.4	0.006	6	0.8	0.9	0.9	0.002	21	2.9	3.3	3.6	0.006	5	0.7	0.7	0.7	0.001
Xb: Malignant extracranial and extragonadal germ cell tumours	5	0.9	1.0	1.0	0.001	14	2.7	2.5	2.3	0.004	86	11.5	10.8	10.1	0.022	24	3.4	3.2	3.0	0.007	20	3.6	3.5	3.4	0.005
Xc: Malignant gonadal germ cell tumours	-	-	-	-	-	-	-	-	-	-	1	0.1	0.1	0.1	0.000	4	0.6	0.5	0.5	0.001	1	0.1	0.1	0.1	0.000
Xd: Gonadal carcinomas	-	-	-	-	-	-	-	-	-	-	1	0.1	0.1	0.1	0.000	2	0.3	0.3	0.2	0.001	54	9.8	9.2	8.8	0.014
Xe: Other and unspecified malignant gonadal tumours	-	-	-	-	-	-	-	-	-	-	1	0.2	0.2	0.2	0.000	1	0.2	0.2	0.2	0.000	73	13.8	13.0	12.3	0.020
XI: Other malignant epithelial neoplasms and malignant melanomas	54	9.8	9.2	8.8	0.014	73	13.8	13.0	12.3	0.020	144	19.3	18.2	17.2	0.038	222	31.1	29.1	27.5	0.060	1	0.2	0.2	0.2	0.000
XIa: Adrenocortical carcinomas	1	0.2	0.2	0.2	0.000	-	-	-	-	-	1	0.1	0.1	0.1	0.000	1	0.1	0.1	0.1	0.000	6	1.1	1.0	0.9	0.002
XIb: Thyroid carcinomas	6	1.1	1.0	0.9	0.002	12	2.3	2.1	2.0	0.003	21	2.8	2.6	2.5	0.005	41	5.7	5.4	5.0	0.011	4	0.7	0.7	0.6	0.001
XIc: Nasopharyngeal carcinomas	4	0.7	0.7	0.6	0.001	2	0.4	0.4	0.3	0.001	5	0.7	0.6	0.6	0.001	3	0.4	0.4	0.4	0.001	13	2.4	2.3	2.2	0.003
XId: Malignant melanomas	13	2.4	2.3	2.2	0.003	12	2.3	2.2	2.1	0.003	36	4.8	4.6	4.4	0.009	54	7.6	7.1	6.7	0.015	6	1.1	1.0	0.9	0.002
XIe: Skin carcinomas	6	1.1	1.0	0.9	0.002	20	3.8	3.6	3.4	0.006	19	2.5	2.4	2.3	0.005	38	5.3	5.0	4.8	0.010	24	4.3	4.1	3.9	0.006
XIf: Other and unspecified carcinomas	24	4.3	4.1	3.9	0.006	27	5.1	4.8	4.5	0.007	62	8.3	7.8	7.4	0.016	85	11.9	11.1	10.5	0.023	2	0.4	0.4	0.4	0.001
XII: Other and unspecified malignant neoplasms	2	0.4	0.4	0.4	0.001	3	0.6	0.6	0.6	0.001	3	0.4	0.4	0.4	0.001	7	1.0	0.9	0.9	0.002	1	0.2	0.2	0.2	0.000
XIIa: Other specified malignant tumours	1	0.2	0.2	0.2	0.000	-	-	-	-	-	1	0.1	0.1	0.1	0.000	4	0.6	0.5	0.5	0.001	1	0.2	0.2	0.2	0.000
XIIb: Other unspecified malignant tumours	1	0.2	0.2	0.2	0.000	3	0.6	0.6	0.6	0.001	2	0.3	0.3	0.3	0.001	3	0.4	0.4	0.4	0.001	1,628	218.0	218.5	218.2	0.433
I-XII: All tumours	1,053	190.7	194.0	195.8	0.286	860	162.9	165.3	166.3	0.244	1,628	218.0	218.5	218.2	0.433	1,345	188.2	188.1	187.4	0.374	1,053	190.7	194.0	195.8	0.286

CR: crude incidence rate (N/1,000,000 person years)
 ESR and WSR: age standardised incidence using the European or World standard population (N/1,000,000 person years)
 CRI: Cumulative Risk, 0-14 year or 0-19 year (%)

Belgium: observed survival rates of cancer in children, by tumour type and sex, in 2004-2009

Belgium: 2004-2009	Boys & Girls (0-14 years)						Boys (0-14 years)						Girls (0-14 years)								
	N at risk	1 yr OS		3 yr OS		5 yr OS		N at risk	1 yr OS		3 yr OS		5 yr OS		N at risk	1 yr OS		3 yr OS		5 yr OS	
		95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)		95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)		95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)	95% CI (5 yr OS)
I: Leukaemias, myeloproliferative and myelodysplastic diseases	491	92.3	86.1	84.0	84.0	[80.4;87.1]	283	92.2	85.7	83.1	83.1	85.7	83.1	208	92.3	86.5	85.2	85.2	86.5	85.2	[79.6;89.4]
Ia: Lymphoid leukaemias	392	94.6	90.2	89.2	89.2	[85.6;91.9]	231	94.8	89.9	88.7	88.7	89.9	88.7	161	94.4	90.7	89.8	89.8	90.7	89.8	[84.1;93.7]
Ib: Acute myeloid leukaemias	68	79.4	61.5	55.1	55.1	[42.7;66.9]	31	77.4	54.4	-	-	54.4	-	37	81.1	67.3	63.6	63.6	67.3	63.6	[47.0;77.5]
Ic: Chronic myeloproliferative diseases	8	-	-	-	-	-	5	-	-	-	-	-	-	3	-	-	-	-	-	-	-
Id: Myelodysplastic syndromes and other myeloproliferative diseases	21	95.2	90.5	-	-	-	14	92.9	92.9	-	-	92.9	-	7	-	-	-	-	-	-	-
Ie: Unspecified and other specified leukaemias	2	-	-	-	-	-	2	-	-	-	-	-	-	0	-	-	-	-	-	-	-
Ii: Lymphomas and reticuloendothelial neoplasms	233	96.6	94.3	93.8	93.8	[89.9;96.3]	147	97.3	95.2	94.3	94.3	95.2	94.3	86	95.3	92.9	92.9	92.9	92.9	92.9	[85.4;96.7]
Iia: Hodgkin lymphomas	90	100.0	98.9	98.9	98.9	[93.9;99.8]	56	100.0	100.0	100.0	100.0	100.0	100.0	34	100.0	97.0	97.0	97.0	97.0	97.0	[84.7;99.5]
Iib: Non-Hodgkin lymphomas	64	96.9	92.1	90.3	90.3	[80.3;95.5]	40	97.5	92.4	89.5	89.5	92.4	89.5	24	95.8	91.7	91.7	91.7	91.7	91.7	[74.2;97.7]
Iic: Burkitt lymphomas	52	94.2	94.2	94.2	94.2	[84.4;98.0]	37	94.6	94.6	94.6	94.6	94.6	94.6	15	93.3	93.3	93.3	93.3	93.3	93.3	-
Iid: Miscellaneous lymphoreticular neoplasms	22	90.9	85.9	-	-	-	11	90.9	-	-	-	-	-	11	90.9	-	-	-	-	-	-
Iie: Unspecified lymphomas	5	-	-	-	-	-	3	-	-	-	-	-	-	2	-	-	-	-	-	-	-
Iii: CNS and miscellaneous intracranial and intraspinal neoplasms	460	88.5	81.8	79.5	79.5	[75.4;83.1]	246	89.8	83.6	80.6	80.6	83.6	80.6	214	86.9	79.7	78.2	78.2	79.7	78.2	[72.1;83.4]
Iiia: Ependymomas and choroid plexus tumours	56	89.3	82.1	80.0	80.0	[67.6;88.5]	24	91.7	79.2	79.2	79.2	79.2	79.2	32	87.5	84.4	80.4	80.4	84.4	80.4	[63.1;90.7]
Iiib: Astrocytomas	199	88.9	83.4	81.1	81.1	[74.9;86.1]	96	89.6	85.4	82.6	82.6	85.4	82.6	103	88.3	81.5	79.8	79.8	81.5	79.8	[70.6;86.6]
Iiic: Intracranial and intraspinal embryonal tumours	72	79.2	66.2	59.9	59.9	[47.6;71.1]	44	81.8	70.1	60.6	60.6	70.1	60.6	28	75.0	60.0	-	-	60.0	-	-
Iiid: Other gliomas	56	91.1	80.2	80.2	80.2	[68.0;88.6]	32	90.6	81.3	81.3	81.3	81.3	81.3	24	91.7	78.7	-	-	78.7	-	-
Iiie: Other specified intracranial and intraspinal neoplasms	61	93.4	93.4	93.4	93.4	[84.3;97.4]	40	97.5	97.5	97.5	97.5	97.5	97.5	21	85.7	85.7	85.7	85.7	85.7	85.7	[65.4;95.0]
Iiif: Unspecified intracranial and intraspinal neoplasms	16	93.8	-	-	-	-	10	-	-	-	-	-	-	6	-	-	-	-	-	-	-
Iv: Neuroblastomas and other peripheral nervous cell tumours	126	95.2	79.5	74.7	74.7	[65.8;82.0]	72	94.4	75.7	66.4	66.4	75.7	66.4	54	96.3	84.7	84.7	84.7	84.7	84.7	[72.5;92.0]
Iva: Neuroblastomas and ganglioneuroblastomas	124	95.2	79.2	74.2	74.2	[65.2;81.6]	71	94.4	75.4	65.8	65.8	75.4	65.8	53	96.2	84.4	84.4	84.4	84.4	84.4	[72.0;91.9]
Ivb: Other peripheral nervous cell tumours	2	-	-	-	-	-	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-
V: Retinoblastomas	57	100.0	98.2	98.2	98.2	[90.7;99.7]	36	100.0	97.2	97.2	97.2	97.2	97.2	21	100.0	100.0	100.0	100.0	100.0	100.0	-
Vi: Renal Tumours	96	95.8	94.7	93.5	93.5	[86.5;97.0]	45	95.5	95.5	92.7	92.7	95.5	92.7	51	96.1	94.1	94.1	94.1	94.1	94.1	[84.1;98.0]
Via: Nephroblastomas and other nonepithelial renal tumours	91	96.7	95.6	94.2	94.2	[87.2;97.5]	42	97.6	97.6	94.6	94.6	97.6	94.6	49	95.9	93.9	93.9	93.9	93.9	93.9	[83.5;97.9]
Vib: Renal carcinomas	3	-	-	-	-	-	2	-	-	-	-	-	-	1	-	-	-	-	-	-	-
Vic: Unspecified malignant renal tumours	2	-	-	-	-	-	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-
Vii: Hepatic tumours	11	100.0	-	-	-	-	5	-	-	-	-	-	-	6	-	-	-	-	-	-	-
ViiA: Hepatoblastomas	10	100.0	-	-	-	-	5	-	-	-	-	-	-	5	-	-	-	-	-	-	-
ViiB: Hepatic carcinomas	1	-	-	-	-	-	0	-	-	-	-	-	-	1	-	-	-	-	-	-	-
ViiC: Unspecified malignant hepatic tumours	0	-	-	-	-	-	0	-	-	-	-	-	-	0	-	-	-	-	-	-	-

Belgium: 2004-2009	Boys & Girls (0-14 years)						Boys (0-14 years)						Girls (0-14 years)													
	N at risk		1 yr OS		5 yr OS		95% CI (5 yr OS)		N at risk		1 yr OS		5 yr OS		95% CI (5 yr OS)		N at risk		1 yr OS		5 yr OS		95% CI (5 yr OS)			
VIII: Malignant bone tumours	96	94.8	78.9	74.9	74.9	[64.9;82.7]		52	94.2	80.2	75.5		44	95.5	77.2	73.8		21	100.0	85.7						
VIIa: Osteosarcomas	44	95.5	79.4	73.1		[57.6;84.5]		23	91.3	73.4			0					0								
VIIb: Chondrosarcomas	0							0					0					0								
VIII: Ewing tumours and related sarcomas of bone	49	93.9	77.0	74.8		[60.9;85.0]		27	96.3	84.7	80.4		22	90.9	67.9	67.9		22	90.9	67.9					[46.9;83.5]	
VIIIa: Other specified malignant bone tumours	3							2					1					1								
VIIIb: Unspecified malignant bone tumours	0							0					0					0								
IX: Soft tissue and other extraosseous sarcomas	103	95.1	83.1	80.8		[71.1;87.8]		65	95.3	84.1	80.1		38	94.7	81.6	81.6		21	95.2	81.0						[66.6;90.8]
IXa: Rhabdomyosarcomas	55	94.4	85.2	85.2		[73.4;92.3]		34	93.9	87.9	87.9		21	95.2	81.0			1								
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	9							8					1					0								
IXc: Kaposi sarcomas	1							1					0					0								
IXd: Other specified soft tissue sarcomas	36	97.2	82.4	74.9		[53.8;88.4]		20	100.0	83.6			16	93.8				16	93.8							
IXe: Unspecified soft tissue sarcomas	2							2					0					0								
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	57	100.0	98.2	92.3		[79.3;97.4]		20	100.0	100.0			37	100.0	97.3	92.7		37	100.0	97.3						[76.0;98.1]
Xa: Intracranial and intraspinal germ cell tumours	13	100.0	100.0					10					3					3								
Xb: Malignant extracranial and extragonadal germ cell tumours	24	100.0	100.0	100.0		[100.0;100.0]		5					19	100.0	100.0	100.0		19	100.0	100.0						[100.0;100.0]
Xc: Malignant gonadal germ cell tumours	19	100.0	94.7					5					14	100.0	92.9			14	100.0	92.9						
Xd: Gonadal carcinomas	0							0					0					0								
Xe: Other and unspecified malignant gonadal tumours	1							0					1					1								
XI: Other malignant epithelial neoplasms and malignant melanomas	118	98.3	95.7	94.4		[88.0;97.4]		50	96.0	91.9	88.6		68	100.0	98.5	98.5		68	100.0	98.5						[92.1;99.7]
XIa: Adenocarcinomas	1							1					0					0								
XIb: Thyroid carcinomas	18	100.0	100.0					6					12	100.0				12	100.0							
XIc: Nasopharyngeal carcinomas	6							4					2					2								
XId: Malignant melanomas	24	100.0	95.8	95.8		[79.8;99.3]		13	100.0	92.3			11	100.0	100.0			11	100.0	100.0						[100.0;100.0]
XIe: Skin carcinomas	22	100.0	100.0	100.0		[100.0;100.0]		5					17	100.0	100.0	100.0		17	100.0	100.0						[100.0;100.0]
XIf: Other and unspecified carcinomas	47	95.7	93.6	89.9		[75.9;96.1]		21	90.5	90.5	82.9		26	100.0	96.2	96.2		26	100.0	96.2						[81.1;99.3]
XII: Other and unspecified malignant neoplasms	5							2					3					3								
XIIa: Other specified malignant tumours	1							1					0					0								
XIIb: Other unspecified malignant tumours	4							1					3					3								
I-XII: All tumours	1,853	93.4	86.9	84.8		[83.0;86.4]		1,023	93.5	86.9	83.9		830	93.2	87.0	85.9		830	93.2	87.0						[83.3;88.2]

1-35 yr OS: one, three and five-year observed survival rates (%)
95% CI (5 yr OS): 95% confidence interval of the five-year observed survival rates (%)
Survival data are not presented when the number of patients at risk is less than 10 cases.

Belgium: observed survival rates of cancer in children and adolescents, by tumour type and sex in 2004-2009

Belgium: 2004-2009	Boys & Girls (0-19 years)						Boys (0-19 years)						Girls (0-19 years)							
	Boys		Girls		Boys & Girls		Boys		Girls		Boys & Girls		Boys		Girls		Boys & Girls			
	N at risk	1 yr OS	3 yr OS	5 yr OS	95% CI (5 yr OS)	N at risk	1 yr OS	3 yr OS	5 yr OS	95% CI (5 yr OS)	N at risk	1 yr OS	3 yr OS	5 yr OS	95% CI (5 yr OS)	N at risk	1 yr OS	3 yr OS	5 yr OS	95% CI (5 yr OS)
I: Leukaemias, myeloproliferative and myelodysplastic diseases	611	91.3	83.5	81.2	[77.7;84.2]	351	91.2	83.0	80.1	[75.3;84.1]	260	91.5	84.1	82.6	[77.3;86.8]	187	94.1	88.2	86.8	[81.0;91.0]
Ia: Lymphoid leukaemias	454	94.1	87.5	86.3	[82.7;89.2]	267	94.0	87.1	86.0	[81.1;89.7]	187	94.1	88.2	86.8	[81.0;91.0]	53	79.2	65.6	63.0	[49.2;75.0]
Ib: Acute myeloid leukaemias	102	77.5	61.3	56.9	[46.8;66.5]	49	75.5	56.5	51.0	[36.9;64.9]	14	92.9	92.9	-	-	11	100.0	-	-	-
Ic: Chronic myeloproliferative diseases	25	96.0	96.0	85.3	[64.3;94.9]	18	94.4	94.4	-	-	9	-	-	-	-	0	-	-	-	-
Id: Myelodysplastic syndromes and other myeloproliferative diseases	27	96.3	92.6	-	-	3	-	-	-	-	0	-	-	-	-	200	97.5	93.9	93.2	[88.7;96.0]
Ie: Unspecified and other specified leukaemias	3	-	-	-	-	3	-	-	-	-	3	-	-	-	-	200	97.5	93.9	93.2	[88.7;96.0]
Ii: Lymphomas and reticuloendothelial neoplasms	485	96.7	93.7	93.2	[90.5;95.1]	285	96.1	93.6	93.1	[89.5;95.6]	114	100.0	96.4	96.4	[91.1;98.6]	57	96.5	93.0	90.8	[80.0;96.0]
Iia: Hodgkin lymphomas	254	99.6	97.5	97.5	[94.7;98.9]	140	99.3	96.4	98.4	[94.4;99.6]	114	100.0	96.4	96.4	[91.1;98.6]	57	96.5	93.0	90.8	[80.0;96.0]
Iib: Non-Hodgkin lymphomas	140	95.0	89.9	88.1	[81.6;92.6]	83	94.0	87.8	86.4	[77.2;92.2]	15	93.3	93.3	-	-	11	90.9	-	-	-
Iic: Burkitt lymphomas	60	93.3	93.3	93.3	[84.1;97.4]	45	93.3	93.3	93.3	[82.1;97.7]	11	90.9	-	-	-	3	-	-	-	-
Iid: Miscellaneous lymphoreticular neoplasms	25	88.0	83.4	83.4	[64.1;93.4]	14	85.7	-	-	-	3	-	-	-	-	272	88.6	82.2	81.0	[75.8;85.3]
Iie: Unspecified lymphomas	6	-	-	-	-	3	-	-	-	-	3	-	-	-	-	272	88.6	82.2	81.0	[75.8;85.3]
III: CNS and miscellaneous intracranial and intraspinal neoplasms	592	89.9	83.1	81.3	[77.8;84.3]	320	90.9	83.9	81.5	[76.7;85.6]	35	88.6	85.7	82.1	[66.0;91.6]	129	89.1	82.1	80.8	[72.8;86.8]
IIIa: Ependymomas and choroid plexus tumours	65	90.8	84.6	82.8	[71.7;90.1]	30	93.3	83.3	83.3	[66.4;92.7]	35	88.6	85.7	82.1	[66.0;91.6]	33	78.8	66.0	-	-
IIIb: Astrocytomas	253	89.3	82.6	80.8	[75.4;85.3]	124	89.5	83.0	80.9	[72.9;87.0]	29	93.1	82.5	82.5	[64.9;92.3]	35	88.6	88.6	88.6	[74.0;95.5]
IIIc: Intracranial and intraspinal embryonal tumours	82	81.7	67.5	61.4	[49.6;72.0]	49	83.7	68.5	59.1	[43.9;72.8]	29	93.1	82.5	82.5	[64.9;92.3]	35	88.6	88.6	88.6	[74.0;95.5]
IIId: Other gliomas	64	90.6	79.6	79.6	[68.1;87.7]	35	88.6	77.1	77.1	[61.0;87.9]	29	93.1	82.5	82.5	[64.9;92.3]	35	88.6	88.6	88.6	[74.0;95.5]
IIIe: Other specified intracranial and intraspinal neoplasms	102	95.1	95.1	95.1	[89.0;97.9]	67	98.5	98.5	98.5	[92.0;99.7]	11	100.0	-	-	-	55	96.4	85.0	85.0	[73.0;92.2]
IIIf: Unspecified intracranial and intraspinal neoplasms	26	96.2	96.2	-	-	15	93.3	-	-	-	55	96.4	85.0	85.0	[73.0;92.2]	54	96.3	84.7	84.7	[72.5;92.0]
IV: Neuroblastomas and other peripheral nervous cell tumours	128	94.5	79.1	74.4	[65.5;81.6]	73	93.2	74.7	65.5	[52.5;76.5]	21	100.0	100.0	-	-	1	-	-	-	-
IVa: Neuroblastomas and ganglioneuroblastomas	126	94.4	78.7	73.9	[64.9;81.2]	72	93.1	74.3	64.8	[51.7;76.1]	54	96.3	84.7	84.7	[72.5;92.0]	1	-	-	-	-
IVb: Other peripheral nervous cell tumours	2	-	-	-	-	1	-	-	-	-	1	-	-	-	-	21	100.0	100.0	-	-
V: Retinoblastomas	57	100.0	98.2	98.2	[90.7;99.7]	36	100.0	97.2	97.2	[85.8;99.5]	52	96.2	94.2	94.2	[84.4;98.0]	49	95.9	93.9	93.9	[83.5;97.9]
VI: Renal Tumours	102	96.0	94.1	92.9	[86.0;96.5]	50	95.9	93.9	91.4	[79.8;96.6]	46	97.8	95.6	92.9	[81.0;97.6]	2	-	-	-	-
Via: Nephroblastomas and other nonepithelial renal tumours	95	96.8	94.7	93.4	[86.4;97.0]	46	97.8	95.6	92.9	[81.0;97.6]	3	-	-	-	-	1	-	-	-	-
Vib: Renal carcinomas	5	-	-	-	-	3	-	-	-	-	1	-	-	-	-	6	-	-	-	-
Vic: Unspecified malignant renal tumours	2	-	-	-	-	1	-	-	-	-	6	-	-	-	-	5	-	-	-	-
Vii: Hepatic tumours	12	100.0	-	-	-	6	-	-	-	-	5	-	-	-	-	1	-	-	-	-
ViiA: Hepatoblastomas	10	100.0	-	-	-	5	-	-	-	-	1	-	-	-	-	0	-	-	-	-
ViiB: Hepatic carcinomas	2	-	-	-	-	1	-	-	-	-	0	-	-	-	-	0	-	-	-	-
ViiC: Unspecified malignant hepatic tumours	0	-	-	-	-	0	-	-	-	-	0	-	-	-	-	0	-	-	-	-

Belgium: observed survival rates of cancer in children and adolescents, by tumour type and sex in 2004-2009

	Boys & Girls (0-19 years)						Boys (0-19 years)						Girls (0-19 years)													
	Belgium: 2004-2009		1 yr OS		5 yr OS		1 yr OS		3 yr OS		5 yr OS		1 yr OS		3 yr OS		5 yr OS		1 yr OS		3 yr OS		5 yr OS		95% CI (5 yr OS)	
	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)	N at risk	95% CI (5 yr OS)
VIII: Malignant bone tumours	169	[64.0;78.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]	98	[56.7;76.1]
VIIIa: Osteosarcomas	82	[60.0;80.3]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]	49	[52.3;79.2]
VIIIb: Chondrosarcomas	7	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-	4	-
VIIIc: Ewing tumours and related sarcomas of bone	73	[58.5;79.6]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]	42	[48.9;77.7]
VIIIId: Other specified malignant bone tumours	5	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-
VIIIe: Unspecified malignant bone tumours	2	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
IX: Soft tissue and other extraosseous sarcomas	183	[71.2;83.9]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]	103	[63.4;82.1]
IXa: Rhabdomyosarcomas	66	[70.4;89.1]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]	42	[68.7;91.5]
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	17	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-	10	-
IXc: Kaposi sarcomas	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-
IXd: Other specified soft tissue sarcomas	91	[70.5;88.0]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]	42	[55.0;84.9]
IXe: Unspecified soft tissue sarcomas	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-	8	-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	165	[88.7;96.8]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]	111	[89.8;98.4]
Xa: Intracranial and intraspinal germ cell tumours	26	[65.2;97.0]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]	22	[62.5;96.6]
Xb: Malignant extracranial and extragonadal germ cell tumours	26	[100.0;100.0]	6	-	6	-	6	-	6	-	6	-	6	-	6	-	6	-	6	-	6	-	6	-	6	-
Xc: Malignant gonadal germ cell tumours	106	[88.5;97.8]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]	82	[91.5;99.3]
Xd: Gonadal carcinomas	4	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
Xe: Other and unspecified malignant gonadal tumours	3	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-
XI: Other malignant epithelial neoplasms and malignant melanomas	342	[92.5;97.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]	132	[86.8;96.5]
XIa: Adenocarcinomas	2	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-
XIb: Thyroid carcinomas	59	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]	19	[100.0;100.0]
XIc: Nasopharyngeal carcinomas	8	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-	5	-
XId: Malignant melanomas	87	[92.0;99.4]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]	35	[85.5;99.5]
XIe: Skin carcinomas	47	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]	15	[100.0;100.0]
XIf: Other and unspecified carcinomas	139	[85.8;96.0]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]	57	[74.8;94.3]
XII: Other and unspecified malignant neoplasms	10	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-	3	-
XIIa: Other specified malignant tumours	5	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-	1	-
XIIb: Other unspecified malignant tumours	5	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-	2	-
I-XII: All tumours	2,856	[84.0;86.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]	1,568	[81.9;85.7]

1-35 yr OS: one, three and five-year observed survival rates (%)
95% CI (5 yr OS): 95% confidence interval of the five-year observed survival rates (%)
Survival data are not presented when the number of patients at risk is less than 10 cases.

Belgium: number of new diagnoses of cancer in children, by tumour type, incidence year and sex in 2004-2009

	Boys & Girls (0-14 years)										Boys (0-14 years)										Girls (0-14 years)														
	2004-2009					2004-2009					2004-2009					2004-2009					2004-2009					2004-2009									
	2004	2005	2006	2007	2008	2009	2008	2007	2006	2005	2004	2005	2006	2007	2008	2009	2008	2007	2006	2005	2004	2005	2006	2007	2008	2009	2008	2007	2006	2005	2004	2005	2006	2007	2008
VIII: Malignant bone tumours	11	24	17	17	17	13	17	17	17	13	10	9	6	12	6	10	10	9	6	15	1	15	11	5	11	3									
VIIIa: Osteosarcomas	4	10	8	8	7	8	8	8	8	4	4	4	2	5	2	6	4	4	6	6	-	6	6	3	5	2									
VIIIb: Chondrosarcomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-									
VIIIc: Ewing tumours and related sarcomas of bone	6	14	9	9	8	4	9	9	8	5	5	4	4	7	3	3	5	5	9	1	9	5	2	5	1										
VIIId: Other specified malignant bone tumours	1	-	-	-	1	1	-	-	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-									
VIIIE: Unspecified malignant bone tumours	-	-	-	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-									
IX: Soft tissue and other extraosseous sarcomas	13	15	16	20	21	20	21	20	21	13	9	7	9	12	16	13	9	7	8	4	8	7	8	5	7										
IXa: Rhabdomyosarcomas	8	6	10	13	10	8	10	8	13	6	2	6	7	8	5	6	2	6	4	4	2	4	6	2	3										
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	-	1	2	1	4	1	4	1	1	-	1	2	1	3	1	-	1	2	-	-	-	-	-	-	-										
IXc: Kaposi sarcomas	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-										
IXd: Other specified soft tissue sarcomas	5	6	3	6	7	10	6	7	10	3	2	2	4	5	6	3	2	4	4	2	4	3	2	4											
IXe: Unspecified soft tissue sarcomas	-	2	1	-	-	-	-	-	-	-	-	2	1	-	-	-	-	2	1	-	-	-	-	-	-										
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	9	10	8	9	14	9	14	9	14	5	2	3	2	6	2	4	2	3	8	4	8	5	7	8	7										
Xa: Intracranial and intraspinal germ cell tumours	5	1	1	-	5	2	5	2	5	5	1	-	-	-	3	1	-	-	-	-	-	-	-	-	1										
Xb: Malignant extracranial and extragonadal germ cell tumours	3	6	5	2	7	2	7	2	7	-	1	1	1	2	-	-	1	1	5	3	5	4	1	5	2										
Xc: Malignant gonadal germ cell tumours	1	3	2	7	2	4	7	2	4	-	-	2	1	1	1	1	-	2	3	1	3	-	6	1	3										
Xd: Gonadal carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-										
Xe: Other and unspecified malignant gonadal tumours	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-										
XI: Other malignant epithelial neoplasms and malignant melanomas	21	19	31	23	18	15	18	15	18	12	8	12	9	8	5	9	8	11	19	9	11	19	14	10	10										
XIa: Adenocortical carcinomas	1	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-										
XIb: Thyroid carcinomas	2	2	5	4	2	3	4	2	3	-	1	1	2	2	-	2	1	4	2	2	1	4	2	-	3										
XIc: Nasopharyngeal carcinomas	2	-	2	-	2	-	-	-	-	1	-	-	2	-	1	-	-	-	-	1	-	-	-	-	1										
XId: Malignant melanomas	5	3	7	4	3	3	4	3	3	3	1	3	3	1	2	2	2	4	2	2	2	4	1	2	1										
XIe: Skin carcinomas	3	4	7	4	5	3	4	5	3	-	1	2	-	2	1	3	-	2	3	3	3	5	4	3	2										
XIf: Other and unspecified carcinomas	8	10	10	11	6	6	6	6	6	7	5	4	4	4	2	2	1	5	6	1	5	6	7	4	4										
XII: Other and unspecified malignant neoplasms	2	1	1	-	1	-	1	-	1	1	-	-	-	-	1	-	-	1	1	-	1	1	-	-	-										
XIIa: Other specified malignant tumours	-	-	-	-	1	-	1	-	1	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-										
XIIb: Other unspecified malignant tumours	2	1	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	1	1	1	-	-	-										
I-XII: All tumours	314	350	318	285	312	334	312	285	312	181	191	164	151	168	198	133	159	154	134	144	144	134	144	136											

Belgium: number of new diagnoses of cancer in children and adolescents, by tumour type, incidence year and sex in 2004-2009

	Boys & Girls (0-19 years)																	
	Boys (0-19 years)									Girls (0-19 years)								
	2004	2005	2006	2007	2008	2009	2004	2005	2006	2007	2008	2009	2004	2005	2006	2007	2008	2009
VIII: Malignant bone tumours	29	37	33	27	31	19	21	18	14	18	16	13	8	19	19	9	15	6
VIIIa: Osteosarcomas	14	19	18	12	14	9	10	11	7	7	8	7	4	8	11	5	6	2
VIIIb: Chondrosarcomas	3	1	1	1	-	1	1	-	1	1	-	1	2	1	-	-	-	-
VIIIc: Ewing tumours and related sarcomas of bone	11	17	13	14	13	7	9	7	6	10	6	4	2	10	7	4	7	3
VIIIid: Other specified malignant bone tumours	1	-	1	-	2	1	1	-	-	-	1	1	-	-	1	-	1	-
VIIIe: Unspecified malignant bone tumours	-	-	-	-	2	1	-	-	-	-	1	-	-	-	-	-	1	1
IX: Soft tissue and other extraosseous sarcomas	25	30	31	34	37	31	15	11	18	20	22	20	10	19	13	14	15	11
IXa: Rhabdomyosarcomas	9	8	10	18	12	11	6	3	6	11	10	8	3	5	4	7	2	3
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms	-	2	3	3	7	2	-	1	2	3	3	1	-	1	1	-	4	1
IXc: Kaposi sarcomas	-	-	-	-	-	1	-	-	-	-	-	1	-	-	-	-	-	-
IXd: Other specified soft tissue sarcomas	15	16	16	11	18	17	8	3	8	4	9	10	7	13	8	7	9	7
IXe: Unspecified soft tissue sarcomas	1	4	2	2	-	-	1	4	2	2	-	-	-	-	-	-	-	-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads	23	26	33	33	29	27	18	15	22	20	20	20	5	11	11	13	9	7
Xa: Intracranial and intraspinal germ cell tumours	6	4	3	2	8	4	6	4	2	1	6	3	-	-	1	1	2	1
Xb: Malignant extracranial and extragonadal germ cell tumours	3	6	5	3	7	3	-	1	1	1	2	1	3	5	4	2	5	2
Xc: Malignant gonadal germ cell tumours	14	16	22	26	14	18	12	10	19	18	12	15	2	6	3	8	2	3
Xd: Gonadal carcinomas	-	-	2	2	-	-	-	-	-	-	-	-	-	-	2	2	-	-
Xe: Other and unspecified malignant gonadal tumours	-	-	1	-	-	2	-	-	-	-	-	1	-	-	1	-	-	1
XI: Other malignant epithelial neoplasms and malignant melanomas	58	52	73	64	56	63	23	20	29	27	23	22	35	32	44	37	33	41
XIa: Adenocarcinomas	2	-	-	-	-	-	1	-	-	-	-	-	1	-	-	-	-	-
XIb: Thyroid carcinomas	6	7	11	13	11	14	-	3	2	6	5	5	6	4	9	7	6	9
XIc: Nasopharyngeal carcinomas	2	-	3	-	2	1	1	-	3	-	1	-	1	-	-	-	1	1
XId: Malignant melanomas	14	12	17	19	12	16	7	3	8	11	4	3	7	9	9	8	8	13
XIe: Skin carcinomas	7	9	11	10	10	10	2	3	5	3	4	2	5	6	6	7	6	8
XIf: Other and unspecified carcinomas	27	24	31	22	21	22	12	11	11	7	9	12	15	13	20	15	12	10
XII: Other and unspecified malignant neoplasms	3	3	1	-	2	1	2	-	-	-	1	-	1	3	1	-	1	1
XIIa: Other specified malignant tumours	-	2	-	-	2	1	-	-	-	-	1	-	-	2	-	-	1	1
XIIb: Other unspecified malignant tumours	3	1	1	-	-	-	2	-	-	-	-	-	1	1	1	-	-	-
I-XII: All tumours	477	524	495	471	490	516	268	279	262	251	269	299	209	245	233	220	221	217

Belgium: Males, number of invasive tumours by primary site and age group in 2010

Belgium: Males 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00 Lip	50	-	-	-	-	-	-	-	-	2	1	2	1	4	6	6	13	12	3
C01 Base of tongue	90	-	-	-	-	-	-	-	1	1	8	10	19	16	14	9	6	4	2
C02 Tongue	148	-	-	-	-	1	2	1	4	8	9	19	27	28	16	14	7	8	4
C03 Gum	31	-	-	-	-	-	-	-	1	-	2	3	6	6	4	2	3	2	1
C04 Floor of mouth	157	-	-	-	-	-	-	1	1	2	13	38	39	27	14	7	11	3	1
C05 Palate	59	-	-	-	-	-	-	-	-	1	4	8	24	7	5	7	1	-	2
C06 Mouth, NOS	61	-	-	-	-	-	-	-	-	2	5	9	5	15	7	6	4	3	5
C07 Parotid gland	60	-	-	1	-	-	1	3	-	1	5	5	3	9	5	5	10	5	7
C08 Salivary glands, NOS	15	-	-	-	1	-	-	-	-	-	-	-	1	3	3	2	2	-	-
C09 Tonsil	135	-	-	-	-	-	-	-	-	4	15	17	27	26	22	13	8	2	1
C10 Oropharynx	134	-	-	-	-	-	-	-	-	2	16	18	26	28	18	14	6	4	2
C11 Nasopharynx	43	-	-	-	-	1	-	3	2	3	5	8	7	2	4	4	1	1	2
C12 Pyriform sinus	125	-	-	-	-	-	-	-	-	-	8	20	28	29	17	12	4	6	1
C13 Hypopharynx	57	-	-	-	-	-	-	1	-	-	4	14	9	11	8	1	3	4	1
C14 Lip, oral cavity and pharynx, NOS	18	-	-	-	-	-	-	-	-	-	-	-	5	4	2	3	2	2	-
C15 Oesophagus	680	-	-	-	-	-	-	2	2	2	25	81	88	99	94	100	83	61	43
C16 Stomach	854	-	-	-	-	-	3	4	8	12	38	46	74	93	109	128	136	122	81
C17 Small intestine	139	-	-	-	-	-	-	-	1	3	7	7	18	25	16	19	18	18	7
C18 Colon	2,967	-	2	3	6	4	8	8	23	33	62	147	226	300	399	486	540	461	259
C19 Rectosigmoid junction	178	-	-	-	-	-	-	-	-	-	4	8	15	21	29	29	31	27	14
C20 Rectum	1,411	-	-	-	-	3	4	3	12	20	54	92	161	211	204	207	188	164	88
C21 Anus and anal canal	56	-	-	-	-	-	-	1	-	1	4	5	6	6	14	8	5	2	4
C22 Liver and intrahepatic bile ducts	479	2	-	1	-	-	4	2	8	3	15	32	52	71	82	83	77	35	12
C23 Gallbladder	36	-	-	-	-	-	1	-	-	1	2	1	2	1	4	8	4	9	3
C24 Biliary tract, NOS	145	-	-	-	-	-	-	-	-	3	6	5	12	16	20	23	20	17	23
C25 Pancreas	785	-	-	-	-	2	3	3	9	7	26	40	66	107	122	122	131	96	51
C26 Other ill-defined digestive organs	22	-	-	-	-	-	-	-	-	-	-	-	3	2	3	-	11	2	1
C30 Nasal cavity and middle ear	30	2	-	-	-	-	-	-	-	-	-	2	1	7	4	6	2	3	3
C31 Accessory sinuses	63	1	-	-	-	1	-	-	1	2	4	6	9	11	6	5	11	3	3
C32 Larynx	541	-	-	-	-	-	-	-	-	8	28	47	83	88	88	69	70	45	15
C33 Trachea	10	-	-	-	-	-	-	-	-	-	-	2	3	1	2	-	1	-	1
C34 Bronchus and lung	5,616	-	-	-	-	1	4	7	10	47	124	320	576	809	811	1,011	964	643	289
C37 Thymus	21	-	-	1	-	-	-	-	-	1	1	4	3	3	1	3	3	1	-
C38 Heart, mediastinum and pleura	24	-	-	-	-	-	2	-	2	2	-	1	4	2	3	2	3	3	-
C39 Respiratory system and intrathoracic organs, NOS	3	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	-	-
C40 Bone and articular cartilage of limbs	36	-	-	6	7	3	1	2	3	-	4	2	-	2	1	2	1	1	1
C41 Bone and articular cartilage, NOS	43	1	1	2	4	-	4	5	1	2	2	1	5	4	3	3	4	1	-
C43 Malignant melanoma of skin	871	-	-	1	5	13	31	32	54	62	75	67	94	96	73	93	88	55	32
C44 Malignant neoplasms of skin	2,531	-	1	-	-	2	5	7	10	18	29	68	87	166	217	356	522	536	507

Belgium: Males 2010																			
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	204	-	-	-	1	-	1	-	2	1	3	7	10	28	34	32	47	28	10
C46 Kaposi's sarcoma	31	-	-	-	-	-	2	1	5	-	7	6	1	1	1	1	2	-	4
C47,C49 Soft tissues	162	5	2	-	2	2	4	2	6	9	9	8	16	18	21	21	18	7	12
C48 Retroperitoneum and peritoneum	23	-	-	-	1	-	1	-	-	-	1	2	4	3	2	6	2	1	-
C50 Breast	83	-	-	-	-	-	-	-	4	5	5	9	11	14	5	13	14	5	3
C60 Penis	85	-	-	-	-	-	-	-	2	2	2	5	5	14	12	10	17	11	5
C61 Prostate	8,663	-	-	-	-	-	-	-	1	17	76	416	830	1,395	1,562	1,597	1,498	814	457
C62 Testis	318	3	-	-	12	34	61	73	37	37	18	10	15	7	4	2	2	3	-
C63 Male genital organs, NOS	14	-	-	-	-	-	-	-	-	1	-	2	1	4	1	1	1	3	-
C64 Kidney	981	4	1	-	-	-	3	1	24	24	51	83	105	158	152	116	135	78	46
C65 Renal pelvis	145	-	-	-	-	-	-	-	1	1	5	5	10	28	13	28	30	18	6
C66 Ureter	101	-	-	-	-	-	-	-	-	-	4	2	5	16	13	18	26	11	6
C67 Bladder	1,755	-	-	-	-	-	-	3	4	10	27	52	109	196	221	319	340	266	208
C68 Urinary organs, NOS	50	-	-	-	-	-	-	-	-	-	-	1	-	6	5	7	18	7	6
C69 Eye and adnexa	61	7	3	2	-	-	-	-	1	3	1	4	5	7	7	5	9	4	3
C70 Meninges	8	-	-	-	-	-	-	-	-	1	1	1	-	-	1	1	-	3	-
C71 Brain	453	11	6	6	7	8	10	19	17	31	28	44	46	53	44	59	35	19	10
C72 Spinal cord, cranial nerves and CNS, NOS	14	2	1	-	1	-	-	1	-	-	3	1	-	1	2	1	-	1	-
C73 Thyroid gland	204	-	1	-	1	5	5	6	15	22	26	21	27	20	18	15	14	8	-
C74 Adrenal gland	29	6	2	1	-	-	1	-	-	-	2	2	3	6	-	2	2	2	-
C75 Endocrine glands, NOS	7	-	-	-	-	1	1	-	1	-	-	-	-	-	1	1	1	-	1
C81 Hodgkin's disease	154	-	2	2	12	11	14	14	17	10	11	10	12	9	6	7	13	2	2
C82-C86 Non-Hodgkin-lymphoma	1,021	2	6	10	8	5	10	18	21	41	66	71	89	109	117	139	131	106	72
C88 Malignant immunoproliferative diseases	103	-	-	-	-	-	-	-	2	2	6	3	11	8	17	10	22	17	5
C90 Multiple myeloma	424	-	-	-	-	-	1	1	5	4	11	20	37	44	63	81	82	49	26
C91 Lymphoid leukaemia	481	15	8	9	6	4	4	4	5	7	19	30	57	55	57	79	50	43	29
C92 Myeloid leukaemia	329	4	1	1	6	3	8	5	13	12	13	20	30	25	19	42	53	45	29
C93 Monocytic leukaemia	55	1	-	-	1	-	-	1	1	1	1	-	2	8	7	11	11	5	5
C94-C95 Leukaemia other	31	-	-	-	-	-	-	-	-	1	1	4	1	3	4	4	6	5	2
C96 Lymphoid, haematopoietic and related tissue, NOS	25	5	4	-	2	1	1	1	1	1	2	-	2	2	-	1	2	-	-
C76 Other and ill-defined sites	2	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	-
C80 Unknown primary site	462	1	2	-	-	1	2	1	3	6	22	29	40	57	53	54	79	69	43
MPD Myeloproliferative Disorders	257	1	-	-	3	-	4	3	4	7	14	16	14	25	35	35	45	29	22
MDS Myelodysplastic syndromes	339	2	2	3	1	1	2	2	1	5	7	6	17	20	39	61	79	58	33
Total	35,798	75	45	49	88	108	268	241	342	513	1,047	2,046	3,330	4,697	4,986	5,649	5,779	4,081	2,514
Total excl. non-melanoma	33,267	75	44	49	88	106	263	234	332	495	1,018	1,978	3,243	4,531	4,769	5,293	5,257	3,545	2,007
Total excl. non-melanoma and MDS, MPD	32,671	72	42	46	84	105	197	229	327	483	997	1,956	3,212	4,486	4,695	5,197	5,133	3,458	1,952

Belgium: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
Belgium: Males 2010																							
C00	50	-	-	-	-	-	-	-	-	0.5	0.2	0.5	0.3	1.3	2.7	2.9	7.5	10.7	4.3	0.9	0.7	0.4	0.0
C01	90	-	-	-	-	-	-	-	0.3	0.2	1.9	2.6	5.5	5.1	6.3	4.3	3.5	3.6	2.9	1.7	1.5	1.0	0.1
C02	148	-	-	-	0.3	0.6	0.3	1.1	2.0	2.2	4.9	7.9	9.0	7.2	6.8	6.8	4.1	7.2	5.8	2.8	2.4	1.8	0.2
C03	31	-	-	-	0.3	-	-	0.3	-	0.5	0.8	1.7	1.9	1.8	1.0	1.7	1.8	1.4	1.4	0.6	0.5	0.4	0.0
C04	157	-	-	-	-	-	-	0.3	0.3	3.1	9.9	11.4	8.7	6.3	3.4	6.4	2.7	1.4	3.0	2.6	1.9	0.2	0.2
C05	59	-	-	-	-	-	-	-	-	0.2	1.0	2.1	7.0	2.3	2.2	3.4	0.6	-	2.9	1.1	1.0	0.7	0.1
C06	61	-	-	-	-	-	-	-	0.5	1.2	2.3	1.5	4.8	3.1	2.9	2.3	2.7	7.2	1.1	1.0	0.7	0.1	0.1
C07	60	-	-	0.3	-	0.3	0.9	-	0.2	1.2	1.3	0.9	2.9	2.2	2.4	5.8	4.5	10.1	1.1	0.9	0.7	0.1	0.1
C08	15	-	-	-	0.3	-	-	-	-	-	-	-	0.3	1.0	1.3	1.4	1.2	1.8	-	0.3	0.2	0.2	0.0
C09	135	-	-	-	-	-	-	-	-	1.0	3.6	4.4	7.9	8.4	9.9	6.3	4.6	1.8	1.4	2.5	2.2	1.6	0.2
C10	134	-	-	-	-	-	-	-	0.5	3.9	4.7	7.6	9.0	8.1	6.8	3.5	3.6	2.9	2.5	2.2	1.6	0.2	0.2
C11	43	-	-	-	-	0.3	-	0.9	0.5	0.7	1.2	2.1	2.0	0.6	1.8	1.9	0.6	0.9	2.9	0.8	0.7	0.6	0.1
C12	125	-	-	-	-	-	-	-	-	1.9	5.2	8.2	9.3	7.6	5.8	2.3	5.4	1.4	2.4	2.0	1.5	0.2	0.2
C13	57	-	-	-	0.3	-	-	0.3	-	-	1.0	3.6	2.6	3.5	3.6	0.5	1.7	3.6	1.4	1.1	0.9	0.7	0.1
C14	18	-	-	-	-	-	-	-	-	-	-	-	1.5	1.3	0.9	1.4	1.2	1.8	-	0.3	0.3	0.2	0.0
C15	680	-	-	-	-	-	0.6	0.5	6.0	6.0	21.1	25.6	31.8	42.1	48.3	48.0	54.5	61.9	12.8	10.4	7.1	0.9	0.9
C16	854	-	-	-	-	0.9	1.1	2.1	3.0	9.2	12.0	21.5	29.9	48.9	61.8	78.7	109.1	116.6	16.1	12.4	8.3	0.9	0.9
C17	139	-	-	-	-	-	-	0.3	0.7	1.7	1.8	5.2	8.0	7.2	9.2	10.4	16.1	10.1	2.6	2.1	1.4	0.2	0.2
C18	2,957	-	0.7	1.0	1.8	1.2	2.3	2.3	6.1	8.2	15.0	38.3	65.8	96.4	178.9	234.6	312.6	412.2	372.9	55.9	42.4	28.0	3.2
C19	178	-	-	-	-	-	-	-	-	-	1.0	2.1	4.4	6.8	13.0	14.0	17.9	24.1	20.2	3.4	2.6	1.7	0.2
C20	1,411	-	-	-	-	0.9	1.2	0.9	3.2	5.0	13.0	23.9	46.9	67.8	91.5	99.9	108.8	146.6	126.7	26.6	21.1	14.5	1.8
C21	56	-	-	-	-	-	0.3	-	0.2	1.0	1.3	1.7	1.9	6.3	3.9	2.9	1.8	5.8	1.1	0.9	0.6	0.1	0.1
C22	479	0.6	-	0.3	-	-	1.2	0.6	2.1	0.7	3.6	8.3	15.1	22.8	36.8	40.1	44.6	31.3	17.3	9.0	7.3	5.1	0.7
C23	36	-	-	-	-	-	0.3	-	-	0.2	0.5	0.3	0.6	0.3	1.8	3.9	2.3	8.0	4.3	0.7	0.5	0.3	0.0
C24	145	-	-	-	-	-	-	-	0.7	1.4	1.3	3.5	5.1	9.0	11.1	11.6	15.2	33.1	2.7	2.1	1.4	0.2	0.2
C25	785	-	-	-	-	0.6	0.9	0.9	2.4	1.7	6.3	10.4	19.2	34.4	54.7	58.9	75.8	85.8	73.4	14.8	11.6	7.8	0.9
C26	22	-	-	-	-	-	-	-	-	-	-	-	0.9	0.6	1.3	-	6.4	1.8	1.4	0.4	0.3	0.2	0.0
C30	30	0.6	-	-	-	-	-	-	-	-	-	0.5	0.3	2.3	1.8	2.9	1.2	2.7	4.3	0.6	0.5	0.4	0.0
C31	63	0.3	-	-	-	0.3	-	-	0.3	0.5	1.0	1.6	2.6	3.5	2.7	2.4	6.4	2.7	4.3	1.2	1.0	0.7	0.1
C32	541	-	-	-	-	-	-	-	-	2.0	6.8	12.2	24.2	28.3	39.5	33.3	40.5	40.2	21.6	10.2	8.3	5.8	0.7
C33	10	-	-	-	-	-	-	-	-	-	-	0.5	0.9	0.3	0.9	-	0.6	-	1.4	0.2	0.2	0.1	0.0
C34	5,616	-	-	-	-	0.3	1.2	2.0	2.6	11.7	30.0	83.3	167.7	260.1	363.6	488.1	558.0	574.9	416.1	105.7	82.5	55.4	6.8
C37	21	-	-	0.3	-	-	-	-	0.2	0.2	1.0	0.9	1.0	0.4	1.4	1.4	1.7	0.9	-	0.4	0.3	0.2	0.0
C38	24	-	-	-	-	-	0.6	-	0.5	0.5	-	0.3	1.2	0.6	1.3	1.0	1.7	2.7	-	0.5	0.4	0.3	0.0
C39	3	-	-	-	-	-	-	-	-	-	-	-	-	0.3	-	0.5	0.6	-	-	0.1	0.0	0.0	0.0
C40	36	-	-	1.9	2.1	0.9	0.3	0.6	0.8	-	1.0	0.5	-	0.6	0.4	1.0	0.6	0.9	1.4	0.7	0.7	0.7	0.1
C41	43	0.3	0.3	0.6	1.2	-	1.2	1.4	0.3	0.5	0.5	0.3	1.5	1.3	1.3	1.4	2.3	0.9	-	0.8	0.8	0.7	0.1
C43	871	-	-	0.3	1.5	3.9	9.0	9.1	14.3	15.5	18.1	17.4	27.4	30.9	32.7	44.9	50.9	49.2	46.1	16.4	14.1	10.7	1.1
C44	2,531	-	0.3	-	-	0.6	1.4	2.0	2.6	4.5	7.0	17.7	25.3	53.4	97.3	171.9	302.2	479.3	730.1	47.6	33.9	20.6	1.9

Belgium: Males 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C45	Mesothelioma	204	-	-	-	0.3	-	0.3	-	0.5	0.2	0.7	1.8	2.9	9.0	15.2	15.4	27.2	25.0	14.4	3.8	2.9	1.9	0.2
C46	Kaposi's sarcoma	31	-	-	-	-	-	0.6	0.3	1.3	-	1.7	1.6	0.3	0.3	0.4	0.5	1.2	-	5.8	0.6	0.5	0.4	0.0
C47,C49	Soft tissues	162	1.6	0.7	-	0.6	0.6	1.2	0.6	1.6	2.2	2.2	2.1	4.7	5.8	9.4	10.1	10.4	6.3	17.3	3.0	2.6	2.1	0.2
C48	Retropertitoneum and peritoneum	23	-	-	-	0.3	-	-	-	-	-	0.2	0.5	1.2	1.0	0.9	2.9	1.2	0.9	-	0.4	0.4	0.3	0.0
C50	Breast	83	-	-	-	-	-	-	-	-	1.0	1.2	2.3	3.2	4.5	2.2	6.3	8.1	4.5	4.3	1.6	1.3	0.9	0.1
C60	Penis	85	-	-	-	-	-	-	-	0.5	0.5	0.5	1.3	1.5	4.5	5.4	4.8	9.8	9.8	7.2	1.6	1.2	0.8	0.1
C61	Prostate	8,669	-	-	-	-	-	-	-	0.3	4.2	18.4	108.3	241.6	448.5	700.3	771.0	867.1	727.8	658.1	163.1	128.4	86.4	10.8
C62	Testis	318	0.9	-	-	3.6	10.3	17.7	20.8	9.8	9.2	4.3	2.6	4.4	2.3	1.8	1.0	1.2	2.7	-	6.0	6.1	5.8	0.4
C63	Male genital organs, NOS	14	-	-	-	-	-	-	-	-	0.2	-	0.5	0.3	1.3	0.4	0.5	0.6	2.7	-	0.3	0.2	0.1	0.0
C64	Kidney	981	1.2	0.3	-	-	-	0.9	0.3	6.3	6.0	12.3	21.6	30.6	50.8	68.1	56.0	78.1	69.7	66.2	18.5	15.1	10.7	1.3
C65	Renal pelvis	145	-	-	-	-	-	-	-	0.3	0.2	1.2	1.3	2.9	9.0	5.8	13.5	17.4	16.1	8.6	2.7	2.1	1.4	0.2
C66	Ureter	101	-	-	-	-	-	-	-	-	-	1.0	0.5	1.5	5.1	5.8	8.7	15.1	9.8	8.6	1.9	1.4	0.9	0.1
C67	Bladder	1,755	-	-	-	-	-	-	0.9	1.1	2.5	6.5	13.5	31.7	63.0	99.1	154.0	196.8	237.8	299.5	33.0	24.7	15.8	1.8
C68	Urinary organs, NOS	50	-	-	-	-	-	-	-	-	-	-	0.3	-	1.9	2.2	3.4	10.4	6.3	8.6	0.9	0.7	0.4	0.0
C69	Eye and adnexa	61	2.2	1.0	0.6	-	-	-	-	0.3	0.7	0.2	1.0	1.5	2.3	3.1	2.4	5.2	3.6	4.3	1.1	1.0	0.9	0.1
C70	Meninges	8	-	-	-	-	-	-	-	-	0.2	0.2	0.3	-	-	0.4	0.5	-	2.7	-	0.2	0.1	0.1	0.0
C71	Brain	453	3.4	2.0	1.9	2.1	2.4	2.9	5.4	4.5	7.7	6.8	11.5	13.4	17.0	19.7	28.5	20.3	17.0	14.4	8.5	7.6	6.2	0.6
C72	Spinal cord, cranial nerves and CNS, NOS	14	0.6	0.3	-	0.3	-	-	0.3	-	-	0.7	0.3	-	0.3	0.9	0.5	-	0.9	-	0.3	0.3	0.3	0.0
C73	Thyroid gland	204	-	0.3	-	0.3	1.5	1.4	1.7	4.0	5.5	6.3	5.5	7.9	6.4	8.1	7.2	8.1	7.2	-	3.8	3.4	2.7	0.3
C74	Adrenal gland	29	1.9	0.7	0.3	-	-	0.3	-	-	-	0.5	0.5	0.9	1.9	-	1.0	1.2	1.8	-	0.5	0.5	0.5	0.0
C75	Endocrine glands, NOS	7	-	-	-	-	0.3	0.3	-	0.3	-	-	-	-	-	0.4	0.5	0.6	-	1.4	0.1	0.1	0.1	0.0
C81	Hodgkin's disease	154	-	0.7	0.6	3.6	3.3	4.1	4.0	4.5	2.5	2.7	2.6	3.5	2.9	2.7	3.4	7.5	1.8	2.9	2.9	2.8	2.5	0.2
C82-C86	Non-Hodgkin-lymphoma	1,021	0.6	2.0	3.2	2.4	1.5	2.9	5.1	5.6	10.2	15.9	18.5	25.9	35.0	52.5	67.1	75.8	94.8	103.7	19.2	15.7	11.4	1.2
C88	Malignant immunoproliferative diseases	103	-	-	-	-	-	-	-	0.5	0.5	1.4	0.8	3.2	2.6	7.6	4.8	12.7	15.2	7.2	1.9	1.5	1.0	0.1
C90	Multiple myeloma	424	-	-	-	-	-	0.3	0.3	1.3	1.0	2.7	5.2	10.8	14.1	28.2	39.1	47.5	43.8	37.4	8.0	6.2	4.1	0.5
C91	Lymphoid leukaemia	481	4.7	2.6	2.9	1.8	1.2	1.2	1.1	1.3	1.7	4.6	7.8	16.6	17.7	25.6	38.1	28.9	38.4	41.8	9.1	7.6	5.9	0.6
C92	Myeloid leukaemia	329	1.2	0.3	0.3	1.8	0.9	2.3	1.4	3.4	3.0	3.1	5.2	8.7	8.0	8.5	20.3	30.7	40.2	41.8	6.2	4.9	3.6	0.3
C93	Monocytic leukaemia	55	0.3	-	-	0.3	-	-	0.3	0.3	0.2	0.2	-	0.6	2.6	3.1	5.3	6.4	4.5	7.2	1.0	0.8	0.6	0.1
C94-C95	Leukaemia other	31	-	-	-	-	-	-	-	-	0.2	0.2	1.0	0.3	1.0	1.8	1.9	3.5	4.5	2.9	0.6	0.4	0.3	0.0
C96	Lymphoid, haematopoietic and related tissue, NOS	25	1.6	1.3	-	0.6	0.3	0.3	0.3	0.3	0.2	0.5	-	0.6	0.6	-	0.5	1.2	-	-	0.5	0.5	0.6	0.0
C76	Other and ill-defined sites	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.9	-	0.0	0.0	0.0	0.0
C80	Unknown primary site	462	0.3	0.7	-	-	0.3	0.6	0.3	0.8	1.5	5.3	7.5	11.6	18.3	23.8	26.1	45.7	61.7	61.9	8.7	6.7	4.5	0.5
MPD	Myeloproliferative Disorders	257	0.3	-	-	0.9	-	1.2	0.9	1.1	1.7	3.4	4.2	4.1	8.0	15.7	16.9	26.0	25.9	31.7	4.8	3.8	2.7	0.3
MDS	Myelodysplastic syndromes	339	0.6	0.7	1.0	0.3	0.3	0.6	0.6	0.3	1.2	1.7	1.6	4.9	6.4	17.5	29.5	45.7	51.9	47.5	6.4	4.7	3.2	0.3
Total		35,798	23.3	14.8	15.8	26.5	32.6	60.2	68.6	90.5	128.0	253.0	532.6	969.5	1,510.0	2,232.3	2,727.3	3,345.3	3,649.0	3,620.0	673.9	531.9	365.1	35.2
Total excl. non-melanoma		33,267	23.3	14.4	15.8	26.5	32.0	58.8	66.6	87.8	123.5	246.0	514.9	944.2	1,456.6	2,138.1	2,555.5	3,043.1	3,169.7	2,890.0	626.2	498.0	344.5	34.0
Total excl. non-melanoma and MDS, MPD		32,671	22.4	13.8	14.8	25.3	31.7	57.1	65.2	86.5	120.5	240.9	509.2	935.1	1,442.1	2,104.9	2,509.1	2,971.3	3,091.9	2,810.8	615.0	489.5	338.7	33.6

CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRI: Cumulative Risk (0-74 years)

Belgium: Females, number of invasive tumours by primary site and age group in 2010

Belgium: Females 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00	Lip	11	-	-	-	-	-	-	-	-	1	1	-	-	1	-	1	1	3	3
C01	Base of tongue	38	-	-	-	1	1	1	1	-	-	1	4	6	12	4	1	2	5	-
C02	Tongue	76	-	-	1	1	-	3	4	3	4	14	8	12	8	7	5	6	6	4
C03	Gum	25	-	-	-	-	-	1	1	1	1	2	1	3	2	4	6	1	3	3
C04	Floor of mouth	48	-	-	-	-	-	1	1	1	2	5	12	11	4	5	3	3	3	1
C05	Palate	26	-	-	-	2	-	-	2	1	-	2	6	2	4	-	6	1	1	1
C06	Mouth, NOS	51	-	-	-	-	-	-	-	-	3	7	7	5	1	7	6	10	5	5
C07	Parotid gland	41	-	-	1	3	1	1	2	-	2	3	4	4	6	2	1	7	4	4
C08	Salivary glands, NOS	19	-	-	1	1	1	1	1	1	1	1	6	1	-	2	1	2	-	1
C09	Tonsil	68	-	-	-	-	-	-	-	2	4	13	14	9	8	4	7	4	3	3
C10	Oropharynx	38	-	-	-	-	-	-	-	-	2	4	11	6	7	3	4	1	-	-
C11	Nasopharynx	15	1	-	1	1	1	1	2	1	2	1	1	-	1	2	-	-	4	-
C12	Pyrimiform sinus	25	-	-	-	-	-	-	-	-	-	6	7	5	2	3	2	-	-	-
C13	Hypopharynx	12	-	-	-	-	-	-	1	1	-	-	2	3	1	-	2	2	-	-
C14	Lip, oral cavity and pharynx, NOS	2	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	1
C15	Oesophagus	242	-	-	-	-	2	2	7	14	26	31	30	34	37	28	28	37	28	28
C16	Stomach	547	-	-	-	1	1	1	5	6	18	23	37	43	57	59	82	91	123	123
C17	Small intestine	113	-	-	-	1	1	-	2	5	4	9	7	15	10	19	15	13	13	13
C18	Colon	2,628	-	2	6	8	9	11	9	18	20	64	94	167	237	272	352	422	493	444
C19	Rectosigmoid junction	129	-	-	-	-	-	-	2	3	5	6	6	13	14	19	19	22	20	20
C20	Rectum	981	-	1	-	1	1	-	4	11	23	40	50	95	113	105	134	147	140	116
C21	Anus and anal canal	102	-	-	-	-	-	-	2	6	7	9	12	20	7	10	16	5	8	8
C22	Liver and intrahepatic bile ducts	192	-	-	-	2	3	3	3	3	3	15	14	21	27	28	34	21	18	18
C23	Gallbladder	94	-	-	-	-	-	-	1	-	1	8	2	7	10	10	22	17	17	17
C24	Biliary tract, NOS	120	-	-	-	-	-	-	1	4	3	6	13	14	14	26	18	21	21	21
C25	Pancreas	738	-	-	-	1	5	11	18	40	54	81	82	135	127	106	75	75	75	75
C26	Other ill-defined digestive organs	14	-	-	-	-	-	-	1	2	-	2	1	2	1	2	-	3	1	2
C30	Nasal cavity and middle ear	12	-	1	-	-	-	-	1	-	1	-	-	2	-	1	3	1	1	2
C31	Accessory sinuses	16	-	-	-	1	-	-	-	-	-	2	-	5	2	1	1	1	3	3
C32	Larynx	83	-	-	-	-	-	-	4	4	4	11	16	17	17	6	4	2	2	2
C33	Trachea	3	-	-	-	-	-	-	-	-	-	-	1	-	1	-	1	-	-	-
C34	Bronchus and lung	2,215	-	-	-	2	2	7	17	44	115	210	326	350	295	291	274	177	105	105
C37	Thymus	17	-	-	-	-	-	-	1	1	2	1	2	3	2	1	2	2	2	-
C38	Heart, mediastinum and pleura	13	1	-	1	-	-	-	1	1	-	-	-	2	1	2	1	-	1	2
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	25	-	1	5	2	-	1	3	3	2	1	4	-	2	1	-	-	-	-
C41	Bone and articular cartilage, NOS	26	-	-	2	-	-	2	-	1	3	2	-	2	3	5	3	1	1	1
C43	Malignant melanoma of skin	1,239	1	1	3	14	29	69	72	98	116	127	94	111	117	82	87	86	68	64
C44	Malignant neoplasms of skin	1,783	-	-	2	3	2	4	10	10	27	37	58	75	94	117	191	283	329	541

Belgium: Females 2010																			
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	51	-	-	-	-	-	-	-	-	-	1	3	6	5	7	13	3	10	3
C46 Kaposi's sarcoma	7	-	-	-	-	-	1	-	-	-	-	-	-	2	-	1	1	-	2
C47,C49 Soft tissues	152	3	1	1	3	1	4	6	6	7	9	14	8	15	9	15	15	16	19
C48 Retroperitoneum and peritoneum	33	2	-	-	-	-	-	1	-	1	2	3	1	3	6	3	2	2	7
C50 Breast	9,908	-	-	-	-	7	37	133	322	634	1,005	1,192	1,173	1,334	1,005	927	882	699	558
C51 Vulva	216	-	-	-	-	-	2	3	2	8	15	22	15	13	19	15	33	37	32
C52 Vagina	43	2	-	-	-	-	-	-	-	-	3	4	5	4	4	1	6	5	9
C53 Cervix uteri	593	-	-	-	1	3	17	36	59	77	84	61	54	46	33	31	30	32	29
C54 Corpus uteri	1,415	-	-	-	-	-	1	-	7	18	46	78	135	208	225	212	236	148	101
C55 Uterus	9	-	-	-	-	-	-	1	-	-	-	-	1	1	-	-	-	1	5
C56 Ovary	865	1	-	1	2	6	4	6	13	25	37	77	93	123	95	117	108	93	64
C57 Female genital organs, NOS	46	-	-	-	-	-	-	1	-	1	1	2	3	9	4	10	5	8	2
C58 Placenta	3	-	-	-	-	1	1	-	-	-	-	1	-	-	-	-	-	-	-
C64 Kidney	551	5	1	-	1	1	3	5	9	16	16	35	42	66	64	89	102	61	35
C65 Renal pelvis	79	-	-	-	-	-	-	-	1	1	1	1	5	4	8	13	18	13	14
C66 Ureter	39	-	-	-	-	-	-	-	-	-	-	2	2	2	6	4	10	8	5
C67 Bladder	477	1	-	-	-	-	-	-	2	5	9	13	28	40	47	73	81	83	95
C68 Urinary organs, NOS	11	-	-	-	-	-	-	-	-	-	-	-	-	1	1	2	4	1	2
C69 Eye and adnexa	56	8	-	-	-	-	3	-	3	1	2	5	3	4	3	7	8	4	5
C70 Meninges	10	-	-	-	-	-	-	1	-	1	-	-	-	1	2	1	3	-	1
C71 Brain	322	9	9	3	5	4	11	13	7	9	15	24	27	30	32	38	46	25	15
C72 Spinal cord, cranial nerves and CNS, NOS	18	3	3	1	1	1	1	-	1	2	-	2	-	-	-	1	2	-	-
C73 Thyroid gland	651	-	1	3	10	16	27	48	62	53	69	78	85	52	45	35	23	29	15
C74 Adrenal gland	29	5	1	-	1	1	1	1	-	3	1	3	3	3	2	2	-	-	2
C75 Endocrine glands, NOS	6	-	1	-	-	-	-	-	-	-	1	1	-	1	1	-	1	-	-
C81 Hodgkin's disease	149	-	1	3	16	22	22	9	14	9	6	7	9	7	10	2	5	5	2
C82-C86 Non-Hodgkin-lymphoma	926	3	3	1	2	8	9	20	22	25	49	50	57	84	107	116	148	128	94
C88 Malignant immunoproliferative diseases	111	1	-	-	-	-	1	-	5	2	7	5	10	6	13	16	18	16	11
C90 Multiple myeloma	327	-	-	-	-	-	-	3	2	3	11	16	27	36	38	47	59	57	28
C91 Lymphoid leukaemia	343	14	8	6	5	-	1	2	3	8	12	23	23	40	32	43	51	36	36
C92 Myeloid leukaemia	292	5	1	3	1	6	4	6	8	17	20	16	19	22	27	38	36	32	31
C93 Monocytic leukaemia	40	-	-	1	-	-	1	1	-	2	4	-	2	2	7	6	5	4	5
C94-C95 Leukaemia other	30	2	-	-	-	-	-	-	1	1	3	1	3	1	-	3	6	6	3
C96 Lymphoid, haematopoietic and related tissue, NOS	28	9	2	1	1	-	-	2	-	4	2	1	-	2	2	2	-	-	-
C76 Other and ill-defined sites	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2
C80 Unknown primary site	408	-	-	-	1	1	1	1	4	2	17	22	26	35	33	59	68	62	76
MPD Myeloproliferative Disorders	247	-	-	1	1	3	2	-	4	7	13	16	14	23	18	40	46	36	23
MDS Myelodysplastic syndromes	212	2	1	-	-	-	2	3	-	1	4	5	10	15	16	27	42	47	37
Total	30,533	78	39	44	83	139	250	423	742	1,233	1,950	2,508	2,928	3,504	3,123	3,448	3,745	3,299	2,997
Total excl. non-melanoma	28,750	78	39	42	80	137	246	413	732	1,206	1,913	2,450	2,853	3,410	3,006	3,257	3,462	2,970	2,456
Total excl. non-melanoma and MDS, MPD	28,291	76	38	41	79	134	242	410	728	1,198	1,896	2,429	2,829	3,372	2,972	3,190	3,374	2,887	2,396

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Belgium: Females 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C00 Lip	11	-	-	-	-	-	-	-	-	0.3	0.2	-	-	0.3	-	0.4	0.4	1.6	1.8	0.2	0.1	0.1	0.0
C01 Base of tongue	38	-	-	-	-	0.3	0.3	0.3	-	-	0.2	1.0	1.7	3.7	1.6	0.4	0.9	2.7	-	0.7	0.6	0.4	0.0
C02 Tongue	76	-	-	-	0.3	0.3	-	0.9	-	0.8	1.0	3.7	2.3	3.7	3.3	2.8	2.1	3.2	2.4	1.4	1.1	0.8	0.1
C03 Gum	25	-	-	-	-	-	-	0.3	-	0.3	0.2	0.5	0.3	0.9	0.8	1.6	2.6	0.5	1.8	0.5	0.3	0.2	0.0
C04 Floor of mouth	48	-	-	-	-	-	-	0.3	-	0.3	0.5	1.3	3.5	3.4	1.6	2.0	1.3	1.6	0.6	0.9	0.7	0.5	0.1
C05 Palate	26	-	-	-	-	0.6	-	-	0.3	-	0.5	1.6	0.6	1.2	-	2.4	0.4	0.5	0.6	0.5	0.4	0.3	0.0
C06 Mouth, NOS	51	-	-	-	-	-	-	-	-	0.7	1.8	2.0	1.6	0.4	2.8	2.6	5.4	3.0	0.9	0.9	0.6	0.4	0.0
C07 Parotid gland	41	-	-	-	0.3	0.9	0.3	0.3	0.5	-	0.5	0.8	1.2	1.2	2.5	0.8	0.4	3.8	2.4	0.7	0.6	0.5	0.0
C08 Salivary glands, NOS	19	-	-	-	0.3	0.3	0.3	0.3	-	0.3	0.2	1.6	0.3	-	0.8	0.4	0.9	-	0.6	0.3	0.3	0.3	0.0
C09 Tonsil	68	-	-	-	-	-	-	-	-	0.5	1.0	3.4	4.0	2.8	3.3	1.6	3.0	2.2	1.8	1.2	1.0	0.7	0.1
C10 Oropharynx	38	-	-	-	-	-	-	-	-	0.5	1.0	3.2	1.9	2.9	1.2	1.7	0.5	-	2.2	-	0.6	0.4	0.1
C11 Nasopharynx	15	0.3	-	-	0.3	0.3	-	0.3	-	0.3	0.5	0.3	-	0.3	0.8	-	-	2.2	-	0.3	0.2	0.2	0.0
C12 Pyriform sinus	25	-	-	-	-	-	-	-	-	0.3	0.6	0.9	0.4	-	0.9	1.1	-	-	0.5	0.4	0.3	0.0	0.0
C13 Hypopharynx	12	-	-	-	-	-	-	-	0.3	-	-	-	-	-	-	-	-	-	-	0.2	0.2	0.1	0.0
C14 Lip, oral cavity and pharynx, NOS	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	0.0	0.0	0.0	0.0
C15 Oesophagus	242	-	-	-	-	-	-	-	0.5	1.7	3.7	7.5	9.7	12.8	12.2	14.5	19.9	16.9	4.4	2.9	2.0	0.2	0.2
C16 Stomach	547	-	-	-	-	0.3	0.3	0.3	1.4	1.5	4.4	6.0	10.7	13.4	23.4	24.0	34.9	49.0	74.1	9.9	5.9	3.9	0.4
C17 Small intestine	113	-	-	-	-	0.3	-	-	0.5	1.3	1.0	2.3	2.0	4.7	4.1	7.7	6.4	7.0	7.8	2.0	1.4	1.0	0.1
C18 Colon	2,628	-	0.7	2.0	2.5	2.7	3.2	2.6	4.9	5.1	15.8	24.5	48.3	73.9	111.9	143.0	179.7	265.2	267.5	47.5	28.8	19.4	2.2
C19 Rectosigmoid junction	129	-	-	-	-	-	-	-	0.5	0.8	1.2	1.6	1.7	4.1	5.8	7.7	8.1	11.8	12.1	2.3	1.5	1.0	0.1
C20 Rectum	981	-	0.3	-	0.3	0.3	-	1.2	3.0	5.9	9.8	13.0	27.5	35.2	43.2	54.4	62.6	75.3	69.9	17.7	11.8	8.2	1.0
C21 Anus and anal canal	102	-	-	-	-	-	-	-	0.5	1.5	1.7	2.3	3.5	6.2	2.9	4.1	6.8	2.7	4.8	1.8	1.4	1.0	0.1
C22 Liver and intrahepatic bile ducts	192	-	-	-	-	0.6	0.3	0.6	0.8	0.8	0.7	3.9	4.0	6.5	11.1	11.4	14.5	11.3	10.8	3.5	2.4	1.7	0.2
C23 Gallbladder	94	-	-	-	-	-	-	-	-	0.3	-	2.1	0.6	2.2	4.1	4.1	9.4	9.1	10.2	1.7	1.0	0.6	0.1
C24 Biliary tract, NOS	120	-	-	-	-	-	-	-	0.3	1.0	0.8	1.7	4.1	5.8	5.7	11.1	11.1	9.7	12.7	2.2	1.3	0.9	0.1
C25 Pancreas	738	-	-	-	-	0.3	-	0.9	1.4	2.8	4.4	10.4	15.6	25.2	33.7	54.8	54.1	57.0	45.2	13.4	8.7	5.9	0.7
C26 Other ill-defined digestive organs	14	-	-	-	-	-	-	-	-	0.3	0.5	-	0.6	0.3	0.8	-	1.3	0.5	1.2	0.3	0.2	0.1	0.0
C30 Nasal cavity and middle ear	12	-	0.3	-	-	-	-	-	-	0.3	-	-	0.6	-	0.4	1.2	0.4	0.5	1.2	0.2	0.2	0.1	0.0
C31 Accessory sinuses	16	-	-	-	-	0.3	-	-	-	-	-	0.5	-	1.6	0.8	0.4	0.4	0.5	1.8	0.3	0.2	0.2	0.0
C32 Larynx	83	-	-	-	-	-	-	-	1.0	1.0	2.9	4.6	5.3	7.0	2.4	1.7	1.1	1.2	1.5	1.5	1.3	0.9	0.1
C33 Trachea	3	-	-	-	-	-	-	-	-	-	-	0.3	-	0.3	-	0.4	-	-	-	0.1	0.0	0.0	0.0
C34 Bronchus and lung	2,215	-	-	-	-	0.6	0.6	2.0	4.6	11.3	28.3	54.8	94.2	109.1	121.4	118.2	116.7	95.2	63.3	40.1	30.6	21.7	2.7
C37 Thymus	17	-	-	-	-	-	-	0.3	0.3	0.5	0.3	0.6	0.9	0.8	0.4	0.4	0.9	1.1	-	0.3	0.2	0.2	0.0
C38 Heart, mediastinum and pleura	13	0.3	-	-	-	-	-	0.3	0.3	-	-	0.6	0.3	0.8	0.4	-	-	0.5	1.2	0.2	0.2	0.2	0.0
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40 Bone and articular cartilage of limbs	25	-	0.3	1.7	0.6	-	0.3	0.9	0.8	0.5	0.2	1.0	-	0.6	0.4	-	-	-	-	0.5	0.5	0.5	0.0
C41 Bone and articular cartilage, NOS	26	-	-	0.7	-	-	0.6	-	0.3	0.8	0.5	-	0.6	0.9	2.1	1.2	0.4	0.5	0.6	0.5	0.4	0.4	0.0
C43 Malignant melanoma of skin	1,239	0.3	0.3	1.0	4.4	8.8	19.9	20.8	26.5	29.8	31.3	24.5	32.1	36.5	33.7	35.3	36.6	36.6	38.6	22.4	19.4	15.8	1.5
C44 Malignant neoplasms of skin	1,783	-	-	0.7	0.9	0.6	1.2	2.9	2.7	6.9	9.1	15.1	21.7	29.3	48.1	77.6	120.5	177.0	326.0	32.3	17.3	11.1	1.1

Belgium: Females 2010												Tot	CR	ESR	WSR	CRI							
	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI	
C45 Mesothelioma	-	-	-	-	-	-	-	-	-	0.2	0.8	1.7	1.6	2.9	5.3	1.3	5.4	1.8	0.9	0.6	0.4	0.1	
C46 Kaposi's sarcoma	-	-	-	-	-	0.3	-	-	-	-	-	-	0.6	-	0.4	0.4	-	1.2	0.1	0.1	0.1	0.0	
C47,C49 Soft tissues	152	1.0	0.3	0.9	0.3	1.2	1.7	1.6	1.8	2.2	3.7	4.7	3.7	4.7	6.1	6.4	8.6	11.4	2.7	2.1	1.7	0.2	
C48 Retroperitoneum and peritoneum	33	0.7	-	-	-	0.3	-	0.3	0.3	0.5	0.8	0.3	0.9	2.5	1.2	0.9	1.1	4.2	0.6	0.4	0.4	0.0	
C50 Breast	9,908	-	-	-	2.1	10.7	38.3	87.1	163.0	247.4	310.9	339.0	415.8	413.4	375.6	376.0	336.2	179.2	143.8	106.2	11.3	11.3	
C51 Vulva	216	-	-	-	-	0.6	0.9	0.5	2.1	3.7	5.7	4.3	4.1	7.8	6.1	14.1	19.9	19.3	3.9	2.6	1.8	0.2	
C52 Vagina	43	0.7	-	-	-	-	-	-	-	0.7	1.0	1.4	1.2	1.6	0.4	2.6	2.7	5.4	0.8	0.5	0.4	0.0	
C53 Cervix uteri	593	-	-	0.3	0.9	4.9	10.4	16.0	19.8	20.7	15.9	15.6	14.3	13.6	12.6	12.8	17.2	17.5	10.7	9.4	7.5	0.7	
C54 Corpus uteri	1,415	-	-	-	-	0.3	-	1.9	4.6	11.3	20.3	39.0	64.8	92.6	86.1	100.5	79.6	60.9	25.6	18.0	12.5	1.6	
C55 Uterus	9	-	-	-	-	0.3	-	-	-	-	-	0.3	0.3	-	-	-	0.5	3.0	0.2	0.1	0.1	0.0	
C56 Ovary	865	0.3	-	0.3	0.6	1.8	1.2	1.7	3.5	6.4	9.1	20.1	26.9	38.3	39.1	47.5	46.0	38.6	15.6	11.5	8.2	1.0	
C57 Female genital organs, NOS	46	-	-	-	-	-	0.3	-	0.3	0.2	0.5	0.9	2.8	1.6	4.1	2.1	4.3	1.2	0.8	0.6	0.4	0.1	
C58 Placenta	3	-	-	-	-	0.3	0.3	-	-	-	0.3	-	-	-	-	-	-	-	0.1	0.1	0.1	0.0	
C64 Kidney	551	1.6	0.3	-	0.3	0.3	0.9	1.4	2.4	4.1	3.9	9.1	12.1	20.6	26.3	36.2	43.4	32.8	21.1	10.0	7.0	0.6	
C65 Renal pelvis	79	-	-	-	-	-	-	0.3	0.3	0.2	0.3	1.4	1.2	3.3	5.3	7.7	7.0	8.4	1.4	0.8	0.5	0.1	
C66 Ureter	39	-	-	-	-	-	-	-	-	-	0.5	0.6	0.6	2.5	1.6	4.3	4.3	3.0	0.7	0.4	0.3	0.0	
C67 Bladder	477	0.3	-	-	-	-	-	0.5	1.3	2.2	3.4	8.1	12.5	19.3	29.7	34.5	44.7	57.2	8.6	5.0	3.3	0.4	
C68 Urinary organs, NOS	11	-	-	-	-	-	-	-	-	-	-	-	0.3	0.4	0.8	1.7	0.5	1.2	0.2	0.1	0.1	0.0	
C69 Eye and adnexa	56	2.6	-	-	-	-	-	0.8	0.3	0.5	1.3	0.9	1.2	1.2	2.8	3.4	2.2	3.0	1.0	0.8	0.8	0.1	
C70 Meninges	10	-	-	-	-	-	-	-	0.3	-	-	-	0.3	0.8	0.4	1.3	-	0.6	0.2	0.1	0.1	0.0	
C71 Brain	322	2.9	3.1	1.0	1.6	1.2	3.2	3.7	1.9	2.3	3.7	6.3	7.8	9.4	13.2	15.4	19.6	13.4	9.0	5.8	4.7	0.4	
C72 Spinal cord, cranial nerves and CNS, NOS	18	1.0	1.0	0.3	0.3	0.3	0.3	-	0.3	0.5	-	0.5	-	-	0.4	0.9	-	-	0.3	0.4	0.4	0.0	
C73 Thyroid gland	651	-	0.3	1.0	3.1	4.9	7.8	13.8	16.8	13.6	17.0	20.3	24.6	16.2	18.5	14.2	9.8	15.6	11.8	10.8	8.8	0.9	
C74 Adrenal gland	29	1.6	0.3	-	0.3	0.3	0.3	-	0.8	0.2	0.8	0.9	0.9	0.8	0.8	-	-	1.2	0.5	0.5	0.5	0.0	
C75 Endocrine glands, NOS	6	-	0.3	-	-	-	-	-	-	0.2	0.3	-	0.3	0.4	-	0.4	-	-	0.1	0.1	0.1	0.0	
C81 Hodgkin's disease	149	-	0.3	1.0	5.0	6.7	6.4	2.6	3.8	2.3	1.5	1.8	2.6	2.2	4.1	0.8	2.1	2.7	1.2	2.7	2.7	0.2	
C82-C86 Non-Hodgkin-lymphoma	926	1.0	1.0	0.3	0.6	2.4	2.6	5.8	6.0	6.4	12.1	13.0	16.5	26.2	44.0	47.1	63.0	68.9	56.6	16.8	11.6	8.4	
C88 Malignant immunoproliferative diseases	111	0.3	-	-	-	-	0.3	-	1.4	0.5	1.7	1.3	2.9	1.9	5.3	6.5	7.7	8.6	6.6	2.0	1.4	0.1	
C90 Multiple myeloma	327	-	-	-	-	-	-	0.9	0.5	0.8	2.7	4.2	7.8	11.2	15.6	19.1	25.1	30.7	16.9	5.9	3.8	2.6	
C91 Lymphoid leukaemia	343	4.6	2.7	2.0	1.6	-	0.3	0.6	0.8	2.1	3.0	6.0	6.6	12.5	13.2	17.5	21.7	19.4	21.7	6.2	4.6	3.8	
C92 Myeloid leukaemia	292	1.6	0.3	1.0	0.3	1.8	1.2	1.7	2.2	4.4	4.9	4.2	5.5	6.9	11.1	15.4	15.3	17.2	18.7	5.3	3.9	3.1	
C93 Monocytic leukaemia	40	-	-	0.3	-	-	0.3	0.3	-	0.5	1.0	-	0.6	0.6	2.9	2.4	2.1	2.2	3.0	0.7	0.5	0.4	
C94-C95 Leukaemia other	30	0.7	-	-	-	-	-	0.3	0.3	0.7	0.3	0.9	0.3	-	1.2	2.6	3.2	1.8	0.5	0.4	0.3	0.0	
C96 Lymphoid, haematopoietic and related tissue, NOS	28	2.9	0.7	0.3	0.3	-	0.6	-	1.0	0.5	0.3	-	0.6	0.8	0.8	-	-	-	0.5	0.6	0.7	0.0	
C76 Other and ill-defined sites	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	1.1	-	0.1	0.0	0.0	-	
C80 Unknown primary site	408	-	-	-	0.3	0.3	0.3	1.1	0.5	4.2	5.7	7.5	10.9	13.6	24.0	29.0	33.4	45.8	7.4	4.5	3.0	0.3	
MPD Myeloproliferative Disorders	247	-	-	0.3	0.3	0.9	0.6	-	1.1	1.8	3.2	4.2	4.0	7.2	7.4	16.2	19.6	19.4	13.9	4.5	3.0	2.1	
MDS Myelodysplastic syndromes	212	0.7	0.3	-	-	-	0.6	0.9	-	0.3	1.0	1.3	2.9	4.7	6.6	11.0	17.9	25.3	22.3	3.8	2.2	1.5	
Total	30,533	25.4	13.4	14.8	26.1	42.2	72.2	122.0	200.7	317.0	480.0	654.2	846.3	1,092.2	1,284.7	1,400.7	1,594.8	1,774.7	1,805.7	552.4	404.5	295.1	28.1
Total excl. non-melanoma	28,750	25.4	13.4	14.1	25.1	41.6	71.0	119.1	198.0	310.1	470.9	639.1	824.6	1,062.9	1,236.6	1,323.1	1,474.3	1,597.7	1,479.7	520.1	387.2	284.0	27.3
Total excl. non-melanoma and MDS, MPD	28,291	24.8	13.0	13.8	24.8	40.7	69.9	118.2	196.9	308.0	466.7	633.6	817.7	1,051.1	1,222.6	1,295.9	1,436.8	1,553.1	1,443.6	511.8	382.1	280.4	27.0

CR: crude (all ages) incidence rate (N/100,000 person years)
 ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
 CRI: Cumulative Risk (0-74-years)

Flemish Region: Males, number of invasive tumours by primary site and age group in 2010

		Total	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00	Lip	41	-	-	-	-	-	-	-	-	2	-	1	1	3	6	3	11	11	3
C01	Base of tongue	51	-	-	-	-	-	-	-	1	1	5	5	11	10	6	4	3	3	2
C02	Tongue	76	-	-	-	1	1	1	-	2	3	6	9	16	11	9	8	3	4	3
C03	Gum	17	-	-	-	-	-	-	-	-	-	-	2	3	3	2	-	3	1	-
C04	Floor of mouth	79	-	-	-	-	-	-	-	-	1	6	27	15	14	3	4	7	2	-
C05	Palate	28	-	-	-	-	-	-	-	-	-	-	1	6	14	2	1	3	-	1
C06	Mouth, NOS	31	-	-	-	-	-	-	-	-	2	2	2	3	6	5	3	4	1	3
C07	Parotid gland	32	-	-	1	-	-	1	-	-	1	3	3	1	5	2	1	7	3	4
C08	Salivary glands, NOS	8	-	-	-	1	-	-	-	-	-	-	-	1	1	3	1	1	-	-
C09	Tonsil	69	-	-	-	-	-	-	-	-	2	8	10	14	14	10	8	3	-	-
C10	Oropharynx	74	-	-	-	-	-	-	-	-	1	10	8	12	14	12	8	4	3	2
C11	Nasopharynx	22	-	-	-	-	1	-	1	2	-	3	4	3	-	3	4	-	-	1
C12	Pyriiform sinus	55	-	-	-	-	-	-	-	-	-	2	5	16	9	11	7	1	3	1
C13	Hypopharynx	29	-	-	-	-	-	-	-	-	-	2	8	4	5	5	1	1	3	-
C14	Lip, oral cavity and pharynx, NOS	6	-	-	-	-	-	-	-	-	-	-	-	1	2	1	-	1	1	-
C15	Oesophagus	408	-	-	-	-	-	-	2	2	2	16	40	44	53	66	69	52	35	27
C16	Stomach	549	-	-	-	-	-	2	2	4	7	24	24	50	57	72	83	90	79	55
C17	Small intestine	94	-	-	-	-	-	-	-	-	2	5	3	9	18	11	14	11	14	7
C18	Colon	1,874	-	1	3	3	3	5	5	13	18	36	76	133	182	268	295	365	298	170
C19	Rectosigmoid junction	104	-	-	-	-	-	-	-	-	-	2	7	9	11	14	20	18	16	7
C20	Rectum	916	-	-	-	-	3	2	2	5	11	35	56	103	131	135	137	131	110	55
C21	Anus and anal canal	30	-	-	-	-	-	-	-	-	1	2	2	2	4	9	4	2	2	2
C22	Liver and intrahepatic bile ducts	250	-	-	1	-	-	1	1	5	1	9	16	23	36	48	47	36	21	5
C23	Gallbladder	22	-	-	-	-	-	-	-	-	1	1	1	1	1	3	3	3	6	2
C24	Biliary tract, NOS	83	-	-	-	-	-	-	-	-	2	2	2	5	8	14	11	14	11	14
C25	Pancreas	446	-	-	-	1	2	2	2	5	4	10	30	38	51	66	79	75	53	30
C26	Other ill-defined digestive organs	9	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	5	2	-
C30	Nasal cavity and middle ear	20	2	-	-	-	-	-	-	-	-	-	1	1	4	2	4	2	1	3
C31	Accessory sinuses	43	-	-	-	-	-	-	-	-	-	3	3	6	10	3	4	9	3	2
C32	Larynx	310	-	-	-	-	-	-	-	-	6	9	26	39	42	58	40	44	36	10
C33	Trachea	5	-	-	-	-	-	-	-	-	-	-	1	-	-	2	-	1	-	1
C34	Bronchus and lung	3,348	-	-	-	-	-	-	4	8	23	67	152	301	431	493	641	621	410	197
C37	Thymus	6	-	-	-	-	-	-	-	-	-	1	-	-	2	-	3	-	-	-
C38	Heart, mediastinum and pleura	17	-	-	-	-	-	2	-	2	1	-	-	3	2	2	1	2	2	-
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	22	-	-	2	4	2	1	2	2	-	2	1	-	-	-	1	2	1	1
C41	Bone and articular cartilage, NOS	26	1	1	1	1	-	1	2	1	1	2	1	3	2	2	3	4	-	-
C43	Malignant melanoma of skin	468	-	-	-	2	4	16	13	27	32	45	35	52	50	39	50	51	33	19
C44	Malignant neoplasms of skin	1,597	-	1	-	-	1	4	2	6	12	19	42	45	94	139	215	348	359	310

Flemish Region: Males 2010																			
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	148	-	-	-	1	-	1	-	2	-	1	5	7	24	23	21	37	20	6
C46 Kaposi's sarcoma	12	-	-	-	-	-	1	1	2	-	3	2	1	-	-	-	-	-	2
C47,C49 Soft tissues	101	3	-	-	1	-	2	2	2	7	7	6	7	13	13	12	16	6	10
C48 Retroperitoneum and peritoneum	13	-	-	-	1	-	-	-	-	-	1	1	3	2	1	2	1	1	-
C50 Breast	47	-	-	-	-	-	-	-	-	3	1	6	7	10	3	7	7	3	-
C60 Penis	51	-	-	-	-	-	-	-	-	1	1	3	1	12	5	6	11	8	3
C61 Prostate	5,651	-	-	-	-	-	-	-	-	11	47	269	511	880	1,068	1,060	998	569	298
C62 Testis	165	3	-	-	7	24	26	39	20	17	10	2	7	6	2	-	1	1	-
C63 Male genital organs, NOS	10	-	-	-	-	-	-	-	-	-	-	-	1	4	1	1	1	2	-
C64 Kidney	651	2	1	-	-	-	2	1	9	17	34	51	62	105	103	71	100	52	41
C65 Renal pelvis	92	-	-	-	-	-	-	-	1	-	4	3	4	18	8	18	19	13	4
C66 Ureter	70	-	-	-	-	-	-	-	-	-	4	2	3	9	8	15	16	9	4
C67 Bladder	1,079	-	-	-	-	-	-	1	-	5	21	34	55	110	132	200	219	170	132
C68 Urinary organs, NOS	35	-	-	-	-	-	-	-	-	-	-	1	-	4	2	4	13	7	4
C69 Eye and adnexa	33	5	1	1	-	-	-	-	-	2	-	-	1	4	5	5	4	3	2
C70 Meninges	3	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	2	-
C71 Brain	262	5	2	3	5	3	4	14	8	13	12	27	24	33	27	39	24	14	5
C72 Spinal cord, cranial nerves and CNS, NOS	11	2	1	-	1	-	-	-	-	-	2	1	-	-	2	1	-	1	-
C73 Thyroid gland	92	-	-	-	-	3	3	4	7	8	13	9	6	10	10	7	9	3	-
C74 Adrenal gland	20	3	2	1	-	-	1	-	-	-	1	2	1	4	-	2	2	1	-
C75 Endocrine glands, NOS	7	-	-	-	-	1	1	1	1	-	-	-	-	-	1	1	1	-	1
C81 Hodgkin's disease	81	-	-	-	7	7	9	8	5	5	5	4	8	5	4	3	8	2	1
C82-C86 Non-Hodgkin-lymphoma	608	2	5	5	5	3	5	8	12	22	35	35	49	62	72	88	84	69	47
C88 Malignant immunoproliferative diseases	59	-	-	-	-	-	-	-	1	1	1	3	6	6	7	5	14	11	4
C90 Multiple myeloma	252	-	-	-	-	-	1	1	5	4	5	11	19	22	48	53	47	26	10
C91 Lymphoid leukaemia	310	10	5	6	4	3	3	1	2	4	13	24	31	37	36	50	40	23	18
C92 Myeloid leukaemia	208	2	-	1	2	1	2	4	6	8	11	14	14	17	15	27	35	30	19
C93 Monocytic leukaemia	28	-	-	-	-	-	-	-	-	1	1	-	1	4	5	5	5	2	4
C94-C95 Leukaemia other	22	-	-	-	-	-	-	-	-	4	1	1	1	3	3	4	4	4	2
C96 Lymphoid, haematopoietic and related tissue, NOS	16	3	2	-	2	-	1	1	1	1	1	-	1	2	-	-	-	1	-
C76 Other and ill-defined sites	2	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	-
C80 Unknown primary site	266	-	1	-	-	1	1	-	-	2	11	18	19	24	38	32	52	36	31
MPD Myeloproliferative Disorders	181	1	-	-	3	-	4	2	4	4	9	13	11	14	23	24	32	20	17
MDS Myelodysplastic syndromes	204	-	1	1	-	1	2	1	-	3	3	5	9	13	22	44	47	31	21
Total	22,055	44	24	26	50	63	107	126	173	276	597	1,168	1,852	2,738	3,153	3,586	3,782	2,667	1,623
Total excl. non-melanoma	20,458	44	23	26	50	62	103	124	167	264	578	1,126	1,807	2,644	3,014	3,371	3,434	2,308	1,313
Total excl. non-melanoma and MDS, MPD	20,073	43	22	25	47	61	97	121	163	257	566	1,108	1,787	2,617	2,969	3,303	3,355	2,257	1,275

Flemish Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
Flemish Region: Males 2010																							
C00 Lip	41	-	-	-	-	-	-	-	-	0.9	-	0.4	0.5	1.6	4.3	2.3	10.1	16.0	7.1	1.3	0.9	0.5	0.0
C01 Base of tongue	51	-	-	-	-	-	-	-	0.5	0.4	2.0	2.2	5.4	5.4	4.3	3.0	2.7	4.4	4.7	1.7	1.4	1.0	0.1
C02 Tongue	76	-	-	-	-	0.5	0.5	-	0.9	1.3	2.4	3.9	7.8	5.9	6.4	6.0	2.7	5.8	7.1	2.5	2.1	1.5	0.2
C03 Gum	17	-	-	-	-	-	-	-	-	0.8	1.3	1.5	1.6	1.4	-	-	2.7	1.5	-	0.6	0.4	0.3	0.0
C04 Floor of mouth	79	-	-	-	-	-	-	-	-	0.4	2.4	11.7	7.4	7.5	2.1	3.0	6.4	2.9	-	2.6	2.2	1.6	0.2
C05 Palate	28	-	-	-	-	-	-	-	-	0.4	2.6	6.9	1.1	0.7	2.3	-	-	-	2.4	0.9	0.8	0.6	0.1
C06 Mouth, NOS	31	-	-	-	-	-	-	-	-	0.9	0.8	0.9	1.5	3.2	3.6	2.3	3.7	1.5	7.1	1.0	0.8	0.6	0.1
C07 Parotid gland	32	-	-	0.6	-	-	0.5	-	-	0.4	1.2	1.3	0.5	2.7	1.4	0.8	6.4	4.4	9.5	1.0	0.8	0.6	0.0
C08 Salivary glands, NOS	8	-	-	-	0.5	-	-	-	-	-	-	-	0.5	0.5	2.1	0.8	0.9	-	-	0.3	0.2	0.2	0.0
C09 Tonsil	69	-	-	-	-	-	-	-	-	0.9	3.2	4.3	6.9	7.5	7.1	6.0	2.7	-	-	2.2	1.9	1.4	0.2
C10 Oropharynx	74	-	-	-	-	-	-	-	-	0.4	4.0	3.5	5.9	7.5	8.5	6.0	3.7	4.4	4.7	2.4	2.0	1.4	0.2
C11 Nasopharynx	22	-	-	-	-	0.5	-	0.5	0.9	1.2	1.7	1.5	-	2.1	3.0	-	-	-	2.4	0.7	0.6	0.5	0.1
C12 Pyriform sinus	55	-	-	-	-	-	-	-	-	0.8	2.2	7.8	4.8	7.8	5.3	0.9	4.4	2.4	4.4	1.8	1.5	1.0	0.1
C13 Hypopharynx	29	-	-	-	-	-	-	-	-	0.8	3.5	2.0	2.7	3.6	0.8	0.8	4.4	-	-	0.9	0.8	0.6	0.1
C14 Lip, oral cavity and pharynx, NOS	6	-	-	-	-	-	-	-	-	-	-	0.5	1.1	0.7	-	-	0.9	1.5	-	0.2	0.1	0.1	0.0
C15 Oesophagus	408	-	-	-	-	-	1.0	0.9	0.9	6.4	17.4	21.6	28.5	46.9	52.1	47.6	50.9	64.0	13.2	10.1	6.9	0.9	0.9
C16 Stomach	549	-	-	-	-	1.0	1.0	1.9	3.0	9.7	10.4	24.5	30.7	51.2	62.6	82.5	114.9	130.4	17.8	12.9	8.6	1.0	1.0
C17 Small intestine	94	-	-	-	-	-	-	-	0.9	2.0	1.3	4.4	9.7	7.8	10.6	10.1	20.4	16.6	3.0	2.2	1.5	0.2	0.2
C18 Colon	1,874	-	0.6	1.7	1.6	1.6	2.6	2.6	6.2	7.7	14.5	33.0	65.3	98.0	190.5	222.7	334.5	433.3	403.2	60.7	43.2	28.4	3.2
C19 Rectosigmoid junction	104	-	-	-	-	-	-	-	-	0.8	3.0	4.4	4.4	5.9	10.0	15.1	16.5	23.3	16.6	3.4	2.4	1.6	0.2
C20 Rectum	916	-	-	-	-	1.6	1.0	1.0	2.4	4.7	14.1	24.3	50.5	70.5	96.0	103.4	120.0	160.0	130.4	29.7	22.2	15.2	1.8
C21 Anus and anal canal	30	-	-	-	-	-	-	-	0.4	0.8	0.9	1.0	2.2	6.4	3.0	1.8	2.9	4.7	1.0	0.8	0.6	0.1	0.1
C22 Liver and intrahepatic bile ducts	250	-	-	0.6	-	0.5	0.5	2.4	2.4	0.4	3.6	6.9	11.3	19.4	34.1	35.5	33.0	30.5	11.9	8.1	6.2	4.4	0.6
C23 Gallbladder	22	-	-	-	-	-	-	-	-	0.4	0.4	0.4	0.5	0.5	2.1	2.3	2.7	8.7	4.7	0.7	0.5	0.3	0.0
C24 Biliary tract, NOS	83	-	-	-	-	-	-	-	-	0.9	0.8	0.9	2.5	4.3	10.0	8.3	12.8	16.0	33.2	2.7	1.9	1.3	0.1
C25 Pancreas	446	-	-	-	-	0.5	1.0	1.0	2.4	1.7	4.0	13.0	18.6	27.4	46.9	59.6	68.7	77.1	71.2	14.5	10.7	7.2	0.9
C26 Other ill-defined digestive organs	9	-	-	-	-	-	-	-	-	-	-	-	0.5	0.5	-	-	4.6	2.9	-	0.3	0.2	0.1	0.0
C30 Nasal cavity and middle ear	20	1.1	-	-	-	-	-	-	-	-	0.4	0.5	2.2	1.4	3.0	1.8	1.5	7.1	0.6	0.5	0.4	0.0	0.0
C31 Accessory sinuses	43	-	-	-	-	-	-	-	-	1.2	1.3	2.9	5.4	2.1	3.0	8.2	4.4	4.7	1.4	1.1	0.7	0.1	0.1
C32 Larynx	310	-	-	-	-	-	-	-	-	2.6	3.6	11.3	19.1	22.6	41.2	30.2	40.3	52.3	23.7	10.0	7.6	5.2	0.7
C33 Trachea	5	-	-	-	-	-	-	-	-	-	-	0.4	-	-	1.4	-	0.9	-	2.4	0.2	0.1	0.1	0.0
C34 Bronchus and lung	33,48	-	-	-	-	-	2.0	3.8	9.8	27.0	65.9	147.7	232.0	350.5	483.8	569.0	596.2	467.2	108.5	78.6	52.2	6.4	6.4
C37 Thymus	6	-	-	-	-	-	-	-	-	0.4	-	-	1.1	1.1	1.4	0.8	1.8	2.9	-	0.2	0.1	0.1	0.0
C38 Heart, mediastinum and pleura	17	-	-	-	-	-	1.0	-	0.9	0.4	-	-	1.5	1.1	1.4	0.8	1.8	2.9	-	0.6	0.5	0.4	0.0
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40 Bone and articular cartilage of limbs	22	-	-	1.2	2.1	1.1	0.5	1.0	0.9	-	0.8	0.4	-	-	0.7	1.5	0.9	1.5	2.4	0.7	0.7	0.7	0.1
C41 Bone and articular cartilage, NOS	26	0.6	0.6	0.6	0.5	-	0.5	1.0	0.5	0.4	0.8	0.4	1.5	1.1	1.4	2.3	3.7	-	-	0.8	0.8	0.7	0.1
C43 Malignant melanoma of skin	468	-	-	-	1.1	2.2	8.2	6.6	12.8	13.6	18.1	15.2	25.5	26.9	27.7	37.7	46.7	48.0	45.1	15.2	12.4	9.4	1.0
C44 Malignant neoplasms of skin	1,597	-	0.6	-	-	0.5	2.1	1.0	2.8	5.1	7.7	18.2	22.1	50.6	98.8	162.3	318.9	522.0	755.2	51.8	34.3	20.8	1.8

Flemish Region: Males 2010																							
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C45	148	-	-	-	0.5	-	0.5	-	0.9	-	0.4	2.2	3.4	12.9	16.4	15.8	33.9	29.1	14.2	4.8	3.4	2.3	0.3
C46	12	-	-	-	-	-	0.5	0.9	0.9	-	1.2	0.9	0.5	-	-	-	-	-	4.7	0.4	0.4	0.3	0.0
C47,C49	101	1.7	-	-	0.5	-	1.0	1.0	0.9	3.0	2.8	3.0	2.9	3.8	9.2	9.1	14.7	8.7	23.7	3.3	2.6	2.0	0.2
C48	13	-	-	-	0.5	-	-	-	-	0.4	0.4	1.5	1.1	0.7	1.5	1.5	0.9	1.5	-	0.4	0.3	0.3	0.0
C50	47	-	-	-	-	-	-	-	-	1.3	0.4	2.6	3.4	5.4	2.1	5.3	6.4	4.4	-	1.5	1.2	0.8	0.1
C60	51	-	-	-	-	-	-	-	0.4	0.4	1.3	0.5	0.5	6.5	3.6	4.5	10.1	11.6	7.1	1.7	1.2	0.8	0.1
C61	5,651	-	-	-	-	-	-	-	4.7	18.9	116.7	250.7	473.6	716.7	800.0	914.5	874.8	706.8	183.2	134.8	90.5	11.2	0.4
C62	165	1.7	-	-	3.7	13.0	13.4	19.9	9.5	7.2	4.0	0.9	3.4	3.2	1.4	-	0.9	1.5	-	5.3	5.6	5.5	0.4
C63	10	-	-	-	-	-	-	-	-	-	-	-	0.5	2.2	0.7	0.8	0.9	2.9	-	0.3	0.2	0.2	0.0
C64	651	1.1	0.6	-	-	-	1.0	0.5	4.3	7.2	13.7	22.1	30.4	56.5	73.2	53.6	91.6	75.6	97.2	21.1	16.3	11.5	1.3
C65	92	-	-	-	-	-	-	-	0.5	-	1.6	1.3	2.0	9.7	5.7	13.6	17.4	18.9	9.5	3.0	2.1	1.4	0.2
C66	70	-	-	-	-	-	-	-	-	-	1.6	0.9	1.5	4.8	5.7	11.3	14.7	13.1	9.5	2.3	1.6	1.0	0.1
C67	1,079	-	-	-	-	-	-	0.5	-	2.1	8.5	14.7	27.0	59.2	93.9	151.0	200.7	247.2	313.1	35.0	24.3	15.5	1.8
C68	35	-	-	-	-	-	-	-	-	-	-	0.4	-	2.2	1.4	3.0	11.9	10.2	9.5	1.1	0.7	0.4	0.0
C69	33	2.8	0.6	0.6	-	-	-	-	-	0.9	-	-	0.5	2.2	3.6	3.8	3.7	4.4	4.7	1.1	0.9	0.9	0.1
C70	3	-	-	-	-	-	-	-	-	-	-	0.4	-	-	-	-	-	2.9	-	0.1	0.1	0.0	0.0
C71	262	2.8	1.2	1.7	2.7	1.6	2.1	7.2	3.8	5.5	4.8	11.7	11.8	17.8	19.2	29.4	22.0	20.4	11.9	8.5	7.2	5.7	0.6
C72	11	1.1	0.6	-	0.5	-	-	-	-	-	0.8	0.4	-	-	1.4	0.8	-	1.5	-	0.4	0.4	0.4	0.0
C73	92	-	-	-	-	1.6	1.5	2.0	3.3	3.4	5.2	3.9	2.9	5.4	7.1	5.3	8.2	4.4	-	3.0	2.6	2.0	0.2
C74	20	1.7	1.2	0.6	-	-	0.5	-	-	-	0.4	0.9	0.5	2.2	-	1.5	1.8	1.5	-	0.6	0.6	0.6	0.0
C75	7	-	-	-	-	0.5	0.5	-	0.5	-	-	-	-	-	0.7	0.8	0.9	-	2.4	0.2	0.2	0.2	0.0
C81	81	-	-	-	3.7	3.8	4.6	4.1	2.4	2.1	2.0	1.7	3.9	2.7	2.8	2.3	7.3	2.9	2.4	2.6	2.5	2.2	0.2
C82-C86	608	1.1	3.0	2.9	2.7	1.6	2.6	4.1	5.7	9.4	14.1	15.2	24.0	33.4	51.2	66.4	77.0	100.3	111.5	19.7	15.2	11.0	1.2
C88	59	-	-	-	-	-	-	-	0.5	0.4	0.4	1.3	2.9	3.2	5.0	3.8	12.8	16.0	9.5	1.9	1.3	0.9	0.1
C90	252	-	-	-	-	-	0.5	0.5	2.4	1.7	2.0	4.8	9.3	11.8	34.1	40.0	43.1	37.8	23.7	8.2	6.0	4.1	0.5
C91	310	5.7	3.0	3.5	2.1	1.6	1.5	0.5	0.9	1.7	5.2	10.4	15.2	19.9	25.6	37.7	36.7	33.4	42.7	10.0	8.2	6.4	0.7
C92	208	1.1	-	0.6	1.1	0.5	1.0	2.0	2.8	3.4	4.4	6.1	6.9	9.1	10.7	20.4	32.1	43.6	45.1	6.7	5.1	3.6	0.4
C93	28	-	-	-	-	-	-	-	-	0.4	0.4	-	0.5	2.2	3.6	3.8	4.6	2.9	9.5	0.9	0.7	0.4	0.1
C94-C95	22	-	-	-	-	-	-	-	-	-	-	1.7	0.5	0.5	2.1	2.3	3.7	5.8	4.7	0.7	0.5	0.3	0.0
C96	16	1.7	1.2	-	1.1	-	0.5	0.5	0.5	0.4	0.4	-	0.5	1.1	-	-	0.9	-	-	0.5	0.6	0.6	0.0
C76	2	-	-	-	-	-	-	-	-	-	-	0.4	-	-	-	-	-	1.5	-	0.1	0.0	0.0	0.0
C80	266	-	0.6	-	-	0.5	0.5	-	-	0.9	4.4	7.8	9.3	12.9	27.0	24.2	47.6	52.3	73.5	8.6	6.3	4.1	0.4
MPD	181	0.6	-	-	1.6	-	2.1	1.0	1.9	1.7	3.6	5.6	5.4	7.5	16.4	18.1	29.3	29.1	40.3	5.9	4.5	3.2	0.3
MDS	204	-	0.6	0.6	-	0.5	1.0	0.5	-	1.3	1.2	2.2	4.4	7.0	15.6	33.2	43.1	45.1	49.8	6.6	4.6	3.0	0.3
Total	22,055	25.0	14.5	15.0	26.6	34.2	55.0	64.4	82.0	117.4	240.4	506.6	908.6	1,473.7	2,241.8	2,706.5	3,465.6	3,878.1	3,849.3	714.8	528.6	360.9	34.7
Total excl. non-melanoma	20,458	25.0	13.9	15.0	26.6	33.7	53.0	63.4	79.2	112.3	232.8	488.4	886.5	1,423.1	2,142.9	2,544.3	3,146.7	3,356.1	3,114.0	663.1	494.3	340.1	33.4
Total excl. non-melanoma and MDS, MPD	20,073	24.5	13.2	14.4	25.0	33.1	49.9	61.9	77.3	109.3	228.0	480.6	876.7	1,408.5	2,110.9	2,492.9	3,074.3	3,282.0	3,032.9	650.6	485.2	333.9	33.0

CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRI: Cumulative Risk (0-74 years)

Flemish Region: Females, number of invasive tumours by primary site and age group in 2010

Flemish Region: Females 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00	Lip	7	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	1	2	2
C01	Base of tongue	23	-	-	-	-	-	1	-	-	-	-	3	3	8	4	-	1	3	-
C02	Tongue	34	-	-	1	-	-	-	1	-	2	4	6	3	3	4	4	3	-	3
C03	Gum	10	-	-	-	-	-	-	-	-	-	1	1	1	2	1	2	1	-	1
C04	Floor of mouth	21	-	-	-	-	-	-	1	-	1	-	1	5	2	4	3	3	1	-
C05	Palate	11	-	-	-	-	-	-	-	1	-	1	3	1	1	-	2	-	1	1
C06	Mouth, NOS	31	-	-	-	-	-	-	-	-	-	1	3	2	4	-	6	4	8	3
C07	Parotid gland	22	-	-	-	-	3	-	1	-	-	2	2	1	2	3	1	-	3	4
C08	Salivary glands, NOS	16	-	-	-	1	1	1	-	-	1	1	5	1	-	1	1	2	-	1
C09	Tonsil	35	-	-	-	-	-	-	-	-	1	1	8	5	3	6	4	3	2	2
C10	Oropharynx	21	-	-	-	-	-	-	-	-	-	1	2	7	3	4	2	1	1	-
C11	Nasopharynx	8	1	-	-	-	1	-	-	-	1	2	1	-	-	-	-	-	2	-
C12	Pyrimiform sinus	7	-	-	-	-	-	-	-	-	-	-	2	3	1	-	-	1	-	-
C13	Hypopharynx	6	-	-	-	-	-	-	-	-	-	-	1	-	3	-	-	1	1	-
C14	Lip, oral cavity and pharynx, NOS	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
C15	Oesophagus	126	-	-	-	-	-	-	-	-	-	3	7	8	14	18	17	19	22	18
C16	Stomach	334	-	-	-	-	-	1	-	2	3	14	16	16	30	30	36	53	60	73
C17	Small intestine	75	-	-	-	-	-	-	-	1	2	4	5	5	10	7	14	9	9	9
C18	Colon	1,676	-	1	4	7	6	7	4	10	12	39	49	107	151	187	247	274	302	269
C19	Rectosigmoid junction	63	-	-	-	-	-	-	-	1	2	3	-	1	8	7	10	8	11	12
C20	Rectum	615	-	-	-	-	1	-	2	7	13	24	27	59	72	64	96	91	92	67
C21	Anus and anal canal	47	-	-	-	-	-	-	-	-	3	2	4	7	9	2	5	8	3	4
C22	Liver and intrahepatic bile ducts	100	-	-	-	-	2	1	1	2	2	1	11	8	7	9	18	17	9	12
C23	Gallbladder	52	-	-	-	-	-	-	-	-	1	-	3	2	4	4	3	14	10	11
C24	Biliary tract, NOS	57	-	-	-	-	-	-	-	-	-	2	2	3	6	6	10	13	10	5
C25	Pancreas	422	-	-	-	-	-	-	1	3	5	13	22	40	41	46	78	70	59	44
C26	Other ill-defined digestive organs	8	-	-	-	-	-	-	-	-	-	2	-	2	-	2	-	-	-	2
C30	Nasal cavity and middle ear	6	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	1	1	2
C31	Accessory sinuses	11	-	-	-	-	-	-	-	-	-	-	2	-	3	2	1	-	1	2
C32	Larynx	37	-	-	-	-	-	-	-	-	2	1	3	6	7	10	3	3	1	1
C33	Trachea	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-
C34	Bronchus and lung	1,195	-	-	-	-	1	2	5	10	23	53	121	178	176	152	162	150	97	65
C37	Thymus	6	-	-	-	-	-	-	-	-	-	-	-	-	1	2	1	2	-	-
C38	Heart, mediastinum and pleura	10	1	-	1	-	-	-	-	1	-	-	-	2	1	1	1	-	-	2
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	18	-	1	5	2	-	-	2	1	1	1	3	-	1	1	-	-	-	-
C41	Bone and articular cartilage, NOS	14	-	2	-	-	-	-	-	1	2	-	-	1	1	4	1	1	-	1
C43	Malignant melanoma of skin	678	1	-	8	10	28	28	35	49	64	78	87	57	72	51	49	55	39	35
C44	Malignant neoplasms of skin	1,116	-	2	2	-	1	1	7	5	15	24	32	43	59	84	126	171	214	331

Flemish Region: Females 2010														Total				
	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	-	-	-	-	-	-	-	-	-	1	3	4	2	5	9	3	6	2
C46 Kaposi's sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1
C47,C49 Soft tissues	96	-	1	-	1	1	3	2	6	6	11	5	11	5	12	10	11	9
C48 Retroperitoneum and peritoneum	18	-	-	-	-	-	-	-	-	2	2	-	3	2	1	2	2	3
C50 Breast	5731	-	-	-	3	24	71	196	369	578	692	632	726	617	547	535	415	326
C51 Vulva	128	-	-	-	-	1	1	1	5	7	11	9	7	7	12	25	23	19
C52 Vagina	28	-	-	-	-	-	-	-	-	2	2	4	3	2	1	4	2	7
C53 Cervix uteri	330	-	-	1	-	10	22	33	38	49	35	31	24	18	20	13	19	17
C54 Corpus uteri	826	-	-	-	-	-	-	5	12	23	51	81	117	135	137	139	76	50
C55 Uterus	4	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	1	2
C56 Ovary	510	-	-	1	4	3	4	11	12	19	52	55	66	59	64	64	55	41
C57 Female genital organs, NOS	26	-	-	-	-	-	-	-	1	-	1	2	6	4	6	-	4	2
C58 Placenta	3	-	-	-	-	1	-	-	-	-	1	-	-	-	-	-	-	-
C64 Kidney	368	4	-	1	1	3	2	4	9	10	19	25	44	46	56	71	46	27
C65 Renal pelvis	52	-	-	-	-	-	-	1	1	-	-	3	2	6	10	9	11	9
C66 Ureter	25	-	-	-	-	-	-	-	-	-	1	-	2	4	2	8	5	3
C67 Bladder	292	1	-	-	-	-	-	1	3	8	8	17	21	30	52	50	44	57
C68 Urinary organs, NOS	5	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	-	1
C69 Eye and adnexa	35	5	-	-	-	2	-	3	1	1	2	1	1	2	4	6	2	5
C70 Meninges	6	-	-	-	-	-	-	-	-	-	-	-	1	1	-	3	-	1
C71 Brain	192	2	4	2	1	3	7	4	6	4	14	15	17	22	29	26	22	7
C72 Spinal cord, cranial nerves and CNS, NOS	14	2	2	-	1	1	-	1	2	-	1	-	-	-	1	2	-	-
C73 Thyroid gland	286	-	1	1	5	7	12	17	26	20	31	28	29	26	24	18	14	10
C74 Adrenal gland	20	3	1	-	-	-	1	-	3	1	2	3	2	2	1	-	-	1
C75 Endocrine glands, NOS	4	-	1	-	-	-	-	-	-	1	-	-	-	-	-	1	-	-
C81 Hodgkin's disease	83	-	1	2	8	13	11	5	7	5	4	6	5	5	1	1	5	-
C82-C86 Non-Hodgkin-lymphoma	545	2	1	1	1	4	6	7	11	18	26	32	30	48	69	79	88	53
C88 Malignant immunoproliferative diseases	62	1	-	-	-	-	-	2	2	4	4	7	3	8	8	9	9	5
C90 Multiple myeloma	206	-	-	-	-	-	2	2	2	7	9	19	28	19	26	37	38	17
C91 Lymphoid leukaemia	187	6	5	3	2	-	1	2	2	5	4	12	11	23	15	27	31	20
C92 Myeloid leukaemia	176	3	1	2	-	4	2	3	4	11	10	12	13	14	12	25	24	18
C93 Monocytic leukaemia	22	-	-	1	-	-	1	-	1	2	-	-	2	4	2	3	2	4
C94-C95 Leukaemia other	23	2	-	-	-	-	-	-	-	3	-	1	1	-	1	6	6	3
C96 Lymphoid, haematopoietic and related tissue, NOS	19	6	2	1	-	-	1	-	3	1	1	-	1	1	2	-	-	-
C76 Other and ill-defined sites	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
C80 Unknown primary site	219	-	-	-	1	1	-	1	1	7	12	13	13	18	39	35	36	41
MPD Myeloproliferative Disorders	171	-	-	-	1	3	1	-	4	6	9	12	19	14	26	33	22	17
MDS Myelodysplastic syndromes	120	1	-	-	-	-	2	-	1	3	-	7	10	9	17	27	25	18
Total	17790	45	21	28	44	71	129	212	415	697	1,098	1,423	1,955	1,883	2,141	2,262	1,974	1,779
Total excl. non-melanoma	16,674	45	21	26	42	71	128	205	410	682	1,074	1,391	1,896	1,799	2,015	2,091	1,760	1,448
Total excl. non-melanoma and MDS, MPD	16,383	44	21	26	41	68	127	203	406	677	1,065	1,382	1,551	1,867	1,776	2,031	1,713	1,413

Flemish Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Flemish Region: Females 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C00 Lip	7	-	-	-	-	-	-	-	-	-	-	-	-	0.5	-	0.7	0.7	1.9	2.2	0.2	0.1	0.1	0.0
C01 Base of tongue	23	-	-	-	-	0.5	-	-	-	-	-	1.3	1.5	4.3	2.7	-	0.7	2.8	-	0.7	0.6	0.4	0.1
C02 Tongue	34	-	-	-	0.6	-	-	0.5	-	0.9	1.7	2.7	1.5	1.6	2.7	2.6	2.1	-	3.2	1.1	0.9	0.7	0.1
C03 Gum	10	-	-	-	-	-	-	-	-	0.4	0.4	0.5	1.1	0.7	1.3	0.7	-	-	1.1	0.3	0.2	0.2	0.0
C04 Floor of mouth	21	-	-	-	-	-	-	0.5	-	0.4	-	0.4	2.5	1.1	2.7	2.0	2.1	0.9	-	0.7	0.5	0.4	0.0
C05 Palate	11	-	-	-	-	-	-	-	0.5	-	0.4	1.3	0.5	0.5	-	1.3	-	0.9	1.1	0.3	0.3	0.2	0.0
C06 Mouth, NOS	31	-	-	-	-	-	-	-	-	0.4	1.3	1.0	2.1	-	4.0	2.8	7.4	3.2	1.0	0.6	0.4	0.0	0.0
C07 Parotid gland	22	-	-	-	-	1.7	-	0.5	-	0.8	0.9	0.5	1.1	2.0	0.7	-	2.8	4.3	0.7	0.5	0.4	0.0	0.0
C08 Salivary glands, NOS	16	-	-	-	0.6	0.6	0.5	-	-	0.4	0.4	2.2	0.5	-	0.7	0.7	1.4	-	1.1	0.5	0.4	0.4	0.0
C09 Tonsil	35	-	-	-	-	-	-	-	-	0.4	0.4	3.5	2.5	1.6	4.0	2.6	2.1	1.9	2.2	1.1	0.9	0.6	0.1
C10 Oropharynx	21	-	-	-	-	-	-	-	-	0.4	0.9	3.5	1.6	2.7	1.3	0.7	0.9	-	-	0.7	0.6	0.4	0.1
C11 Nasopharynx	8	0.6	-	-	-	0.6	-	-	-	0.4	0.8	0.4	-	-	-	-	-	1.9	-	0.3	0.2	0.2	0.0
C12 Pyriform sinus	7	-	-	-	-	-	-	-	-	0.9	1.5	0.5	-	1.6	-	-	0.7	-	-	0.2	0.2	0.1	0.0
C13 Hypopharynx	6	-	-	-	-	-	-	-	-	0.4	-	-	-	1.6	-	-	0.7	-	-	0.2	0.1	0.1	0.0
C14 Lip, oral cavity and pharynx, NOS	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.1	0.0	0.0	0.0	-
C15 Oesophagus	126	-	-	-	-	-	-	-	-	1.2	3.1	4.0	7.5	12.1	11.2	13.4	20.5	19.4	4.0	2.4	1.6	1.6	0.2
C16 Stomach	334	-	-	-	-	0.5	-	-	1.0	1.3	5.8	7.1	8.0	16.1	20.2	23.8	37.4	55.8	78.6	10.5	6.0	4.0	0.4
C17 Small intestine	75	-	-	-	-	-	-	-	0.5	0.9	1.7	2.2	2.5	5.4	4.7	9.3	6.4	8.4	9.7	2.4	1.6	1.1	0.1
C18 Colon	1,676	-	0.6	2.4	3.9	3.3	3.7	2.1	4.8	5.3	16.2	21.7	53.5	81.0	195.8	163.3	193.6	280.9	289.8	52.9	31.2	21.2	2.4
C19 Rectosigmoid junction	63	-	-	-	-	-	-	-	0.5	0.9	1.2	-	0.5	4.3	4.7	6.6	5.7	10.2	12.9	2.0	1.2	0.8	0.1
C20 Rectum	615	-	-	-	-	0.6	-	1.0	3.4	5.7	9.9	12.0	29.5	38.6	43.0	63.5	64.3	85.6	72.2	19.4	12.5	8.6	1.0
C21 Anus and anal canal	47	-	-	-	-	-	-	-	-	1.3	0.8	1.8	3.5	4.8	1.3	3.3	5.7	2.8	4.3	1.5	1.1	0.7	0.1
C22 Liver and intrahepatic bile ducts	100	-	-	-	-	1.1	0.5	0.5	1.0	0.9	0.4	4.9	4.0	3.8	6.1	11.9	12.0	8.4	12.9	3.2	2.1	1.5	0.2
C23 Gallbladder	52	-	-	-	-	-	-	-	-	0.4	-	1.3	1.0	2.1	2.7	2.0	9.9	9.3	11.9	1.6	0.9	0.5	0.0
C24 Biliary tract, NOS	57	-	-	-	-	-	-	-	-	0.8	0.9	1.5	3.2	4.0	6.6	9.2	9.3	5.4	1.8	1.1	0.7	0.1	0.1
C25 Pancreas	422	-	-	-	-	-	-	0.5	1.4	2.2	5.4	9.8	20.0	22.0	30.9	51.6	49.5	54.9	47.4	13.3	8.4	5.7	0.7
C26 Other ill-defined digestive organs	8	-	-	-	-	-	-	-	-	-	0.8	-	1.0	-	1.3	-	-	-	2.2	0.3	0.2	0.1	0.0
C30 Nasal cavity and middle ear	6	-	-	-	-	-	-	-	-	-	-	-	0.5	-	0.7	-	0.7	0.9	2.2	0.2	0.1	0.1	0.0
C31 Accessory sinuses	11	-	-	-	-	-	-	-	-	-	-	0.9	-	1.6	1.3	0.7	-	0.9	2.2	0.3	0.2	0.2	0.0
C32 Larynx	37	-	-	-	-	-	-	-	-	0.9	0.4	1.3	3.0	3.8	6.7	2.0	2.1	0.9	1.1	1.2	0.9	0.7	0.1
C33 Trachea	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.7	-	-	-	0.0	0.0	0.0	0.0
C34 Bronchus and lung	1,195	-	-	-	-	0.6	1.0	2.6	4.8	10.1	22.0	53.7	88.9	94.4	102.2	107.1	106.0	90.2	70.0	37.7	27.7	19.6	2.4
C37 Thymus	6	-	-	-	-	-	-	-	-	-	-	-	1.0	0.5	0.7	0.7	1.4	-	-	0.2	0.1	0.1	0.0
C38 Heart, mediastinum and pleura	10	0.6	-	-	-	-	-	-	0.5	-	-	-	-	0.5	0.7	0.7	-	-	2.2	0.3	0.3	0.3	0.0
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40 Bone and articular cartilage of limbs	18	-	0.6	3.0	1.1	-	-	1.0	0.5	0.4	0.4	1.3	-	0.5	0.7	-	-	-	-	0.6	0.6	0.7	0.0
C41 Bone and articular cartilage, NOS	14	-	-	1.2	-	-	-	-	0.5	0.9	-	-	0.5	0.5	2.7	0.7	0.7	-	1.1	0.4	0.4	0.3	0.0
C43 Malignant melanoma of skin	678	0.6	-	4.4	5.5	14.6	18.2	23.7	28.2	32.3	20.9	28.5	38.6	34.3	32.4	38.9	36.3	37.7	21.4	17.9	14.4	14.4	1.4
C44 Malignant neoplasms of skin	1,116	-	-	1.2	1.1	-	0.5	3.6	2.4	6.6	9.9	14.2	21.5	31.7	56.5	83.3	120.8	199.0	356.6	35.2	18.4	11.8	1.2

Brussels Capital Region: Males, number of invasive tumours by primary site and age group in 2010

Brussels Capital Region: Males 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00	Lip	3	-	-	-	-	-	-	-	-	-	1	1	-	-	-	1	-	-	-
C01	Base of tongue	8	-	-	-	-	-	-	-	-	-	1	1	1	-	2	1	1	1	-
C02	Tongue	17	-	-	-	-	-	-	-	1	-	1	4	1	3	3	2	1	1	-
C03	Gum	2	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1
C04	Floor of mouth	12	-	-	-	-	-	-	-	-	-	1	1	5	2	2	-	1	-	-
C05	Palate	6	-	-	-	-	-	-	-	-	-	1	1	1	2	-	-	1	-	-
C06	Mouth, NOS	6	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	-	-	1
C07	Parotid gland	2	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-
C08	Salivary glands, NOS	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-
C09	Tonsil	12	-	-	-	-	-	-	-	-	-	1	1	1	2	3	1	1	2	-
C10	Oropharynx	13	-	-	-	-	-	-	-	-	1	2	4	2	2	1	1	-	-	-
C11	Nasopharynx	8	-	-	-	-	-	-	-	-	2	1	1	1	1	-	-	1	1	-
C12	Pyriiform sinus	11	-	-	-	-	-	-	-	-	-	3	1	1	1	1	1	2	1	-
C13	Hypopharynx	5	-	-	-	1	-	-	-	-	-	-	1	1	1	1	-	-	-	-
C14	Lip, oral cavity and pharynx, NOS	2	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	1	-	-
C15	Oesophagus	41	-	-	-	-	-	-	-	-	-	-	6	9	5	3	4	5	5	4
C16	Stomach	71	-	-	-	-	-	1	-	1	2	6	3	3	8	7	9	11	12	8
C17	Small intestine	11	-	-	-	-	-	-	-	1	-	-	1	2	1	1	-	3	2	-
C18	Colon	239	-	1	-	1	-	1	1	5	1	9	10	13	34	26	36	38	39	24
C19	Rectosigmoid junction	24	-	-	-	-	-	-	-	-	-	-	1	2	2	5	3	4	4	3
C20	Rectum	91	-	-	-	-	-	1	1	3	-	4	9	10	14	16	15	6	5	7
C21	Anus and anal canal	7	-	-	-	-	-	-	1	-	-	1	-	-	1	1	2	1	-	-
C22	Liver and intrahepatic bile ducts	56	1	-	-	-	-	1	-	1	2	5	4	6	4	6	8	12	3	3
C23	Gallbladder	4	-	-	-	-	-	1	-	-	-	-	-	-	-	-	3	-	-	-
C24	Biliary tract, NOS	15	-	-	-	-	-	-	-	-	-	2	2	2	2	1	3	1	-	2
C25	Pancreas	65	-	-	-	-	-	-	-	1	1	4	3	6	7	11	6	11	7	8
C26	Other ill-defined digestive organs	4	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	2	-	-
C30	Nasal cavity and middle ear	4	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1	-	1	-
C31	Accessory sinuses	6	1	-	-	-	1	-	-	-	-	1	1	-	-	1	-	1	-	-
C32	Larynx	36	-	-	-	-	-	-	-	-	-	1	3	4	9	7	4	6	2	-
C33	Trachea	1	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-
C34	Bronchus and lung	450	-	-	-	-	-	2	-	1	7	11	37	50	72	68	72	66	40	24
C37	Thymus	3	-	-	-	-	-	-	-	-	1	-	-	-	1	-	-	1	-	-
C38	Heart, mediastinum and pleura	2	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	8	-	-	-	2	1	-	-	1	-	2	-	-	2	-	-	-	-	-
C41	Bone and articular cartilage, NOS	6	-	-	-	2	-	1	1	-	-	-	-	1	-	1	-	-	-	-
C43	Malignant melanoma of skin	80	-	-	-	-	1	2	6	6	5	3	5	10	14	6	7	8	5	2
C44	Malignant neoplasms of skin	242	-	-	-	-	-	1	2	2	-	3	8	4	17	7	28	52	52	66

Brussels Capital Region: Males 2010																			
Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	
C45	4	-	-	-	-	-	-	-	-	-	-	-	-	-	2	2	-	-	-
C46	13	-	-	-	-	1	-	2	-	3	2	-	-	-	1	1	1	-	2
C47,C49	12	-	-	-	1	1	-	-	-	1	1	3	2	1	-	-	2	-	-
C48	4	-	-	-	-	1	-	-	-	-	1	-	-	-	-	2	-	-	-
C50	9	-	-	-	-	-	-	-	-	2	-	2	1	1	1	2	-	1	-
C60	7	-	-	-	-	-	-	-	1	-	-	1	-	2	1	1	1	1	-
C61	536	-	-	-	-	-	-	-	1	7	28	48	72	86	95	101	45	43	-
C62	32	-	-	1	1	9	6	4	4	1	3	1	-	1	1	-	-	-	-
C63	3	-	-	-	-	-	-	-	1	-	1	-	-	-	-	-	-	1	-
C64	75	1	-	-	-	1	-	4	1	6	9	12	12	8	4	12	4	1	-
C65	10	-	-	-	-	-	-	-	1	-	-	2	1	-	2	1	1	1	2
C66	6	-	-	-	-	-	-	-	-	-	-	-	2	1	-	2	1	-	-
C67	140	-	-	-	-	-	-	3	1	1	2	12	15	21	27	28	12	18	-
C68	1	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-
C69	8	2	-	1	-	-	-	-	-	-	1	-	1	1	1	-	1	1	-
C70	2	-	-	-	-	-	-	-	1	1	-	-	-	-	-	-	-	-	-
C71	44	2	-	1	2	2	1	4	3	3	6	3	4	2	5	2	1	3	-
C72	2	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-
C73	30	-	-	-	1	1	2	3	2	4	2	6	2	2	2	1	1	-	-
C74	3	2	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-
C75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	27	-	1	-	1	2	4	8	2	1	2	2	-	2	1	1	-	-	-
C82-C86	89	-	-	1	2	2	2	2	6	11	6	9	4	11	8	11	8	7	-
C88	8	-	-	-	-	-	-	-	-	1	-	3	-	1	2	1	-	-	-
C90	41	-	-	-	-	-	-	-	-	3	2	4	6	4	7	9	3	3	-
C91	37	2	1	1	-	-	2	-	-	1	2	8	5	2	2	2	5	4	-
C92	24	1	1	-	2	1	-	4	-	1	-	1	1	-	3	5	-	2	-
C93	3	1	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-
C94-C95	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-
C96	2	-	1	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
C76	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C80	57	-	-	-	-	1	1	1	1	2	4	5	7	6	8	9	8	4	-
MPD	16	-	-	-	-	-	-	-	-	1	2	-	2	1	3	3	2	2	-
MDS	19	1	1	1	-	-	-	1	2	-	-	1	2	3	1	3	3	-	-
Total	2,830	14	6	5	13	11	31	59	49	116	186	262	351	344	389	437	282	244	-
Total excl. non-melanoma	2,588	14	6	5	13	11	30	57	49	113	178	258	334	337	361	385	230	178	-
Total excl. non-melanoma and MDS, MPD	2,553	13	5	4	13	11	30	56	47	112	176	257	330	333	357	379	225	176	-

Brussels Capital Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Brussels Capital Region: Males 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI	
C00	Lip	3	-	-	-	-	-	-	-	-	-	2.8	3.2	-	-	-	6.9	-	-	-	-	0.6	0.6	0.5	0.1
C01	Base of tongue	8	-	-	-	-	-	-	-	-	-	2.8	3.2	3.7	-	11.8	6.9	8.1	11.4	-	-	1.5	1.6	1.1	0.1
C02	Tongue	17	-	-	-	-	-	-	-	2.2	-	2.8	12.9	3.7	13.2	17.8	13.7	8.1	11.4	-	-	3.2	3.5	2.6	0.3
C03	Gum	2	-	-	-	-	-	-	-	-	-	-	-	-	4.4	-	-	-	-	-	-	14.9	0.4	0.4	0.0
C04	Floor of mouth	12	-	-	-	-	-	-	-	-	-	2.8	3.2	18.6	8.8	11.8	-	8.1	-	-	-	2.3	2.6	1.9	0.2
C05	Palate	6	-	-	-	-	-	-	-	-	-	2.8	3.2	3.7	8.8	-	-	8.1	-	-	-	1.1	1.2	0.9	0.1
C06	Mouth, NOS	6	-	-	-	-	-	-	-	-	-	-	3.2	3.7	4.4	5.9	6.9	-	11.4	-	-	1.1	1.2	0.9	0.1
C07	Parotid gland	2	-	-	-	-	-	-	-	-	-	-	3.2	-	-	5.9	-	-	-	-	-	0.4	0.5	0.3	0.0
C08	Salivary glands, NOS	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.9	-	11.4	-	-	0.4	0.3	0.2	0.0
C09	Tonsil	12	-	-	-	-	-	-	-	-	-	2.8	3.2	3.7	8.8	17.8	6.9	8.1	22.8	-	-	2.3	2.4	1.7	0.2
C10	Oropharynx	13	-	-	-	-	-	-	-	-	2.4	5.5	12.9	7.4	8.8	5.9	6.9	-	-	-	-	2.5	2.8	2.1	0.2
C11	Nasopharynx	8	-	-	-	-	-	-	-	-	4.8	2.8	3.2	3.7	4.4	-	-	8.1	11.4	-	-	1.5	1.5	1.1	0.1
C12	Pyiform sinus	11	-	-	-	-	-	-	-	-	-	8.3	3.2	3.7	4.4	5.9	6.9	16.3	11.4	-	-	2.1	2.1	1.5	0.2
C13	Hypopharynx	5	-	-	-	-	-	-	-	-	-	-	3.2	3.7	4.4	5.9	-	-	-	-	-	0.9	1.1	1.0	0.1
C14	Lip, oral cavity and pharynx, NOS	2	-	-	-	3.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	0.4	0.2	0.0
C15	Oesophagus	41	-	-	-	-	-	-	-	-	-	-	19.3	33.5	21.9	17.8	27.5	40.7	56.9	59.6	7.8	8.0	5.3	0.6	
C16	Stomach	71	-	-	-	-	-	2.2	-	2.2	4.8	16.5	9.7	11.2	35.1	41.4	61.9	89.5	136.6	119.3	13.5	12.8	8.6	0.9	
C17	Small intestine	11	-	-	-	-	-	-	-	2.2	-	-	3.2	7.4	4.4	5.9	-	24.4	22.8	-	-	2.1	2.0	1.3	0.1
C18	Colon	239	-	3.0	-	3.3	-	2.2	2.1	10.9	2.4	24.8	32.2	48.4	149.2	153.9	247.5	309.0	444.0	357.8	45.4	43.8	29.4	3.3	
C19	Rectosigmoid junction	24	-	-	-	-	-	-	-	-	-	-	3.2	7.4	8.8	29.6	20.6	32.5	45.5	44.7	4.6	4.5	2.9	0.3	
C20	Rectum	91	-	-	-	-	-	2.2	2.1	6.6	-	11.0	29.0	37.2	61.5	94.7	103.1	48.8	56.9	104.4	17.3	18.3	12.9	1.7	
C21	Anus and anal canal	7	-	-	-	-	-	-	2.1	-	-	2.8	-	-	4.4	5.9	13.7	8.1	-	-	1.3	1.4	1.0	0.1	
C22	Liver and intrahepatic bile ducts	56	2.4	-	-	-	-	2.2	2.2	4.8	4.8	13.8	12.9	22.3	17.6	35.5	55.0	97.6	34.2	44.7	10.6	10.7	7.5	0.8	
C23	Gallbladder	4	-	-	-	-	-	2.2	-	-	-	-	-	-	-	-	20.6	-	-	-	-	0.8	0.8	0.6	0.1
C24	Biliary tract, NOS	15	-	-	-	-	-	-	-	-	-	5.5	6.4	7.4	8.8	5.9	20.6	8.1	-	29.8	2.8	3.0	2.1	0.3	
C25	Pancreas	65	-	-	-	-	-	-	2.2	2.4	2.4	11.0	9.7	22.3	30.7	65.1	41.2	89.5	79.7	119.3	12.3	12.3	8.2	0.9	
C26	Other ill-defined digestive organs	4	-	-	-	-	-	-	-	-	-	-	-	-	4.4	5.9	-	16.3	-	-	-	0.8	0.8	0.5	0.1
C30	Nasal cavity and middle ear	4	-	-	-	-	-	-	-	-	-	-	-	-	4.4	5.9	6.9	-	11.4	-	-	0.8	0.8	0.5	0.1
C31	Accessory sinuses	6	2.4	-	-	-	2.9	-	-	-	-	2.8	3.2	-	-	5.9	-	8.1	-	-	-	1.1	1.2	1.1	0.1
C32	Larynx	36	-	-	-	-	-	-	-	-	-	2.8	9.7	14.9	39.5	41.4	27.5	48.8	22.8	-	-	6.8	7.4	5.2	0.7
C33	Trachea	1	-	-	-	-	-	-	-	-	-	-	-	-	3.7	-	-	-	-	-	-	0.2	0.2	0.1	0.0
C34	Bronchus and lung	450	-	-	-	-	-	4.4	-	2.2	16.9	30.3	119.0	186.1	316.1	402.6	495.0	536.7	455.4	357.8	85.4	88.9	60.8	7.6	
C37	Thymus	3	-	-	-	-	-	-	-	-	2.4	-	-	-	4.4	-	-	8.1	-	-	-	0.6	0.6	0.4	0.0
C38	Heart, mediastinum and pleura	2	-	-	-	-	-	-	-	-	-	-	-	-	-	5.9	-	-	-	-	-	0.4	0.5	0.3	0.0
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	8	-	-	-	6.6	2.9	-	-	2.2	-	5.5	-	-	8.8	-	-	-	-	-	-	1.5	1.6	1.6	0.1
C41	Bone and articular cartilage, NOS	6	-	-	-	6.6	-	2.2	2.1	-	-	-	-	3.7	-	5.9	-	-	-	-	-	1.1	1.2	1.2	0.1
C43	Malignant melanoma of skin	80	-	-	-	-	2.9	4.4	12.4	13.1	12.1	8.3	16.1	37.2	61.5	35.5	48.1	65.1	56.9	29.8	15.2	15.2	11.2	1.3	
C44	Malignant neoplasms of skin	242	-	-	-	-	-	2.2	4.1	4.4	-	8.3	25.7	14.9	74.6	41.4	19.2.5	422.9	592.1	984.0	45.9	39.4	23.3	1.8	

Brussels Capital Region: Females, number of invasive tumours by primary site and age group in 2010

Brussels Capital Region: Females 2010																				
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C01	Base of tongue	4	-	-	-	1	-	-	-	-	1	-	-	1	-	-	1	-	-	-
C02	Tongue	8	-	-	-	-	-	1	-	-	-	1	2	2	1	-	-	-	1	-
C03	Gum	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C04	Floor of mouth	6	-	-	-	-	-	-	-	-	-	1	2	1	-	2	-	-	-	-
C05	Palate	3	-	-	-	1	-	-	-	-	-	-	-	2	-	-	-	-	-	-
C06	Mouth, NOS	4	-	-	-	-	-	-	-	-	-	1	-	1	-	-	1	-	-	1
C07	Parotid gland	1	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-
C08	Salivary glands, NOS	2	-	-	-	-	-	1	-	-	-	-	-	-	1	-	-	-	-	-
C09	Tonsil	5	-	-	-	-	-	-	-	-	1	1	1	-	1	-	1	-	-	-
C10	Oropharynx	4	-	-	-	-	-	-	-	-	-	-	1	1	-	1	1	-	-	-
C11	Nasopharynx	3	-	-	-	-	-	-	-	-	-	-	-	1	2	-	-	-	-	-
C12	Pyrimform sinus	3	-	-	-	-	-	-	-	-	-	1	-	1	-	-	1	-	-	-
C13	Hypopharynx	3	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	1	-
C14	Lip, oral cavity and pharynx, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	25	-	-	-	-	-	-	-	-	1	1	4	3	6	1	4	2	3	-
C16	Stomach	48	-	-	-	-	-	-	-	2	-	3	4	4	4	5	9	8	9	-
C17	Small intestine	4	-	-	-	-	-	-	1	-	-	1	-	-	-	1	1	-	-	-
C18	Colon	236	-	1	1	1	1	1	3	3	3	10	17	22	22	19	32	51	49	-
C19	Rectosigmoid junction	16	-	-	-	-	-	-	-	1	1	1	2	-	2	1	2	4	2	-
C20	Rectum	65	-	-	-	1	-	1	-	4	4	2	6	10	10	2	10	8	7	-
C21	Anus and anal canal	15	-	-	-	-	-	-	2	-	2	4	1	2	1	1	-	2	-	-
C22	Liver and intrahepatic bile ducts	21	-	-	-	-	-	1	-	-	-	1	1	2	5	4	3	2	2	-
C23	Gallbladder	9	-	-	-	-	-	-	-	-	-	1	-	1	2	3	1	-	1	-
C24	Biliary tract, NOS	17	-	-	-	-	-	-	-	1	1	-	2	1	2	-	3	2	5	-
C25	Pancreas	68	-	-	-	-	-	-	-	-	1	2	3	11	7	16	11	11	6	-
C26	Other ill-defined digestive organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C30	Nasal cavity and middle ear	2	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-
C31	Accessory sinuses	3	-	-	-	1	-	-	-	-	-	-	-	1	-	-	1	-	-	-
C32	Larynx	12	-	-	-	-	-	-	-	1	-	4	3	1	2	1	-	-	-	-
C33	Trachea	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C34	Bronchus and lung	206	-	-	-	-	2	1	6	14	12	30	30	30	30	22	24	24	11	-
C37	Thymus	2	-	-	-	-	-	-	-	-	1	1	-	-	-	-	-	-	-	-
C38	Heart, mediastinum and pleura	2	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	1	-
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C41	Bone and articular cartilage, NOS	5	-	-	-	-	-	-	-	1	1	-	-	2	1	-	-	-	-	-
C43	Malignant melanoma of skin	102	-	-	1	1	-	4	9	10	3	15	11	9	5	11	6	8	6	-
C44	Malignant neoplasms of skin	189	-	-	1	1	1	1	2	2	3	4	5	2	8	17	37	32	72	-

Brussels Capital Region: Females 2010																				
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	
C45	Mesothelioma	6	-	-	-	-	-	-	-	-	-	-	-	2	1	-	-	2	1	
C46	Kaposi's sarcoma	4	-	-	-	-	1	-	-	-	-	-	-	1	-	-	-	-	1	
C47,C49	Soft tissues	15	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	2	2	
C48	Retroperitoneum and peritoneum	3	-	-	-	-	1	-	-	-	-	-	-	2	-	-	-	-	-	
C50	Breast	927	-	-	-	-	5	26	38	62	94	98	92	124	94	84	81	72	57	
C51	Vulva	19	-	-	-	-	-	1	1	1	3	2	1	-	2	-	1	4	3	
C52	Vagina	3	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	1	
C53	Cervix uteri	57	-	-	-	-	1	5	3	15	4	3	4	7	2	2	5	5	1	
C54	Corpus uteri	115	-	-	-	-	-	-	1	1	9	7	6	13	19	12	21	15	11	
C55	Uterus	1	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	
C56	Ovary	83	-	-	1	-	1	-	-	3	5	6	11	10	5	13	7	12	9	
C57	Female genital organs, NOS	5	-	-	-	-	-	1	-	-	-	-	-	-	-	1	1	2	-	
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C64	Kidney	39	1	-	-	-	-	1	1	-	-	1	3	6	1	9	7	6	3	
C65	Renal pelvis	4	-	-	-	-	-	-	-	-	-	-	-	-	-	1	3	-	-	
C66	Ureter	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	
C67	Bladder	43	-	-	-	-	-	-	-	-	-	-	1	2	6	8	9	10	7	
C68	Urinary organs, NOS	2	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	
C69	Eye and adnexa	7	1	-	-	-	1	-	-	-	-	1	1	2	-	-	1	-	-	
C70	Meninges	2	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-	
C71	Brain	28	1	2	-	2	1	-	2	2	4	1	-	2	2	2	3	1	3	
C72	Spinal cord, cranial nerves and CNS, NOS	1	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C73	Thyroid gland	88	-	-	2	-	1	11	8	10	7	15	13	3	2	7	2	4	1	
C74	Adrenal gland	3	1	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	1	
C75	Endocrine glands, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C81	Hodgkin's disease	13	-	-	-	-	2	2	2	-	-	-	1	1	2	-	1	-	1	
C82-C86	Non-Hodgkin-lymphoma	95	1	1	-	1	2	4	4	-	6	5	10	9	9	9	10	14	10	
C88	Malignant immunoproliferative diseases	13	-	-	-	-	-	-	-	-	-	-	2	2	2	3	-	2	2	
C90	Multiple myeloma	29	-	-	-	-	-	-	-	-	2	6	-	-	2	7	1	6	5	
C91	Lymphoid leukaemia	29	2	1	-	-	-	-	1	1	1	1	3	2	2	3	2	5	5	
C92	Myeloid leukaemia	34	-	-	-	-	1	1	1	2	2	1	1	5	5	3	3	4	4	
C93	Monocytic leukaemia	3	-	-	-	-	-	-	-	-	-	-	1	-	1	-	1	-	-	
C94-C95	Leukaemia other	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	
C96	Lymphoid, haematopoietic and related tissue, NOS	5	3	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-	
C76	Other and ill-defined sites	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C80	Unknown primary site	42	-	-	-	-	-	-	-	-	1	2	1	6	2	4	11	5	10	
MPD	Myeloproliferative Disorders	15	-	-	-	-	-	-	-	-	3	1	-	-	-	4	2	4	1	
MDS	Myelodysplastic syndromes	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	2	
Total		2,837	11	5	6	7	13	22	72	83	122	178	218	252	311	276	283	324	339	315
Total excl. non-melanoma		2,648	11	5	6	6	12	21	70	81	119	176	214	247	309	268	266	287	307	243
Total excl. non-melanoma and MDS, MPD		2,624	11	5	6	6	12	21	70	81	119	173	213	247	309	268	262	283	298	240

Brussels Capital Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Brussels Capital Region: Females 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI	
C00	Lip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C01	Base of tongue	4	-	-	-	-	2.6	-	-	-	-	2.8	-	-	3.8	-	-	5.3	-	-	-	0.7	0.7	0.6	0.0
C02	Tongue	8	-	-	-	-	-	2.1	-	-	-	-	3.1	6.8	7.7	4.9	-	-	6.1	-	-	1.4	1.4	1.0	0.1
C03	Gum	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C04	Floor of mouth	6	-	-	-	-	-	-	-	-	-	-	3.1	6.8	3.8	-	10.3	-	-	-	-	1.1	1.1	0.8	0.1
C05	Palate	3	-	-	-	-	2.6	-	-	-	-	-	-	-	7.7	-	-	-	-	-	-	0.5	0.6	0.5	0.1
C06	Mouth, NOS	4	-	-	-	-	-	-	-	-	-	-	3.1	-	3.8	-	-	5.3	-	-	-	0.7	0.6	0.4	0.0
C07	Parotid gland	1	-	-	-	-	-	-	-	-	-	-	-	-	3.8	-	-	-	-	-	-	0.2	0.2	0.2	0.0
C08	Salivary glands, NOS	2	-	-	-	-	-	-	2.1	-	-	-	-	-	-	4.9	-	-	-	-	-	0.4	0.3	0.3	0.0
C09	Tonsil	5	-	-	-	-	-	-	-	-	-	2.8	3.1	3.4	-	4.9	-	5.3	-	-	-	0.9	0.9	0.7	0.1
C10	Oropharynx	4	-	-	-	-	-	-	-	-	-	-	3.4	3.8	-	5.2	5.3	-	-	-	-	0.7	0.7	0.4	0.1
C11	Nasopharynx	3	-	-	-	-	-	-	-	-	-	-	-	3.8	9.8	-	-	-	-	-	-	0.5	0.6	0.4	0.1
C12	Pyiform sinus	3	-	-	-	-	-	-	-	-	-	-	3.1	-	3.8	-	-	5.3	-	-	-	0.5	0.5	0.4	0.0
C13	Hypopharynx	3	-	-	-	-	-	-	-	-	-	-	-	6.8	-	-	-	-	6.1	-	-	0.5	0.5	0.3	0.0
C14	Lip, oral cavity and pharynx, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	25	-	-	-	-	-	-	-	-	2.8	3.1	13.6	11.5	29.5	5.2	21.3	12.1	16.8	4.4	-	3.9	2.7	0.3	0.3
C16	Stomach	48	-	-	-	-	-	-	-	5.3	-	9.2	13.6	15.3	19.7	25.9	47.9	48.5	50.3	8.5	-	6.1	4.0	0.4	0.4
C17	Small intestine	4	-	-	-	-	-	-	-	2.4	-	-	3.1	-	-	4.9	5.2	-	-	-	-	0.7	0.7	0.5	0.1
C18	Colon	236	-	-	3.5	3.4	2.6	2.0	2.1	7.1	8.0	8.5	30.8	57.7	84.4	108.2	98.3	170.3	309.1	273.6	41.9	29.0	19.6	2.1	2.1
C19	Rectosigmoid junction	16	-	-	-	-	-	-	-	-	2.7	2.8	3.1	6.8	-	9.8	5.2	10.6	24.2	11.2	2.8	2.1	1.4	0.2	0.2
C20	Rectum	65	-	-	-	3.4	-	-	2.1	-	10.7	11.4	6.2	20.4	38.4	49.2	10.3	53.2	48.5	39.1	11.6	9.7	7.1	0.8	0.8
C21	Anus and anal canal	15	-	-	-	-	-	-	-	4.7	-	5.7	12.3	3.4	7.7	4.9	5.2	-	12.1	-	2.7	2.7	2.0	0.2	0.2
C22	Liver and intrahepatic bile ducts	21	-	-	-	-	-	-	2.1	-	-	-	3.1	3.4	7.7	24.6	20.7	16.0	12.1	11.2	3.7	3.1	2.1	0.3	0.3
C23	Gallbladder	9	-	-	-	-	-	-	-	-	-	-	3.1	-	3.8	9.8	15.5	5.3	-	5.6	1.6	1.4	1.0	0.2	0.2
C24	Biliary tract, NOS	17	-	-	-	-	-	-	-	-	2.7	2.8	-	6.8	3.8	9.8	-	16.0	12.1	27.9	3.0	2.1	1.4	0.1	0.1
C25	Pancreas	68	-	-	-	-	-	-	-	-	2.8	2.8	6.2	10.2	42.2	34.4	82.8	58.5	66.7	33.5	12.1	9.4	6.3	0.9	0.9
C26	Other ill-defined digestive organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C30	Nasal cavity and middle ear	2	-	-	-	-	-	-	-	-	-	-	-	3.4	-	-	5.2	-	-	-	-	0.4	0.4	0.2	0.0
C31	Accessory sinuses	3	-	-	-	-	2.6	-	-	-	-	-	-	-	3.8	-	-	5.3	-	-	-	0.5	0.5	0.4	0.0
C32	Larynx	12	-	-	-	-	-	-	-	-	2.7	-	12.3	10.2	3.8	9.8	5.2	-	-	-	-	2.1	2.4	1.7	0.2
C33	Trachea	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C34	Bronchus and lung	206	-	-	-	-	-	-	4.2	2.4	16.0	39.8	37.0	101.9	115.1	147.6	113.8	127.7	145.5	61.4	36.6	32.8	23.3	2.8	2.8
C37	Thymus	2	-	-	-	-	-	-	-	-	2.8	3.1	-	-	-	-	-	-	-	-	-	0.4	0.4	0.3	0.0
C38	Heart, mediastinum and pleura	2	-	-	-	-	-	-	2.1	-	-	-	-	-	-	-	-	-	6.1	-	0.4	0.2	0.2	0.0	
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C41	Bone and articular cartilage, NOS	5	-	-	-	-	-	-	-	-	2.7	2.8	-	-	7.7	4.9	-	-	-	-	-	0.9	1.0	0.8	0.1
C43	Malignant melanoma of skin	102	-	-	3.5	3.4	-	8.0	18.7	23.6	8.0	8.5	46.2	37.3	34.5	24.6	56.9	31.9	48.5	33.5	18.1	16.5	12.6	1.4	1.4
C44	Malignant neoplasms of skin	189	-	-	-	3.4	2.6	2.0	4.2	4.7	8.0	5.7	12.3	17.0	7.7	39.3	88.0	19.6	194.0	402.1	33.6	18.5	11.5	1.0	1.0

Walloon Region: Males, number of invasive tumours by primary site and age group in 2010

Walloon Region: Males 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C00 Lip	6	-	-	-	-	-	-	-	-	-	-	-	-	1	-	2	2	1	-
C01 Base of tongue	31	-	-	-	-	-	-	-	-	-	2	4	7	6	6	4	2	-	-
C02 Tongue	55	-	-	-	-	-	1	1	1	5	2	6	10	14	4	4	3	3	1
C03 Gum	12	-	-	-	-	1	-	-	1	-	-	-	3	2	2	2	-	1	-
C04 Floor of mouth	66	-	-	-	-	-	-	1	1	1	6	10	19	11	9	3	3	1	1
C05 Palate	25	-	-	-	-	-	-	-	-	1	2	1	9	3	4	4	-	-	1
C06 Mouth, NOS	24	-	-	-	-	-	-	-	-	-	3	6	1	8	1	2	-	1	2
C07 Parotid gland	26	-	-	-	-	-	-	3	-	-	2	1	2	4	2	4	3	2	3
C08 Salivary glands, NOS	5	-	-	-	-	-	-	-	-	-	-	-	-	2	-	1	1	1	-
C09 Tonsil	54	-	-	-	-	-	-	-	-	2	6	6	12	10	9	4	4	-	1
C10 Oropharynx	47	-	-	-	-	-	-	-	-	-	4	6	12	12	5	5	2	1	-
C11 Nasopharynx	13	-	-	-	-	-	-	2	-	1	1	3	3	1	1	-	-	-	1
C12 Pyriform sinus	59	-	-	-	-	-	-	-	-	3	14	11	19	5	4	1	2	-	-
C13 Hypopharynx	23	-	-	-	-	-	-	1	-	-	2	5	4	5	2	-	2	1	1
C14 Lip, oral cavity and pharynx, NOS	10	-	-	-	-	-	-	-	-	-	-	-	3	2	1	3	-	1	-
C15 Oesophagus	231	-	-	-	-	-	-	-	-	-	9	35	35	41	25	27	26	21	12
C16 Stomach	234	-	-	-	-	-	-	2	3	3	8	19	21	28	30	36	35	31	18
C17 Small intestine	34	-	-	-	-	-	-	-	-	1	2	3	7	6	4	5	4	2	-
C18 Colon	854	-	-	-	2	1	2	2	5	14	17	61	80	84	105	155	137	124	65
C19 Rectosigmoid junction	50	-	-	-	-	-	-	-	-	-	2	-	4	8	10	6	9	7	4
C20 Rectum	404	-	-	-	-	-	1	-	4	9	15	27	48	66	53	55	51	49	26
C21 Anus and anal canal	19	-	-	-	-	-	-	-	-	-	1	3	4	1	4	2	2	-	2
C22 Liver and intrahepatic bile ducts	173	1	-	-	-	-	2	1	2	-	1	12	23	31	28	28	29	11	4
C23 Gallbladder	10	-	-	-	-	-	-	-	-	-	1	-	1	-	1	2	1	3	1
C24 Biliary tract, NOS	47	-	-	-	-	-	-	-	-	1	2	1	5	6	5	9	5	6	7
C25 Pancreas	274	-	-	-	-	1	1	1	3	2	12	7	22	49	45	37	45	36	13
C26 Other ill-defined digestive organs	9	-	-	-	-	-	-	-	-	-	-	-	2	-	2	-	4	-	1
C30 Nasal cavity and middle ear	6	-	-	-	-	-	-	-	-	-	-	1	-	2	1	1	-	1	-
C31 Accessory sinuses	14	-	-	-	-	-	-	-	1	2	-	2	3	1	2	1	1	-	1
C32 Larynx	195	-	-	-	-	-	-	-	-	2	18	18	40	37	23	25	20	7	5
C33 Trachea	4	-	-	-	-	-	-	-	-	-	-	1	2	1	-	-	-	-	-
C34 Bronchus and lung	1,818	-	-	-	-	1	2	3	1	17	46	131	225	306	250	298	277	193	68
C37 Thymus	12	-	-	1	-	-	-	-	-	-	-	4	3	-	1	-	2	1	-
C38 Heart, mediastinum and pleura	5	-	-	-	-	-	-	-	-	1	-	-	1	-	-	1	1	1	-
C39 Respiratory system and intrathoracic organs, NOS	3	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	1	-	-
C40 Bone and articular cartilage of limbs	6	-	-	4	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-
C41 Bone and articular cartilage, NOS	11	-	-	1	1	-	2	2	-	1	-	-	1	2	-	-	-	-	1
C43 Malignant melanoma of skin	323	-	-	1	3	8	13	13	21	25	27	27	32	32	28	36	29	17	11
C44 Malignant neoplasms of skin	692	-	-	-	-	1	-	3	2	6	7	18	38	55	71	113	122	125	131

Wallonia Region: Males 2010																			
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	52	-	-	-	-	-	-	-	-	1	2	2	3	4	9	9	10	8	4
C46 Kaposi's sarcoma	6	-	-	-	-	-	-	-	1	-	1	2	-	1	-	-	1	-	-
C47/C49 Soft tissues	49	2	2	-	1	1	1	-	4	2	1	-	7	9	7	9	-	1	2
C48 Retroperitoneum and peritoneum	6	-	-	-	-	-	-	-	-	-	-	-	1	1	1	2	1	-	-
C50 Breast	27	-	-	-	-	-	-	-	-	1	2	3	2	3	1	6	5	2	2
C60 Penis	27	-	-	-	-	-	-	-	2	-	1	2	3	2	5	3	5	2	2
C61 Prostate	2,486	-	-	-	-	-	-	-	1	5	22	119	271	443	468	442	399	200	116
C62 Testis	121	-	-	4	9	26	28	13	16	7	5	7	1	1	1	1	1	2	-
C63 Male genital organs, NOS	1	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-
C64 Kidney	255	1	-	-	-	-	-	-	11	6	11	23	31	41	41	41	23	22	4
C65 Renal pelvis	43	-	-	-	-	-	-	-	-	-	1	2	4	9	5	8	10	4	-
C66 Ureter	25	-	-	-	-	-	-	-	-	-	-	-	2	5	4	3	8	1	2
C67 Bladder	536	-	-	-	-	-	-	2	1	4	5	16	42	71	68	92	93	84	58
C68 Urinary organs, NOS	14	-	-	-	-	-	-	-	-	-	-	-	-	1	3	3	5	-	2
C69 Eye and adnexa	20	-	2	-	-	-	-	-	1	1	1	3	4	2	1	-	4	-	1
C70 Meninges	3	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	1	-
C71 Brain	147	4	4	2	-	3	6	4	5	15	13	11	19	16	15	15	9	4	2
C72 Spinal cord, cranial nerves and CNS, NOS	1	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-
C73 Thyroid gland	82	-	1	-	-	1	1	-	5	12	9	10	15	8	6	6	4	4	-
C74 Adrenal gland	6	1	-	-	-	-	-	-	-	-	-	-	2	2	-	-	-	1	-
C75 Endocrine glands, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81 Hodgkin's disease	46	-	1	2	4	4	3	2	4	3	5	4	2	4	-	3	4	-	1
C82-C86 Non-Hodgkin-lymphoma	324	-	1	4	3	1	3	8	7	13	20	30	31	43	34	43	36	29	18
C88 Malignant immunoproliferative diseases	36	-	-	-	-	-	-	-	1	1	4	-	2	2	9	3	7	6	1
C90 Multiple myeloma	131	-	-	-	-	-	-	-	-	-	3	7	14	16	11	21	26	20	13
C91 Lymphoid leukaemia	134	3	2	2	2	1	1	1	3	3	5	4	18	13	19	27	8	15	7
C92 Myeloid leukaemia	97	1	-	-	2	-	5	1	3	4	1	6	15	7	4	12	13	15	8
C93 Monocytic leukaemia	24	-	-	-	1	-	-	1	1	-	-	-	1	4	2	5	5	3	1
C94-C95 Leukaemia other	8	-	-	-	-	-	-	-	1	1	1	-	-	2	1	1	1	1	-
C96 Lymphoid, haematopoietic and related tissue, NOS	7	2	1	-	-	1	-	-	-	-	1	-	1	-	-	-	1	-	-
C76 Other and ill-defined sites	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C80 Unknown primary site	139	1	1	-	-	-	-	-	2	3	9	7	16	26	9	14	18	25	8
MPD Myeloproliferative Disorders	60	-	-	-	-	-	-	1	-	3	4	1	3	9	11	8	10	7	3
MDS Myelodysplastic syndromes	116	1	-	1	1	-	-	1	-	-	4	1	7	5	14	16	29	24	12
Total	10,913	17	15	18	25	34	70	84	110	188	334	692	1,216	1,608	1,489	1,674	1,560	1,132	647
Total excl. non-melanoma	10,221	17	15	18	25	33	70	81	108	182	327	674	1,178	1,553	1,418	1,561	1,438	1,007	516
Total excl. non-melanoma and MDS, MPD	10,045	16	15	17	24	33	70	79	108	179	319	672	1,168	1,539	1,393	1,537	1,399	976	501

Walloon Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Walloon Region: Males 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C00 Lip	6	-	-	-	-	-	-	-	-	-	-	-	-	1.0	-	3.3	3.9	2.9	-	0.4	0.3	0.2	0.0
C01 Base of tongue	31	-	-	-	-	-	-	-	-	-	1.5	3.3	6.2	5.9	9.2	6.7	3.9	-	-	1.8	1.6	1.2	0.2
C02 Tongue	55	-	-	-	-	0.9	0.9	0.8	4.0	1.5	4.9	8.9	13.7	6.1	6.7	5.8	8.7	4.9	3.2	2.8	2.1	0.2	0.2
C03 Gum	12	-	-	-	-	0.9	-	-	0.8	-	-	-	2.7	2.0	3.1	3.3	-	2.9	-	0.7	0.6	0.5	0.1
C04 Floor of mouth	66	-	-	-	-	0.9	0.8	0.8	4.6	8.2	16.8	10.7	13.7	5.0	5.8	2.9	4.9	4.9	3.9	3.5	2.6	0.3	0.3
C05 Palate	25	-	-	-	-	-	-	-	0.8	1.5	0.8	8.0	2.9	6.1	6.7	-	-	-	4.9	1.5	1.3	1.0	0.1
C06 Mouth, NOS	24	-	-	-	-	-	-	-	2.3	4.9	0.9	7.8	1.5	3.3	-	-	-	-	9.7	1.4	1.2	0.9	0.1
C07 Parotid gland	26	-	-	-	-	-	-	2.8	-	1.5	0.8	1.8	3.9	3.1	6.7	5.8	5.8	14.6	1.5	1.3	0.9	0.1	
C08 Salivary glands, NOS	5	-	-	-	-	-	-	-	-	-	-	-	-	2.0	-	1.7	1.9	2.9	-	0.3	0.2	0.1	0.0
C09 Tonsil	54	-	-	-	-	-	-	-	1.6	4.6	4.9	10.6	9.8	13.7	6.7	7.8	-	4.9	3.2	2.9	2.1	0.3	0.3
C10 Oropharynx	47	-	-	-	-	-	-	-	3.1	4.9	10.6	11.7	7.6	8.3	3.9	2.9	-	2.8	2.4	1.8	0.2	0.2	0.2
C11 Nasopharynx	13	-	-	-	-	1.9	-	0.8	2.4	2.7	1.0	1.5	-	-	-	-	-	-	4.9	0.8	0.7	0.5	0.1
C12 Pyriform sinus	59	-	-	-	-	-	-	-	2.3	11.4	9.8	18.5	7.6	6.7	1.9	5.8	-	3.5	3.1	2.3	0.3	0.3	0.3
C13 Hypopharynx	23	-	-	-	-	0.9	-	-	1.5	4.1	3.5	4.9	3.1	-	3.9	2.9	4.9	4.9	1.4	1.2	0.9	0.1	0.1
C14 Lip, oral cavity and pharynx, NOS	10	-	-	-	-	-	-	-	-	-	2.7	2.0	1.5	5.0	-	2.9	-	2.9	-	0.6	0.5	0.3	0.1
C15 Oesophagus	231	-	-	-	-	-	-	-	7.0	28.6	31.0	40.0	38.2	44.9	59.7	61.2	58.3	13.6	11.4	7.8	0.9	0.9	0.9
C16 Stomach	234	-	-	-	-	1.9	-	-	2.5	2.4	6.2	15.5	18.6	27.3	45.8	59.9	68.2	90.4	87.5	13.8	11.2	7.5	0.9
C17 Small intestine	34	-	-	-	-	-	-	-	0.8	1.5	2.4	6.2	5.9	6.1	8.3	7.8	5.8	-	2.0	1.7	1.2	0.2	0.2
C18 Colon	854	-	-	1.8	0.9	1.9	1.9	4.1	11.3	13.2	49.8	70.9	82.0	160.3	238.0	266.9	361.7	315.9	50.2	40.5	26.8	3.2	3.2
C19 Rectosigmoid junction	50	-	-	-	-	-	-	-	1.5	-	1.5	-	3.5	7.8	15.3	10.0	17.5	20.4	19.4	2.9	2.4	1.6	0.2
C20 Rectum	404	-	-	-	-	0.9	-	0.9	3.3	7.2	11.6	22.0	42.6	64.4	80.9	91.5	99.4	142.9	126.4	23.8	19.6	13.4	1.6
C21 Anus and anal canal	19	-	-	-	-	-	-	-	0.8	2.4	3.5	1.0	6.1	3.3	3.9	-	9.7	-	1.1	1.0	0.7	0.1	0.1
C22 Liver and intrahepatic bile ducts	173	1.0	-	-	-	1.9	0.9	1.6	-	0.8	9.8	20.4	30.2	42.7	46.6	56.5	32.1	19.4	10.2	8.6	6.0	0.8	0.8
C23 Gallbladder	10	-	-	-	-	-	-	-	0.8	-	0.8	-	0.9	-	1.5	3.3	1.9	8.7	4.9	0.6	0.4	0.3	0.0
C24 Biliary tract, NOS	47	-	-	-	-	-	-	-	0.8	1.5	0.8	4.4	5.9	7.6	15.0	9.7	17.5	34.0	2.8	2.2	1.5	0.2	0.2
C25 Pancreas	274	-	-	-	0.9	0.9	0.9	2.5	1.6	9.3	5.7	19.5	47.8	68.7	61.6	87.7	105.0	63.2	16.1	13.1	9.0	1.1	1.1
C26 Other ill-defined digestive organs	9	-	-	-	-	-	-	-	-	-	-	1.8	-	3.1	-	7.8	-	4.9	0.5	0.4	0.3	0.0	0.0
C30 Nasal cavity and middle ear	6	-	-	-	-	-	-	-	0.8	-	0.8	-	2.0	1.5	1.7	-	2.9	-	0.4	0.3	0.2	0.0	0.0
C31 Accessory sinuses	14	-	-	-	-	-	-	0.8	1.6	-	1.6	2.7	1.0	3.1	1.7	1.9	-	4.9	0.8	0.8	0.5	0.1	0.1
C32 Larynx	195	-	-	-	-	-	-	-	1.6	13.9	14.7	35.5	36.1	35.1	41.6	39.0	20.4	24.3	11.5	9.9	7.0	0.9	0.9
C33 Trachea	4	-	-	-	-	-	-	-	-	0.8	1.8	1.0	-	-	-	-	-	-	0.2	0.2	0.2	0.0	0.0
C34 Bronchus and lung	1818	-	-	-	0.9	1.9	2.8	0.8	13.7	35.6	106.9	199.5	298.6	381.6	496.0	539.7	562.9	330.5	106.9	88.2	59.9	7.4	7.4
C37 Thymus	12	-	-	-	-	-	-	-	-	-	3.3	2.7	-	1.5	-	3.9	2.9	-	0.7	0.6	0.5	0.0	0.0
C38 Heart, mediastinum and pleura	5	-	-	-	-	-	-	-	0.8	-	0.8	-	0.9	-	1.7	1.9	2.9	-	0.3	0.2	0.2	0.0	0.0
C39 Respiratory system and intrathoracic organs, NOS	3	-	-	-	-	-	-	-	-	-	-	-	1.0	-	1.7	1.9	-	-	0.2	0.1	0.1	0.0	0.0
C40 Bone and articular cartilage of limbs	6	-	-	3.8	0.9	-	-	-	-	-	0.8	-	-	-	-	-	-	-	-	0.4	0.4	0.5	0.0
C41 Bone and articular cartilage, NOS	11	-	-	0.9	0.9	-	1.9	1.9	-	0.8	-	-	0.9	2.0	-	-	-	2.9	-	0.6	0.6	0.6	0.0
C43 Malignant melanoma of skin	323	-	-	0.9	2.6	7.1	12.3	12.1	17.3	20.1	20.9	22.0	28.4	31.2	42.7	59.9	56.5	49.6	53.5	19.0	17.0	13.1	1.4
C44 Malignant neoplasms of skin	692	-	-	-	0.9	-	2.8	1.6	4.8	5.4	14.7	33.7	53.7	108.4	188.1	237.7	364.6	636.7	40.7	31.6	19.6	2.0	2.0

Walloon Region: Males 2010															Tot								
	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI	
C45 Mesothelioma	52	-	-	-	-	-	-	-	0.8	1.5	1.6	2.7	3.9	13.7	15.0	19.5	23.3	19.4	3.1	2.4	1.6	0.2	
C46 Kaposi's sarcoma	6	-	-	-	-	-	-	0.8	1.6	0.8	1.6	-	1.0	-	-	1.9	-	-	0.4	0.3	0.2	0.0	
C47,C49 Soft tissues	49	1.9	1.9	0.9	0.9	0.9	-	3.3	1.6	0.8	-	6.2	8.8	10.7	15.0	-	2.9	9.7	2.9	2.7	2.3	0.3	
C48 Retroperitoneum and peritoneum	6	-	-	-	-	-	-	-	0.8	1.5	2.4	1.8	2.9	1.5	10.0	9.7	5.8	9.7	1.6	1.3	0.9	0.1	
C50 Breast	27	-	-	-	-	-	-	1.6	0.8	1.5	2.4	1.8	2.7	2.0	7.6	5.0	9.7	5.8	1.6	1.3	0.9	0.1	
C60 Penis	27	-	-	-	-	-	-	0.8	4.0	17.0	97.1	240.3	432.2	714.4	735.6	777.4	583.3	563.8	146.2	122.0	82.7	10.6	
C61 Prostate	2,486	-	-	-	-	-	-	0.8	4.0	17.0	97.1	240.3	432.2	714.4	735.6	777.4	583.3	563.8	146.2	122.0	82.7	10.6	
C62 Testis	121	-	-	3.5	8.0	24.6	26.1	10.7	12.9	5.4	4.1	6.2	1.0	1.5	1.7	1.9	5.8	-	7.1	7.3	6.8	0.5	
C63 Male genital organs, NOS	1	-	-	-	-	-	-	-	-	-	0.8	-	-	-	-	-	-	-	0.1	0.1	0.0	0.0	
C64 Kidney	255	1.0	-	-	-	-	-	9.1	4.8	8.5	18.8	27.5	40.0	62.6	68.2	44.8	64.2	19.4	15.0	12.9	9.2	1.2	
C65 Renal pelvis	43	-	-	-	-	-	-	-	0.8	1.6	3.5	8.8	7.6	13.3	19.5	11.7	-	2.5	2.0	1.4	0.2	0.2	
C66 Ureter	25	-	-	-	-	-	-	-	-	-	1.8	4.9	6.1	5.0	15.6	2.9	9.7	1.5	1.5	1.2	0.8	0.1	
C67 Bladder	536	-	-	-	-	-	1.9	0.8	3.2	3.9	13.1	37.2	69.3	103.8	153.1	181.2	245.0	281.9	31.5	24.9	16.1	1.9	
C68 Urinary organs, NOS	14	-	-	-	-	-	-	-	-	-	-	-	1.0	4.6	5.0	9.7	-	9.7	0.8	0.7	0.4	0.1	
C69 Eye and adnexa	20	-	1.9	-	-	-	-	0.8	0.8	0.8	2.4	3.5	2.0	1.5	-	7.8	-	4.9	1.2	1.0	0.8	0.1	
C70 Meninges	3	-	-	-	-	-	-	-	-	-	-	-	-	1.5	1.7	-	2.9	-	0.2	0.1	0.1	0.0	
C71 Brain	147	3.8	3.8	1.9	-	2.7	5.7	3.7	4.1	12.1	10.1	16.8	15.6	22.9	25.0	17.5	11.7	9.7	8.6	8.0	6.7	0.7	
C72 Spinal cord, cranial nerves and CNS, NOS	1	-	-	-	-	-	-	-	-	-	-	-	1.0	-	-	-	-	-	0.1	0.0	0.0	0.0	
C73 Thyroid gland	82	-	1.0	-	-	0.9	0.9	-	4.1	9.6	7.0	8.2	13.3	7.8	9.2	10.0	7.8	11.7	-	4.8	4.3	3.3	0.4
C74 Adrenal gland	6	1.0	-	-	-	-	-	-	-	-	-	1.8	2.0	-	-	-	2.9	-	0.4	0.3	0.3	0.0	
C75 Endocrine glands, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C81 Hodgkin's disease	46	-	1.0	1.9	3.5	3.5	2.8	1.9	3.3	2.4	3.9	3.3	1.8	3.9	-	5.0	7.8	-	4.9	2.7	2.6	2.4	0.2
C82-C86 Non-Hodgkin-lymphoma	324	-	1.0	3.8	2.6	0.9	2.8	7.5	5.8	10.5	15.5	24.5	27.5	42.0	51.9	71.6	70.1	84.6	87.5	19.1	16.3	11.9	1.3
C88 Malignant immunoproliferative diseases	36	-	-	-	-	-	-	-	0.8	0.8	3.1	-	1.8	2.0	13.7	5.0	13.6	17.5	4.9	2.1	1.7	1.2	0.1
C90 Multiple myeloma	131	-	-	-	-	-	-	-	-	2.3	5.7	12.4	15.6	16.8	35.0	50.7	58.3	63.2	7.7	6.0	3.9	0.4	
C91 Lymphoid leukaemia	134	2.9	1.9	1.8	0.9	0.9	0.9	2.5	2.4	3.9	3.3	16.0	12.7	29.0	44.9	15.6	43.7	34.0	7.9	6.8	5.2	0.6	
C92 Myeloid leukaemia	97	1.0	-	-	1.8	-	4.7	0.9	2.5	3.2	0.8	4.9	13.3	6.8	6.1	20.0	25.3	43.7	38.9	5.7	4.7	3.4	0.3
C93 Monocytic leukaemia	24	-	-	-	0.9	-	-	0.9	0.8	-	-	0.9	3.9	3.1	8.3	9.7	8.7	4.9	1.4	1.1	0.8	0.1	
C94-C95 Leukaemia other	8	-	-	-	-	-	-	-	0.8	0.8	-	-	2.0	1.5	1.7	1.9	2.9	-	0.5	0.4	0.3	0.0	
C96 Lymphoid, haematopoietic and related tissue, NOS	7	1.9	1.0	-	-	0.9	-	-	-	0.8	-	-	-	-	1.9	-	-	-	0.4	0.4	0.5	0.0	
C76 Other and ill-defined sites	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C80 Unknown primary site	139	1.0	1.0	-	-	-	-	1.6	2.4	7.0	5.7	14.2	25.4	13.7	23.3	35.1	72.9	38.9	8.2	6.5	4.5	0.5	
MPD Myeloproliferative Disorders	60	-	-	-	-	-	-	0.9	-	2.4	3.1	0.8	2.7	8.8	16.8	13.3	19.5	20.4	14.6	3.5	2.9	2.0	0.2
MDS Myelodysplastic syndromes	116	1.0	-	0.9	0.9	-	-	0.9	-	3.1	0.8	6.2	4.9	21.4	26.6	56.5	70.0	58.3	6.8	5.2	3.4	0.3	
Total	10,913	16.3	14.3	16.9	22.0	30.1	66.1	78.4	90.6	151.1	258.5	564.7	1,078.2	1,569.0	2,272.8	2,786.1	3,039.6	3,301.5	3,144.4	641.9	534.7	370.0	36.3
Total excl. non-melanoma	10,221	16.3	14.3	16.9	22.0	29.2	66.1	75.6	89.0	146.3	253.1	550.0	1,044.5	1,515.3	2,164.4	2,598.0	2,801.9	2,937.0	2,507.8	601.2	503.1	350.4	35.0
Total excl. non-melanoma and MDS, MPD	10,045	15.4	14.3	16.0	21.1	29.2	66.1	73.7	89.0	143.9	246.9	548.4	1,035.6	1,501.6	2,126.3	2,558.0	2,725.9	2,846.6	2,434.9	590.8	495.0	346.6	34.6

CR: crude (all ages) incidence rate (N/100,000 person years)
 ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
 CRI: Cumulative Risk (0-74 years)

Walloon Region: Females, number of invasive tumours by primary site and age group in 2010

Walloon Region: Females 2010		Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	
C00	Lip	4	-	-	-	-	-	-	-	-	1	1	-	-	-	-	-	-	-	1	1
C01	Base of tongue	11	-	-	-	-	-	-	1	-	-	-	1	3	3	-	1	-	-	2	-
C02	Tongue	34	-	-	-	1	-	-	1	-	1	-	7	3	7	3	3	2	5	1	1
C03	Gum	15	-	-	-	-	-	-	1	-	1	-	1	-	1	1	2	5	1	2	1
C04	Floor of mouth	21	-	-	-	-	-	-	-	-	-	2	3	5	8	-	-	-	2	1	-
C05	Palate	12	-	-	-	-	1	-	-	-	-	1	3	1	1	-	4	1	-	-	-
C06	Mouth, NOS	16	-	-	-	-	-	-	-	-	-	2	3	5	-	1	1	1	2	1	1
C07	Parotid gland	18	-	-	-	1	-	1	-	2	-	-	1	3	1	3	1	1	4	-	-
C08	Salivary glands, NOS	1	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-
C09	Tonsil	28	-	-	-	-	-	-	-	-	1	2	4	8	6	1	-	3	2	1	1
C10	Oropharynx	13	-	-	-	-	-	-	-	-	-	1	2	3	2	3	-	2	-	-	-
C11	Nasopharynx	4	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	2	-	-
C12	Pyiform sinus	15	-	-	-	-	-	-	-	-	-	-	3	4	3	2	3	-	-	-	-
C13	Hypopharynx	3	-	-	-	-	-	-	-	1	-	-	-	-	-	-	1	-	-	-	-
C14	Lip, oral cavity and pharynx, NOS	1	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-
C15	Oesophagus	91	-	-	-	-	-	-	-	2	2	3	6	14	14	7	12	11	13	7	7
C16	Stomach	165	-	-	-	-	1	-	1	3	1	4	4	17	9	23	18	20	23	41	41
C17	Small intestine	34	-	-	-	-	1	-	-	-	3	-	3	2	5	2	4	6	4	4	4
C18	Colon	716	-	1	1	-	2	3	4	5	5	22	35	43	64	63	86	116	140	126	126
C19	Rectosigmoid junction	50	-	-	-	-	-	-	-	1	-	1	5	3	5	5	8	9	7	6	6
C20	Rectum	301	-	1	-	-	-	-	1	4	6	12	21	30	31	31	36	46	40	42	42
C21	Anus and anal canal	40	-	-	-	-	-	-	-	-	3	3	1	4	9	4	4	8	-	4	4
C22	Liver and intrahepatic bile ducts	71	-	-	-	-	-	-	-	1	1	2	3	5	12	13	6	14	10	4	4
C23	Gallbladder	33	-	-	-	-	-	-	-	-	-	-	4	-	2	4	4	7	7	5	5
C24	Biliary tract, NOS	46	-	-	-	-	-	-	-	-	-	1	1	1	6	6	4	10	6	11	11
C25	Pancreas	248	-	-	-	-	1	-	2	2	6	4	16	11	29	29	41	46	36	25	25
C26	Other ill-defined digestive organs	6	-	-	-	-	-	-	-	-	1	-	-	-	1	-	-	3	1	-	-
C30	Nasal cavity and middle ear	4	-	1	-	-	-	-	-	-	1	-	-	-	-	-	2	-	-	-	-
C31	Accessory sinuses	2	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	1
C32	Larynx	34	-	-	-	-	-	-	-	-	1	3	4	7	9	5	2	1	1	1	1
C33	Trachea	2	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	-	-	-	-
C34	Bronchus and lung	814	-	-	-	-	1	-	-	6	15	48	77	118	144	113	107	100	56	29	29
C37	Thymus	9	-	-	-	-	-	-	-	1	1	1	-	2	2	-	-	-	2	-	-
C38	Heart, mediastinum and pleura	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	7	-	-	-	-	-	-	1	1	2	1	-	1	-	1	-	-	-	-	-
C41	Bone and articular cartilage, NOS	7	-	-	-	-	-	2	-	-	-	1	-	1	-	-	2	-	1	-	-
C43	Malignant melanoma of skin	459	-	1	2	5	19	37	28	39	49	46	32	43	36	26	27	25	21	23	23
C44	Malignant neoplasms of skin	478	-	-	-	-	1	2	1	3	9	11	22	27	33	25	48	75	83	138	138

Walloon Region: Females 2010																			
	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C45 Mesothelioma	10	-	-	-	-	-	-	-	-	-	-	-	2	1	1	4	-	2	-
C46 Kaposi's sarcoma	1	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-
C47,C49 Soft tissues	41	-	-	2	-	1	2	1	3	1	3	3	2	2	3	4	2	4	3
C48 Retroperitoneum and peritoneum	12	-	-	-	-	-	-	-	-	1	-	1	1	-	2	2	-	-	4
C50 Breast	3,250	-	-	-	4	8	36	88	203	333	402	449	484	294	266	212	175	-	-
C51 Vulva	69	-	-	-	-	-	1	1	2	5	9	5	6	10	3	7	10	10	-
C52 Vagina	12	1	-	-	-	-	-	-	-	-	1	2	-	1	2	-	2	2	1
C53 Cervix uteri	206	-	-	-	3	6	9	23	24	31	23	19	15	13	9	12	8	11	-
C54 Corpus uteri	474	-	-	-	-	1	-	1	5	14	20	48	78	71	63	76	57	40	-
C55 Uterus	4	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	3
C56 Ovary	272	1	-	1	1	1	2	2	10	13	19	27	47	31	40	37	26	14	-
C57 Female genital organs, NOS	15	-	-	-	-	-	-	-	-	1	1	1	1	3	-	3	4	2	-
C58 Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64 Kidney	144	-	1	-	-	-	2	4	7	6	15	14	16	17	24	24	9	5	-
C65 Renal pelvis	23	-	-	-	-	-	-	-	-	1	1	2	2	2	2	6	2	5	-
C66 Ureter	13	-	-	-	-	-	-	-	-	-	-	1	2	-	2	2	2	2	2
C67 Bladder	142	-	-	-	-	-	-	1	2	1	5	10	17	11	13	22	29	31	-
C68 Urinary organs, NOS	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1
C69 Eye and adnexa	14	2	-	-	-	-	-	-	-	1	2	1	1	1	1	3	1	2	-
C70 Meninges	2	-	-	-	-	-	-	1	-	1	-	-	-	-	-	-	-	-	-
C71 Brain	102	6	3	1	2	1	3	6	1	1	7	9	12	11	8	7	17	2	5
C72 Spinal cord, cranial nerves and CNS, NOS	3	1	1	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-
C73 Thyroid gland	277	-	-	-	5	7	14	20	28	23	31	35	43	23	19	10	7	8	4
C74 Adrenal gland	6	1	-	-	1	-	1	-	-	-	-	1	-	1	-	1	-	-	-
C75 Endocrine glands, NOS	2	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	-	-	-
C81 Hodgkin's disease	53	-	-	1	8	7	9	4	5	4	2	2	2	1	3	1	3	-	1
C82-C86 Non-Hodgkin-lymphoma	286	-	1	-	1	3	1	9	7	7	17	13	17	27	29	28	50	45	31
C88 Malignant immunoproliferative diseases	36	-	-	-	-	-	1	-	3	-	3	1	1	1	1	3	5	9	4
C90 Multiple myeloma	92	-	-	-	-	-	-	1	-	1	2	1	8	8	17	14	21	13	6
C91 Lymphoid leukaemia	127	6	2	3	3	-	-	-	-	2	7	10	9	15	15	13	18	13	11
C92 Myeloid leukaemia	82	2	-	1	1	1	1	2	3	4	8	3	5	3	10	10	9	10	9
C93 Monocytic leukaemia	15	-	-	-	-	-	-	1	-	1	2	-	1	-	2	4	1	2	1
C94-C95 Leukaemia other	6	-	-	-	-	-	-	-	-	1	-	1	2	-	-	-	-	-	-
C96 Lymphoid, haematopoietic and related tissue, NOS	4	-	-	-	1	-	-	1	-	1	-	-	-	1	-	-	-	-	-
C76 Other and ill-defined sites	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-
C80 Unknown primary site	147	-	-	-	-	-	1	-	3	1	9	8	12	16	13	16	22	21	25
MPD Myeloproliferative Disorders	61	-	-	1	-	-	1	-	-	3	4	6	2	4	4	10	11	10	5
MDS Myelodysplastic syndromes	83	1	1	-	-	-	2	1	-	-	1	5	3	5	7	10	13	17	17
Total	9,906	22	13	10	32	55	99	139	244	414	674	867	1,063	1,238	964	1,024	1,159	986	903
Total excl. non-melanoma	9,428	22	13	10	32	54	97	138	241	405	663	845	1,036	1,205	939	976	1,084	903	765
Total excl. non-melanoma and MDS, MPD	9,284	21	12	9	32	54	94	137	241	402	658	834	1,031	1,196	928	956	1,060	876	743

Walloon Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)

Walloon Region: Females 2010	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C00 Lip	4	-	-	-	-	-	-	-	0.8	0.8	-	-	-	-	-	-	-	1.6	1.8	0.2	0.1	0.1	0.0
C01 Base of tongue	11	-	-	-	-	-	0.9	-	-	-	0.8	2.6	2.8	-	-	1.3	-	3.2	-	0.6	0.5	0.4	0.0
C02 Tongue	34	-	-	-	-	0.9	-	0.9	-	0.8	-	5.6	2.6	6.5	4.1	4.0	2.7	8.1	1.8	1.9	1.5	1.1	0.1
C03 Gum	15	-	-	-	-	-	-	0.9	-	0.8	-	0.8	-	0.9	1.4	2.6	6.7	1.6	3.6	0.8	0.5	0.4	0.0
C04 Floor of mouth	21	-	-	-	-	-	-	-	-	1.5	2.4	4.3	7.4	-	-	-	-	3.2	1.8	1.2	1.0	0.7	0.1
C05 Palate	12	-	-	-	-	0.9	-	-	-	0.8	2.4	0.9	0.9	-	-	5.3	1.3	-	-	0.7	0.6	0.4	0.1
C06 Mouth, NOS	16	-	-	-	-	-	-	-	-	1.5	2.4	4.3	-	1.4	1.3	1.3	3.2	3.2	1.8	0.9	0.7	0.5	0.1
C07 Parotid gland	18	-	-	-	0.9	-	1.0	-	1.7	-	0.8	2.6	0.9	4.1	1.3	1.3	6.5	-	1.0	0.8	0.6	0.1	0.1
C08 Salivary glands, NOS	1	-	-	-	-	-	-	-	-	-	0.8	-	-	-	-	-	-	-	-	0.1	0.1	0.0	0.0
C09 Tonsil	28	-	-	-	-	-	-	-	-	0.8	1.5	3.2	6.9	5.5	1.4	-	4.0	3.2	1.8	1.6	1.3	0.9	0.1
C10 Oropharynx	13	-	-	-	-	-	-	-	-	0.8	1.6	2.6	1.8	4.1	-	-	2.7	-	-	0.7	0.6	0.5	0.1
C11 Nasopharynx	4	-	-	-	0.9	-	-	-	-	-	-	-	-	-	-	-	-	3.2	-	0.2	0.2	0.2	0.0
C12 Pyriform sinus	15	-	-	-	-	-	-	-	-	-	2.4	3.4	2.8	2.7	4.0	-	-	-	-	0.8	0.7	0.5	0.1
C13 Hypopharynx	3	-	-	-	-	-	-	0.8	-	-	-	-	-	-	1.4	-	-	-	-	0.2	0.1	0.1	0.0
C14 Lip, oral cavity and pharynx, NOS	1	-	-	-	-	-	-	-	-	-	0.8	-	-	-	-	-	-	-	-	0.1	0.1	0.0	0.0
C15 Oesophagus	91	-	-	-	-	-	-	-	1.7	1.6	2.3	4.8	12.0	12.9	9.5	15.9	14.8	21.0	12.7	5.1	3.6	2.5	0.3
C16 Stomach	165	-	-	-	-	0.9	-	0.9	2.5	0.8	3.1	3.2	14.6	8.3	31.1	23.8	26.9	37.2	74.2	9.2	5.7	3.8	0.4
C17 Small intestine	34	-	-	-	-	0.9	-	-	-	2.4	-	2.4	1.7	4.6	2.7	5.3	8.1	6.5	7.2	1.9	1.3	0.9	0.1
C18 Colon	716	-	1.0	1.0	-	1.8	2.9	3.8	4.2	4.0	17.0	27.9	37.0	59.1	85.1	113.8	155.7	226.3	228.1	39.8	24.1	16.2	1.8
C19 Rectosigmoid junction	50	-	-	-	-	-	-	-	0.8	0.8	4.0	2.6	4.6	6.8	10.6	12.1	11.3	10.9	2.8	1.8	1.2	0.2	0.2
C20 Rectum	301	-	1.0	-	-	-	-	0.9	3.3	4.8	9.3	16.7	25.8	28.6	41.9	47.6	61.8	64.6	76.0	16.7	11.2	7.7	0.9
C21 Anus and anal canal	40	-	-	-	-	-	-	-	-	2.4	2.3	0.8	3.4	8.3	5.4	5.3	10.7	-	7.2	2.2	1.7	1.2	0.1
C22 Liver and intrahepatic bile ducts	71	-	-	-	-	-	-	-	0.8	0.8	1.5	2.4	4.3	11.1	17.6	7.9	18.8	16.2	7.2	3.9	2.8	1.9	0.2
C23 Gallbladder	33	-	-	-	-	-	-	-	-	-	3.2	-	1.8	5.4	5.3	9.4	11.3	9.0	1.8	1.1	0.7	0.1	0.1
C24 Biliary tract, NOS	46	-	-	-	-	-	-	-	-	0.8	0.8	0.9	5.5	8.1	8.1	5.3	13.4	9.7	19.9	2.6	1.5	1.0	0.1
C25 Pancreas	248	-	-	-	-	0.9	-	1.9	1.7	4.8	3.1	12.7	9.5	26.8	39.2	54.3	61.8	58.2	45.2	13.8	9.1	6.2	0.8
C26 Other ill-defined digestive organs	6	-	-	-	-	-	-	-	-	0.8	-	-	-	0.9	-	-	4.0	1.6	-	0.3	0.2	0.1	0.0
C30 Nasal cavity and middle ear	4	-	1.0	-	-	-	-	-	-	0.8	-	-	-	-	-	2.6	-	-	-	0.2	0.2	0.2	0.0
C31 Accessory sinuses	2	-	-	-	-	-	-	-	-	-	-	-	0.9	-	-	-	-	-	1.8	0.1	0.1	0.0	0.0
C32 Larynx	34	-	-	-	-	-	-	-	-	0.8	2.3	3.2	6.0	8.3	6.8	2.6	1.3	1.6	1.8	1.9	1.6	1.2	0.2
C33 Trachea	2	-	-	-	-	-	-	-	-	-	-	0.8	-	0.9	-	-	-	-	-	0.1	0.1	0.1	0.0
C34 Bronchus and lung	814	-	-	-	-	0.9	-	-	5.0	12.1	37.0	61.3	101.4	132.9	152.6	141.6	194.3	90.5	52.5	45.3	35.3	25.2	3.2
C37 Thymus	9	-	-	-	-	-	-	-	0.8	0.8	0.8	-	1.7	1.8	-	-	-	-	3.2	-	0.5	0.4	0.0
C38 Heart, mediastinum and pleura	1	-	-	-	-	-	-	-	-	-	-	-	-	1.4	-	-	-	-	-	0.1	0.1	0.0	0.0
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40 Bone and articular cartilage of limbs	7	-	-	-	-	-	1.0	0.9	1.7	0.8	-	0.8	-	0.9	-	-	-	-	-	0.4	0.4	0.4	0.0
C41 Bone and articular cartilage, NOS	7	-	-	-	-	-	1.9	-	-	0.8	-	0.9	-	0.9	-	2.6	-	1.6	-	0.4	0.3	0.3	0.0
C43 Malignant melanoma of skin	459	-	1.0	2.0	4.6	17.2	35.3	26.3	32.4	39.5	35.5	25.5	37.0	33.2	35.1	35.7	33.6	33.9	41.6	25.5	23.1	19.5	1.8
C44 Malignant neoplasms of skin	478	-	-	-	-	0.9	1.9	0.9	2.5	7.3	8.5	17.5	23.2	30.5	33.8	63.5	100.7	134.1	249.8	26.6	14.8	9.6	0.9

Flemish Region: Males, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2001-2010

Primary site	N										WSR									
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
C00 Lip	39	48	49	44	45	39	20	22	36	41	0.7	0.8	0.9	0.7	0.8	0.7	0.3	0.4	0.5	0.5
C01 Base of tongue	36	27	32	37	21	29	58	59	68	51	0.8	0.6	0.7	0.8	0.5	0.6	1.2	1.2	1.3	1.0
C02 Tongue	77	81	65	95	98	79	71	86	85	76	1.7	1.9	1.4	2.1	2.1	1.6	1.4	1.8	1.8	1.5
C03 Gum	6	10	11	11	8	14	9	16	15	17	0.1	0.2	0.3	0.2	0.2	0.2	0.2	0.3	0.2	0.3
C04 Floor of mouth	72	77	75	92	84	74	72	89	92	79	1.7	1.8	1.7	2.0	1.8	1.6	1.6	1.8	1.8	1.6
C05 Palate	23	26	19	26	27	29	30	32	32	28	0.6	0.6	0.4	0.5	0.6	0.6	0.6	0.7	0.7	0.6
C06 Mouth, NOS	41	38	41	42	44	51	32	26	32	31	1.0	0.8	0.9	0.9	0.8	1.0	0.6	0.5	0.6	0.6
C07 Parotid gland	24	37	30	38	30	24	31	29	35	32	0.6	0.7	0.6	0.8	0.6	0.5	0.6	0.5	0.6	0.6
C08 Salivary glands, NOS	7	8	12	8	14	5	10	8	13	8	0.2	0.2	0.3	0.1	0.2	0.1	0.2	0.1	0.2	0.2
C09 Tonsil	76	72	85	84	79	92	88	97	90	69	1.7	1.6	1.9	1.7	1.7	1.9	1.8	2.0	1.8	1.4
C10 Oropharynx	39	30	34	44	35	40	52	63	52	74	0.9	0.6	0.7	1.0	0.8	0.9	1.1	1.2	1.1	1.4
C11 Nasopharynx	21	15	23	21	15	21	18	22	22	22	0.6	0.4	0.5	0.5	0.4	0.5	0.4	0.5	0.5	0.5
C12 Pyriform sinus	49	50	45	76	55	55	68	42	65	55	1.1	1.2	1.0	1.6	1.2	1.1	1.5	0.9	1.2	1.0
C13 Hypopharynx	23	21	31	39	30	41	45	35	43	29	0.6	0.5	0.7	0.8	0.6	0.9	0.9	0.7	0.8	0.6
C14 Lip, oral cavity and pharynx, NOS	21	16	10	9	16	8	10	14	9	6	0.5	0.4	0.3	0.2	0.4	0.2	0.2	0.3	0.2	0.1
C15 Oesophagus	384	366	350	362	397	422	435	387	410	408	8.0	7.5	7.0	7.1	7.6	7.8	8.1	7.0	7.1	6.9
C16 Stomach	533	525	513	533	523	512	523	537	545	549	9.8	9.6	9.1	9.2	9.0	8.4	8.5	8.5	8.5	8.6
C17 Small intestine	49	54	76	62	56	73	44	70	61	94	0.9	1.1	1.4	1.2	1.1	1.4	0.8	1.2	1.0	1.5
C18 Colon	1,410	1,437	1,512	1,582	1,697	1,743	1,701	1,890	1,930	1,874	25.9	25.8	26.6	26.7	28.6	28.8	27.2	29.7	29.8	28.4
C19 Rectosigmoid junction	167	159	149	205	118	100	88	104	101	104	3.1	2.9	2.6	3.5	2.1	1.7	1.4	1.7	1.6	1.6
C20 Rectum	721	749	816	831	832	905	906	947	963	916	13.9	14.1	15.0	15.2	15.0	15.8	15.5	16.1	15.8	15.2
C21 Anus and anal canal	21	24	27	27	29	20	24	31	40	30	0.4	0.4	0.6	0.6	0.6	0.4	0.4	0.5	0.7	0.6
C22 Liver and intrahepatic bile ducts	122	106	119	141	167	168	185	228	206	250	2.4	2.1	2.6	2.7	3.2	3.2	3.3	4.2	3.6	4.4
C23 Gallbladder	13	16	9	20	18	23	21	17	19	22	0.2	0.3	0.2	0.3	0.3	0.4	0.4	0.2	0.3	0.3
C24 Biliary tract, NOS	50	49	61	74	62	84	83	83	98	83	1.0	0.9	1.0	1.3	1.1	1.4	1.4	1.4	1.6	1.3
C25 Pancreas	266	310	337	347	327	361	352	360	395	446	5.2	6.0	6.1	6.5	5.9	6.2	6.2	6.2	6.5	7.2
C26 Other ill-defined digestive organs	2	1	6	3	3	1	3	6	7	9	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
C30 Nasal cavity and middle ear	9	10	13	10	16	15	14	20	17	20	0.2	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.3	0.4
C31 Accessory sinuses	43	40	34	36	46	34	40	47	31	43	1.0	0.8	0.7	0.7	0.9	0.7	0.8	0.9	0.6	0.7
C32 Larynx	352	341	369	348	315	319	342	313	307	310	7.2	7.1	7.5	7.0	6.0	6.0	6.6	5.7	5.5	5.2
C33 Trachea	3	10	8	8	5	4	9	1	7	5	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.1
C34 Bronchus and lung	3,066	3,008	3,047	3,263	3,190	3,255	3,350	3,283	3,256	3,348	58.1	55.7	55.2	58.0	56.0	55.9	56.6	54.7	52.4	52.2
C37 Thymus	6	8	5	18	10	10	8	7	12	6	0.1	0.2	0.1	0.4	0.2	0.2	0.2	0.1	0.2	0.1
C38 Heart, mediastinum and pleura	11	6	7	5	7	8	12	9	9	17	0.3	0.1	0.1	0.1	0.2	0.2	0.3	0.2	0.2	0.4
C39 Respiratory system and intrathoracic organs, NOS	-	-	1	-	1	-	-	-	-	-	-	-	0.0	-	0.0	-	-	-	-	-
C40 Bone and articular cartilage of limbs	24	19	21	28	23	21	22	17	14	22	0.8	0.6	0.7	1.0	0.8	0.8	0.8	0.5	0.5	0.7
C41 Bone and articular cartilage, NOS	20	22	23	25	23	20	22	23	14	26	0.5	0.7	0.7	0.8	0.6	0.6	0.5	0.6	0.4	0.7
C43 Malignant melanoma of skin	256	283	340	370	377	385	446	423	404	468	5.9	6.1	7.8	8.2	8.3	8.3	9.5	8.7	8.0	9.4

C44	Malignant neoplasms of skin	741	772	887	961	1,063	1,191	1,340	1,356	1,539	1,597	12.9	13.1	14.9	15.7	16.6	18.3	19.8	19.0	20.7	20.8
C45	Mesothelioma	129	98	119	138	142	150	136	148	135	148	2.5	1.9	2.2	2.5	2.5	2.6	2.3	2.5	2.2	2.3
C46	Kaposi's sarcoma	7	9	19	8	10	10	15	14	16	12	0.1	0.2	0.4	0.2	0.3	0.3	0.4	0.3	0.4	0.3
C47-C49	Soft tissues	94	94	120	118	102	100	122	118	123	101	2.2	2.1	2.8	2.7	2.2	2.4	2.5	2.5	2.7	2.0
C48	Retroperitoneum and peritoneum	17	11	13	16	18	17	14	13	13	13	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.3
C50	Breast	54	50	54	57	50	37	53	51	54	47	1.0	0.9	1.0	1.0	1.0	0.6	1.0	0.9	0.9	0.8
C60	Penis	30	31	36	38	37	53	44	41	49	51	0.5	0.6	0.6	0.7	0.6	1.0	0.8	0.6	0.8	0.8
C61	Prostate	5,438	5,012	5,575	5,927	6,133	5,941	5,969	5,818	5,742	5,651	99.5	91.5	100.5	105.2	107.5	104.1	102.1	97.6	94.8	90.5
C62	Testis	134	129	129	128	158	149	171	175	181	165	4.5	4.3	4.2	4.2	5.0	5.3	5.7	5.9	6.1	5.5
C63	Male genital organs, NOS	6	-	6	6	5	10	8	10	5	10	0.1	-	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.2
C64	Kidney	472	458	521	502	520	538	573	585	601	651	9.7	9.5	10.7	10.1	10.2	10.2	10.5	10.8	10.8	11.5
C65	Renal pelvis	61	57	77	57	73	62	72	68	85	92	1.2	1.0	1.4	0.9	1.1	1.0	1.2	1.0	1.3	1.4
C66	Ureter	47	40	37	51	40	57	49	66	69	70	0.8	0.7	0.7	0.8	0.7	0.9	0.8	1.0	1.0	1.0
C67	Bladder	1,005	928	885	954	977	1,021	1,043	1,046	1,062	1,079	17.7	16.0	15.1	15.9	15.8	16.2	16.1	15.3	15.3	15.5
C68	Urinary organs, NOS	12	12	11	14	9	11	14	17	11	35	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.3	0.2	0.4
C69	Eye and adnexa	33	37	25	29	19	31	38	42	39	33	0.9	1.0	1.0	0.7	0.5	0.8	0.9	0.7	1.0	0.9
C70	Meninges	4	8	7	7	3	4	1	3	3	3	0.1	0.2	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0
C71	Brain	221	250	270	255	263	256	277	270	288	262	5.7	6.2	6.8	6.0	6.5	5.9	6.3	5.7	6.7	5.7
C72	Spinal cord, cranial nerves and CNS, NOS	7	7	7	11	9	8	6	7	10	11	0.2	0.3	0.2	0.5	0.3	0.3	0.3	0.2	0.4	0.4
C73	Thyroid gland	49	54	57	63	69	79	76	91	110	92	1.1	1.2	1.4	1.4	1.6	1.8	1.8	2.0	2.2	2.0
C74	Adrenal gland	12	11	10	10	7	11	8	13	12	20	0.6	0.3	0.3	0.4	0.3	0.5	0.3	0.4	0.5	0.6
C75	Endocrine glands, NOS	3	6	6	8	5	9	3	7	8	7	0.1	0.2	0.2	0.3	0.2	0.3	0.1	0.2	0.3	0.2
C81	Hodgkin's disease	74	79	94	81	107	91	86	102	96	81	2.4	2.6	2.8	2.4	3.5	2.6	2.6	3.0	2.9	2.2
C82-C86	Non-Hodgkin-lymphoma	495	472	516	560	556	645	592	588	597	608	10.8	9.9	10.6	11.3	11.0	12.6	11.6	11.1	10.8	11.0
C88	Malignant immunoproliferative diseases	20	36	43	66	59	64	63	68	70	59	0.4	0.7	0.8	1.3	1.2	1.1	1.2	1.2	1.2	0.9
C90	Multiple myeloma	198	202	250	227	229	243	259	274	263	252	3.7	3.7	4.6	4.0	3.9	4.2	4.5	4.6	4.3	4.1
C91	Lymphoid leukaemia	263	235	248	282	269	255	266	309	282	310	6.4	5.7	6.1	6.3	6.2	5.7	5.8	6.6	6.0	6.4
C92	Myeloid leukaemia	181	147	158	147	170	156	194	185	185	208	4.1	3.2	3.4	2.9	3.7	3.0	3.7	3.5	3.5	3.6
C93	Monocytic leukaemia	23	15	22	23	22	23	32	40	23	28	0.6	0.3	0.5	0.4	0.4	0.4	0.5	0.6	0.4	0.4
C94-C95	Leukaemia other	21	19	17	21	16	15	13	15	12	22	0.4	0.4	0.3	0.4	0.4	0.3	0.2	0.3	0.2	0.3
C96	Lymphoid, haematopoietic and related tissue, NOS	11	3	5	2	3	9	8	8	3	16	0.5	0.1	0.3	0.1	0.1	0.4	0.2	0.2	0.1	0.6
C76	Other and ill-defined sites	15	24	13	12	10	8	-	1	1	2	0.4	0.6	0.3	0.2	0.3	0.2	-	0.0	0.0	0.0
C80	Unknown primary site	547	365	353	327	303	310	308	308	289	266	10.3	6.9	6.3	5.8	5.2	5.2	5.2	5.0	4.6	4.1
MPD	Myeloproliferative Disorders	10	73	90	128	129	128	144	147	147	181	0.2	1.4	1.7	2.5	2.4	2.3	2.5	2.6	2.6	3.2
MDS	Myelodysplastic syndromes	9	77	81	165	165	188	178	206	200	204	0.2	1.3	1.4	2.6	2.8	2.9	2.8	3.0	3.0	3.0
Total		18,535	17,920	19,166	20,363	20,593	20,964	21,419	21,653	21,858	22,055	359.9	342.9	362.0	375.4	374.9	375.0	375.8	370.9	366.4	360.9
Total excl. non-melanoma		17,784	17,148	18,279	19,402	19,530	19,773	20,079	20,297	20,319	20,458	347.0	329.8	347.1	359.7	358.4	356.7	356.0	351.9	345.7	340.1
Total excl. non-melanoma and MDS, MPD		17,765	16,998	18,108	19,109	19,236	19,457	19,757	19,944	19,972	20,073	346.6	327.1	344.0	354.5	353.2	351.5	350.8	346.3	340.1	333.9

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)

EAPC: Estimated annual percentage change (%)

Flemish Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2001-2010

Females		N										WSR									
		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Primary site																					
C00	Lip	12	10	16	14	14	11	6	12	15	7	0.1	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0.1
C01	Base of tongue	6	8	9	10	6	10	10	15	14	23	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.4
C02	Tongue	26	29	36	30	43	35	20	42	42	34	0.5	0.5	0.6	0.7	0.9	0.7	0.4	0.7	0.8	0.7
C03	Gum	5	6	14	12	10	8	15	16	11	10	0.1	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2
C04	Floor of mouth	17	27	14	29	29	20	30	14	19	21	0.4	0.6	0.3	0.6	0.6	0.4	0.6	0.3	0.4	0.4
C05	Palate	17	17	8	17	16	13	16	17	8	11	0.4	0.4	0.2	0.4	0.3	0.2	0.3	0.3	0.1	0.2
C06	Mouth, NOS	14	20	15	21	29	15	20	16	13	31	0.2	0.3	0.2	0.4	0.4	0.2	0.3	0.2	0.2	0.4
C07	Parotid gland	23	18	22	17	24	18	20	25	19	22	0.4	0.3	0.4	0.3	0.4	0.4	0.3	0.5	0.4	0.4
C08	Salivary glands, NOS	8	7	8	5	20	10	11	5	11	16	0.1	0.2	0.1	0.1	0.4	0.2	0.3	0.1	0.2	0.4
C09	Tonsil	20	17	22	21	21	33	19	30	31	35	0.5	0.3	0.5	0.4	0.4	0.7	0.4	0.5	0.6	0.6
C10	Oropharynx	7	3	4	14	4	5	12	15	24	21	0.2	0.1	0.1	0.3	0.1	0.1	0.3	0.3	0.5	0.4
C11	Nasopharynx	5	7	5	4	3	5	10	6	9	8	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.3	0.2
C12	Pyiform sinus	7	8	5	8	7	7	7	11	14	7	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.2	0.2	0.1
C13	Hypopharynx	5	3	5	6	5	3	13	3	10	6	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.2	0.1
C14	Lip, oral cavity and pharynx, NOS	5	4	3	2	-	6	2	4	3	1	0.1	0.1	0.1	0.0	-	0.1	0.0	0.1	0.1	0.0
C15	Oesophagus	93	89	116	122	130	128	136	114	137	126	1.5	1.3	1.8	1.7	1.9	1.9	1.9	1.5	1.9	1.6
C16	Stomach	326	354	306	328	339	336	274	288	337	334	4.1	4.6	3.7	4.1	4.3	4.4	3.6	3.5	4.3	4.0
C17	Small intestine	40	42	49	45	47	58	71	47	63	75	0.7	0.8	0.8	0.7	0.7	0.9	1.1	0.7	0.9	1.1
C18	Colon	1,383	1,363	1,415	1,388	1,396	1,473	1,556	1,610	1,675	1,676	19.4	18.5	19.8	18.5	18.7	20.0	20.1	21.2	21.4	21.2
C19	Rectosigmoid junction	114	114	125	141	107	80	65	75	81	63	1.9	1.6	1.8	2.0	1.5	1.1	0.9	1.0	1.1	0.8
C20	Rectum	518	489	540	526	508	582	598	613	583	615	8.2	7.3	8.1	7.7	7.6	8.7	8.6	8.9	8.1	8.6
C21	Anus and anal canal	21	35	48	28	33	32	40	35	45	47	0.4	0.6	0.9	0.5	0.5	0.5	0.6	0.5	0.7	0.7
C22	Liver and intrahepatic bile ducts	90	76	71	75	92	89	82	106	106	100	1.4	1.2	1.0	1.3	1.4	1.4	1.3	1.7	1.6	1.5
C23	Gallbladder	49	42	39	39	43	43	46	46	53	52	0.7	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.6	0.5
C24	Biliary tract, NOS	35	46	64	77	64	74	69	77	85	57	0.5	0.6	0.9	1.1	0.8	0.9	1.0	0.9	1.1	0.7
C25	Pancreas	251	310	298	286	312	305	319	318	378	422	3.7	4.2	4.0	4.0	4.0	4.4	4.6	4.5	5.0	5.7
C26	Other ill-defined digestive organs	2	4	3	2	3	2	3	10	5	8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1
C30	Nasal cavity and middle ear	4	3	8	7	14	8	13	5	6	6	0.1	0.1	0.2	0.1	0.3	0.2	0.2	0.1	0.1	0.1
C31	Accessory sinuses	9	7	12	8	11	8	6	20	9	11	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.3	0.1	0.2
C32	Larynx	39	38	53	45	34	29	45	38	46	37	0.8	0.7	0.9	0.9	0.6	0.6	0.8	0.7	0.7	0.7
C33	Trachea	2	1	3	1	3	5	3	1	1	1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0
C34	Bronchus and lung	656	681	692	831	868	886	998	971	1,084	1,195	11.9	12.7	12.7	14.8	14.9	15.3	16.7	16.3	17.9	19.6
C37	Thymus	8	8	6	9	5	8	4	8	8	6	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1
C38	Heart, mediastinum and pleura	13	4	-	3	5	3	4	7	4	10	0.3	0.1	-	0.1	0.1	0.1	0.1	0.1	0.2	0.1
C39	Respiratory system and intrathoracic organs, NOS	-	-	1	-	-	-	-	-	-	-	-	-	0.0	-	-	-	-	-	-	-
C40	Bone and articular cartilage of limbs	20	18	20	21	30	20	22	17	11	18	0.6	0.5	0.5	0.6	1.0	0.7	0.6	0.5	0.3	0.7
C41	Bone and articular cartilage, NOS	17	21	31	14	21	23	21	15	20	14	0.4	0.7	0.8	0.4	0.5	0.6	0.5	0.4	0.4	0.3
C43	Malignant melanoma of skin	446	438	480	497	561	598	573	684	717	678	10.3	9.5	10.8	11.2	12.4	13.1	12.0	14.8	14.9	14.4
C44	Malignant neoplasms of skin	504	522	582	690	701	747	860	949	955	1,116	6.5	6.4	7.3	8.5	8.4	8.9	10.0	10.9	10.2	11.8
C45	Mesothelioma	21	21	14	19	34	24	32	37	28	35	0.4	0.3	0.3	0.3	0.6	0.4	0.4	0.5	0.3	0.5

C46	Kaposi's sarcoma	1	4	7	4	2	4	3	4	2	2	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
C47-C49	Soft tissues	88	83	84	100	92	84	96	101	100	96	2.1	1.9	2.0	2.0	2.3	1.7	2.0	1.8	1.8	1.8	1.8	1.8	
C48	Retroperitoneum and peritoneum	26	23	21	27	25	21	18	33	30	18	0.5	0.5	0.4	0.5	0.5	0.4	0.4	0.6	0.4	0.3	0.3	0.3	
C50	Breast	5,300	5,245	5,521	5,312	5,466	5,495	5,676	5,475	5,540	5,731	110.1	107.2	112.0	105.4	106.4	105.3	107.2	102.3	101.3	103.8	103.8	103.8	
C51	Vulva	72	88	88	85	102	102	80	113	115	128	1.1	1.3	1.4	1.3	1.5	1.5	1.2	1.6	1.5	1.7	1.7	1.7	
C52	Vagina	23	25	22	27	28	27	26	20	26	28	0.3	0.4	0.3	0.5	0.4	0.4	0.3	0.2	0.2	0.4	0.4	0.4	
C53	Cervix uteri	391	363	354	372	403	360	401	357	355	330	8.9	8.4	8.0	8.4	9.3	8.1	9.1	7.8	7.8	7.8	7.8	7.1	
C54	Corpus uteri	810	768	796	858	827	834	856	919	890	826	14.5	13.5	13.5	14.4	13.4	13.9	13.9	14.2	13.8	12.4	12.4	12.4	
C55	Uterus	26	39	49	20	28	16	4	6	4	4	0.5	0.6	0.9	0.3	0.5	0.3	0.1	0.1	0.0	0.0	0.0	0.0	
C56	Ovary	597	568	607	566	563	583	547	535	482	510	11.3	10.5	10.9	10.1	9.8	10.1	9.8	8.8	7.9	8.2	8.2	8.2	
C57	Female genital organs, NOS	10	14	13	16	19	14	22	24	30	26	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.4	0.4	0.4	
C58	Placenta	1	5	3	2	3	1	6	2	3	3	0.0	0.2	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1	
C64	Kidney	273	287	330	353	337	337	349	352	339	368	5.1	5.2	5.5	5.9	5.5	5.7	5.9	5.5	5.5	5.5	5.5	5.6	
C65	Renal pelvis	30	36	37	44	44	43	45	47	51	52	0.4	0.5	0.4	0.6	0.6	0.5	0.5	0.6	0.5	0.5	0.6	0.6	
C66	Ureter	23	26	25	17	12	18	27	27	26	25	0.3	0.3	0.4	0.2	0.1	0.2	0.3	0.3	0.3	0.2	0.3	0.3	
C67	Bladder	249	225	218	246	270	254	255	292	273	292	3.0	2.8	2.8	3.0	3.3	3.0	3.1	3.4	3.1	3.4	3.1	3.5	
C68	Urinary organs, NOS	3	1	2	4	4	-	4	6	4	5	0.1	0.0	0.0	0.1	0.0	-	0.0	0.1	0.0	0.1	0.0	0.1	
C69	Eye and adnexa	27	20	29	28	21	16	30	27	39	35	0.5	0.5	0.5	0.7	0.5	0.3	0.7	0.7	0.7	0.7	0.7	0.8	
C70	Meninges	6	10	18	11	7	6	10	6	9	6	0.1	0.2	0.4	0.3	0.2	0.1	0.2	0.1	0.2	0.1	0.2	0.1	
C71	Brain	181	214	175	205	163	158	190	195	207	192	4.4	4.9	4.1	4.3	3.7	4.2	4.2	4.2	4.2	4.3	4.3	3.7	
C72	Spinal cord, cranial nerves and CNS, NOS	5	5	2	11	7	10	7	6	8	14	0.2	0.2	0.1	0.6	0.3	0.5	0.2	0.3	0.3	0.3	0.3	0.5	
C73	Thyroid gland	134	165	158	166	228	220	209	223	263	286	3.1	3.8	4.0	4.2	5.3	5.4	4.9	5.2	6.3	6.3	6.5	6.5	
C74	Adrenal gland	13	7	7	12	8	11	11	12	10	20	0.4	0.1	0.3	0.6	0.4	0.3	0.3	0.4	0.4	0.4	0.6	0.6	
C75	Endocrine glands, NOS	5	2	2	4	3	7	2	4	2	4	0.1	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.1	0.1	
C81	Hodgkin's disease	87	71	55	74	77	68	57	71	71	83	2.8	2.4	1.7	2.4	2.5	2.3	1.9	1.9	2.3	2.7	2.7	2.7	
C82-C86	Non-Hodgkin-lymphoma	430	397	420	462	440	482	489	499	509	545	7.4	7.2	7.2	7.9	7.2	8.1	8.1	7.8	7.8	7.9	8.4	8.4	
C88	Malignant immunoproliferative diseases	9	34	36	47	56	45	42	47	42	62	0.1	0.7	0.5	0.7	0.9	0.7	0.7	0.7	0.6	0.6	1.0	1.0	
C90	Multiple myeloma	197	185	166	220	200	190	211	223	202	206	3.0	2.6	2.6	3.2	2.9	3.0	3.2	3.2	2.7	2.8	2.8	2.8	
C91	Lymphoid leukaemia	171	191	177	217	188	169	190	162	207	187	3.8	3.7	3.7	4.5	3.8	3.8	4.1	3.1	4.0	3.5	3.5	3.5	
C92	Myeloid leukaemia	143	117	134	154	150	125	162	131	120	176	2.7	2.3	2.6	2.8	3.0	2.4	3.0	2.3	2.4	3.1	3.1	3.1	
C93	Monocytic leukaemia	11	9	10	13	16	16	22	35	21	22	0.3	0.2	0.2	0.3	0.3	0.2	0.6	0.7	0.3	0.4	0.4	0.4	
C94-C95	Leukaemia other	25	18	17	10	11	8	5	10	11	23	0.4	0.3	0.2	0.2	0.3	0.1	0.1	0.1	0.2	0.4	0.4	0.4	
C96	Lymphoid, haematopoietic and related tissue, NOS	12	1	4	3	5	3	6	5	9	19	0.5	0.0	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.3	0.8	0.8	
C76	Other and ill-defined sites	16	10	24	15	3	7	2	2	1	1	0.4	0.2	0.5	0.4	0.1	0.2	0.1	0.1	0.0	0.0	0.0	0.0	
C80	Unknown primary site	483	296	314	271	256	209	272	276	197	219	7.9	4.2	4.3	3.8	3.5	2.8	3.8	3.6	2.4	2.4	2.7	2.7	
MPD	Myeloproliferative Disorders	9	78	97	109	123	138	160	138	153	171	0.2	1.3	1.5	1.5	2.0	2.1	2.3	2.1	2.4	2.5	2.5	2.5	
MDS	Myelodysplastic syndromes	12	57	79	121	137	93	131	154	138	120	0.2	0.7	1.0	1.5	1.7	1.2	1.6	1.9	1.7	1.4	1.4	1.4	
Total		14,737	14,597	15,263	15,618	15,916	15,934	16,674	16,861	17,169	17,790	274.3	265.4	275.0	276.3	279.5	278.0	284.3	280.4	280.9	287.9	287.9	287.9	
Total excl. non-melanoma		14,233	14,075	14,681	14,928	15,215	15,187	15,814	15,912	16,214	16,674	267.8	259.0	267.7	267.8	271.1	269.2	274.3	269.5	270.7	276.1	276.1	276.1	
Total excl. non-melanoma and MDS, MPD		14,212	13,940	14,505	14,698	14,955	14,956	15,523	15,620	15,923	16,383	267.5	257.0	265.3	264.8	267.3	265.9	270.3	265.5	266.6	272.2	272.2	272.2	

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)

Primary site	N										WSR									
	2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010						
C00 Lip	59	62	54	35	42	56	50	0.6	0.7	0.6	0.4	0.4	0.5	0.4						
C01 Base of tongue	64	55	69	97	108	118	90	0.9	0.7	0.9	1.2	1.3	1.4	1.0						
C02 Tongue	187	177	166	151	167	177	148	2.5	2.3	2.1	1.9	2.1	2.2	1.8						
C03 Gum	29	32	35	32	34	30	31	0.4	0.4	0.4	0.4	0.4	0.3	0.4						
C04 Floor of mouth	167	159	133	163	157	169	157	2.2	2.1	1.7	2.1	2.0	2.0	1.9						
C05 Palate	53	67	61	61	63	59	59	0.7	0.9	0.8	0.8	0.8	0.7	0.7						
C06 Mouth, NOS	81	67	67	60	55	56	61	1.0	0.8	0.8	0.7	0.6	0.7	0.7						
C07 Parotid gland	54	48	49	57	50	54	60	0.7	0.6	0.6	0.6	0.6	0.6	0.7						
C08 Salivary glands, NOS	19	26	8	22	11	21	15	0.2	0.3	0.1	0.3	0.1	0.3	0.2						
C09 Tonsil	164	160	157	196	193	174	135	2.1	2.1	2.0	2.5	2.4	2.1	1.6						
C10 Oropharynx	99	100	92	107	138	115	134	1.4	1.3	1.2	1.4	1.7	1.4	1.6						
C11 Nasopharynx	43	35	45	38	39	46	43	0.6	0.5	0.6	0.5	0.5	0.6	0.6						
C12 Pyriform sinus	146	127	132	158	122	145	125	2.0	1.6	1.7	2.1	1.6	1.8	1.5						
C13 Hypopharynx	58	51	66	77	70	81	57	0.8	0.7	0.9	0.9	0.9	0.9	0.7						
C14 Lip, oral cavity and pharynx, NOS	42	46	25	19	23	21	18	0.6	0.6	0.3	0.3	0.3	0.3	0.2						
C15 Oesophagus	626	666	691	691	660	681	680	7.5	7.9	8.0	7.9	7.3	7.5	7.1						
C16 Stomach	884	874	862	872	821	848	854	9.4	9.4	8.8	8.9	8.1	8.2	8.3						
C17 Small intestine	95	100	109	82	116	107	139	1.1	1.2	1.2	0.9	1.3	1.1	1.4						
C18 Colon	2,554	2,704	2,722	2,737	2,912	2,931	2,967	26.7	27.9	27.6	26.9	28.4	28.4	28.0						
C19 Rectosigmoid junction	303	203	156	145	159	147	178	3.2	2.2	1.6	1.4	1.7	1.4	1.7						
C20 Rectum	1,259	1,262	1,385	1,378	1,450	1,456	1,411	14.1	13.6	14.8	14.6	15.1	14.9	14.5						
C21 Anus and anal canal	45	49	44	47	51	66	56	0.5	0.6	0.5	0.5	0.5	0.7	0.6						
C22 Liver and intrahepatic bile ducts	259	300	346	375	429	409	479	3.0	3.4	4.0	4.3	4.8	4.5	5.1						
C23 Gallbladder	36	27	30	27	31	22	36	0.3	0.3	0.3	0.3	0.3	0.2	0.3						
C24 Biliary tract, NOS	122	108	126	145	132	151	145	1.4	1.1	1.3	1.5	1.4	1.5	1.4						
C25 Pancreas	588	545	616	648	595	702	785	6.6	5.9	6.6	7.0	6.3	7.3	7.8						
C26 Other ill-defined digestive organs	13	10	9	7	16	16	22	0.1	0.1	0.1	0.1	0.2	0.2	0.2						
C30 Nasal cavity and middle ear	23	21	21	27	30	34	30	0.3	0.3	0.2	0.3	0.3	0.4	0.4						
C31 Accessory sinuses	47	72	51	57	66	43	63	0.6	0.8	0.6	0.7	0.8	0.5	0.7						
C32 Larynx	627	560	538	623	592	558	541	7.9	6.7	6.3	7.3	6.8	6.2	5.8						
C33 Trachea	12	11	7	14	3	10	10	0.1	0.1	0.1	0.1	0.0	0.1	0.1						
C34 Bronchus and lung	5,519	5,426	5,389	5,524	5,488	5,519	5,616	60.7	59.1	57.8	58.4	57.1	56.1	55.4						
C37 Thymus	23	17	18	15	12	20	21	0.3	0.2	0.2	0.2	0.1	0.2	0.2						
C38 Heart, mediastinum and pleura	8	9	12	20	11	16	24	0.1	0.1	0.2	0.3	0.1	0.2	0.3						
C39 Respiratory system and intrathoracic organs, NOS	1	1	-	-	-	1	3	0.0	0.0	-	-	-	0.0	0.0						
C40 Bone and articular cartilage of limbs	48	34	34	39	33	30	36	1.0	0.7	0.7	0.8	0.6	0.6	0.7						
C41 Bone and articular cartilage, NOS	42	37	33	37	33	25	43	0.7	0.7	0.5	0.6	0.6	0.4	0.7						
C43 Malignant melanoma of skin	634	638	628	737	761	732	871	8.5	8.1	8.1	9.5	9.3	8.9	10.7						

C44	Malignant neoplasms of skin	1,673	1,755	1,893	2,218	2,191	2,383	2,531	16.3	16.7	17.7	19.9	18.9	20.0	20.6
C45	Mesothelioma	210	211	206	198	208	194	204	2.3	2.3	2.1	2.0	2.2	1.9	1.9
C46	Kaposi's sarcoma	22	24	18	35	35	40	31	0.3	0.3	0.2	0.5	0.4	0.6	0.4
C47-C49	Soft tissues	182	180	169	193	193	181	162	2.4	2.3	2.4	2.5	2.5	2.4	2.1
C48	Retroperitoneum and peritoneum	24	22	24	20	28	14	23	0.3	0.3	0.3	0.3	0.4	0.2	0.3
C50	Breast	88	83	65	81	85	99	83	1.0	0.9	0.7	0.9	0.9	1.1	0.9
C60	Penis	66	68	76	74	72	80	85	0.7	0.8	0.8	0.8	0.7	0.9	0.8
C61	Prostate	9,738	9,725	9,279	8,983	8,844	8,698	8,663	105.5	104.3	100.1	95.1	91.8	89.0	86.4
C62	Testis	251	284	274	304	322	314	318	4.7	5.2	5.3	5.8	6.1	5.8	5.8
C63	Male genital organs, NOS	10	11	13	13	13	8	14	0.1	0.2	0.2	0.2	0.2	0.1	0.1
C64	Kidney	816	845	854	893	954	957	981	10.0	10.0	10.1	10.1	10.8	10.8	10.7
C65	Renal pelvis	96	114	98	123	117	119	145	0.9	1.1	1.0	1.2	1.1	1.1	1.4
C66	Ureter	89	69	81	84	92	117	101	0.9	0.7	0.8	0.8	0.9	1.1	0.9
C67	Bladder	1,664	1,632	1,606	1,680	1,700	1,730	1,755	16.9	16.2	15.7	16.2	15.7	15.7	15.8
C68	Urinary organs, NOS	18	28	23	27	26	22	50	0.2	0.3	0.2	0.2	0.3	0.2	0.4
C69	Eye and adnexa	39	38	53	58	62	54	61	0.6	0.7	0.7	0.8	0.7	0.9	0.9
C70	Meninges	11	7	4	1	5	4	8	0.1	0.1	0.1	0.0	0.1	0.1	0.1
C71	Brain	422	435	418	434	437	464	453	6.1	6.4	5.9	5.9	5.8	6.6	6.2
C72	Spinal cord, cranial nerves and CNS, NOS	29	11	14	14	10	13	14	0.5	0.2	0.4	0.4	0.2	0.3	0.3
C73	Thyroid gland	156	170	175	186	211	259	204	2.1	2.4	2.4	2.6	2.8	3.4	2.7
C74	Adrenal gland	17	13	15	18	21	25	29	0.4	0.3	0.3	0.4	0.5	0.6	0.5
C75	Endocrine glands, NOS	9	6	13	4	10	10	7	0.2	0.1	0.2	0.1	0.2	0.2	0.1
C81	Hodgkin's disease	158	179	177	162	181	173	154	2.8	3.4	3.0	2.8	3.1	3.0	2.5
C82-C86	Non-Hodgkin-lymphoma	970	981	1,009	993	1,005	1,000	1,021	11.9	11.7	12.0	11.8	11.8	11.0	11.4
C88	Malignant immunoproliferative diseases	106	89	98	107	116	105	103	1.3	1.1	1.1	1.3	1.3	1.1	1.0
C90	Multiple myeloma	368	369	397	416	392	407	424	4.0	3.9	4.2	4.5	4.0	4.1	4.1
C91	Lymphoid leukaemia	434	439	392	404	474	470	481	6.2	6.3	5.3	5.5	6.2	6.3	5.9
C92	Myeloid leukaemia	255	290	254	318	300	323	329	3.2	3.9	3.1	3.9	3.4	3.7	3.6
C93	Monocytic leukaemia	37	32	37	60	61	50	55	0.4	0.4	0.4	0.6	0.6	0.6	0.6
C94-C95	Leukaemia other	29	31	25	24	23	17	31	0.3	0.4	0.3	0.2	0.3	0.2	0.3
C96	Lymphoid, haematopoietic and related tissue, NOS	9	5	16	11	14	7	25	0.2	0.1	0.4	0.2	0.2	0.1	0.6
C76	Other and ill-defined sites	16	18	19	2	1	2	2	0.2	0.3	0.3	0.0	0.0	0.0	0.0
C80	Unknown primary site	644	577	584	557	579	512	462	7.0	6.2	6.1	5.9	5.9	5.0	4.5
MPD	Myeloproliferative Disorders	178	173	173	195	217	218	257	2.2	1.9	1.9	2.0	2.3	2.4	2.7
MDS	Myelodysplastic syndromes	270	247	252	230	306	330	339	2.7	2.4	2.4	2.2	2.7	3.0	3.2
Total		34,137	34,047	33,790	34,640	34,978	35,245	35,798	385.6	380.0	372.7	376.2	371.7	368.7	365.1
Total excl. non-melanoma		32,464	32,292	31,897	32,422	32,787	32,862	33,267	369.3	363.2	354.9	356.3	352.7	348.7	344.5
Total excl. non-melanoma and MDS, MPD		32,016	31,872	31,472	31,997	32,264	32,314	32,671	364.5	358.9	350.6	352.0	347.7	343.4	338.7

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)

Primary site		N										WSR				
		2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010	
C00	Lip	18	23	20	12	15	15	11	0.1	0.2	0.2	0.1	0.1	0.1	0.1	
C01	Base of tongue	17	13	23	23	28	37	38	0.2	0.2	0.2	0.3	0.3	0.4	0.4	
C02	Tongue	69	70	74	52	72	75	76	0.8	0.8	0.9	0.6	0.7	0.9	0.8	
C03	Gum	30	24	22	30	32	32	25	0.3	0.2	0.2	0.3	0.3	0.3	0.2	
C04	Floor of mouth	46	40	30	58	30	46	48	0.5	0.5	0.4	0.7	0.3	0.5	0.5	
C05	Palate	32	29	32	27	36	19	26	0.4	0.4	0.4	0.3	0.4	0.2	0.3	
C06	Mouth, NOS	40	45	25	32	29	30	51	0.4	0.4	0.2	0.3	0.2	0.3	0.4	
C07	Parotid gland	34	44	34	46	40	37	41	0.4	0.4	0.4	0.5	0.4	0.4	0.5	
C08	Salivary glands, NOS	14	25	18	14	9	16	19	0.2	0.3	0.2	0.2	0.1	0.2	0.3	
C09	Tonsil	56	54	62	66	74	64	68	0.7	0.7	0.8	0.8	0.8	0.8	0.7	
C10	Oropharynx	27	21	22	31	35	44	38	0.3	0.3	0.2	0.4	0.4	0.5	0.4	
C11	Nasopharynx	10	9	9	17	14	20	15	0.2	0.1	0.2	0.2	0.2	0.3	0.2	
C12	Pyiform sinus	16	15	24	16	23	35	25	0.2	0.2	0.3	0.2	0.3	0.4	0.3	
C13	Hypopharynx	13	16	8	18	17	16	12	0.2	0.2	0.1	0.2	0.2	0.2	0.1	
C14	Lip, oral cavity and pharynx, NOS	9	12	13	5	9	8	2	0.1	0.1	0.2	0.0	0.1	0.1	0.0	
C15	Oesophagus	233	231	217	251	227	237	242	2.0	2.1	2.0	2.1	1.9	2.0	2.0	
C16	Stomach	512	526	530	455	503	518	547	3.9	4.0	4.1	3.6	3.9	3.9	3.9	
C17	Small intestine	86	87	105	114	86	107	113	0.8	0.8	1.0	1.0	0.8	0.9	1.0	
C18	Colon	2,396	2,425	2,514	2,571	2,623	2,672	2,628	18.4	19.0	19.6	19.5	20.0	19.9	19.4	
C19	Rectosigmoid junction	238	171	136	102	121	140	129	2.0	1.4	1.1	0.8	0.9	1.2	1.0	
C20	Rectum	880	886	937	979	975	923	981	7.5	7.9	8.0	8.3	8.2	7.7	8.2	
C21	Anus and anal canal	69	71	74	78	76	84	102	0.7	0.7	0.7	0.7	0.7	0.8	1.0	
C22	Liver and intrahepatic bile ducts	116	169	156	144	196	199	192	1.1	1.7	1.4	1.2	1.8	1.8	1.7	
C23	Gallbladder	63	60	70	67	70	71	94	0.4	0.4	0.6	0.5	0.5	0.5	0.6	
C24	Biliary tract, NOS	118	102	100	116	117	142	120	1.0	0.8	0.7	0.9	0.8	1.0	0.9	
C25	Pancreas	503	534	580	544	585	655	738	4.3	4.7	4.9	4.7	4.9	5.3	5.9	
C26	Other ill-defined digestive organs	10	12	8	9	16	12	14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
C30	Nasal cavity and middle ear	12	17	14	18	14	17	12	0.1	0.2	0.2	0.2	0.2	0.1	0.1	
C31	Accessory sinuses	17	21	14	15	24	14	16	0.2	0.2	0.2	0.2	0.2	0.1	0.2	
C32	Larynx	100	84	82	72	85	104	83	1.1	0.9	0.9	0.8	1.0	1.1	0.9	
C33	Trachea	3	4	5	7	2	6	3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	
C34	Bronchus and lung	1,567	1,602	1,715	1,889	1,813	2,093	2,215	16.6	16.7	17.7	19.2	18.4	21.1	21.7	
C37	Thymus	18	9	11	12	15	13	17	0.2	0.1	0.1	0.1	0.2	0.1	0.2	
C38	Heart, mediastinum and pleura	4	11	6	7	14	9	13	0.1	0.1	0.1	0.1	0.2	0.1	0.2	
C39	Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C40	Bone and articular cartilage of limbs	34	41	34	37	34	21	25	0.6	0.8	0.7	0.6	0.7	0.4	0.5	
C41	Bone and articular cartilage, NOS	29	36	42	34	31	27	26	0.5	0.5	0.7	0.5	0.5	0.3	0.4	
C43	Malignant melanoma of skin	893	975	970	984	1,161	1,192	1,239	11.8	12.7	12.3	12.3	14.6	14.6	15.8	
C44	Malignant neoplasms of skin	1,167	1,228	1,225	1,473	1,563	1,576	1,783	8.1	8.6	8.3	9.9	10.3	9.8	11.1	
C45	Mesothelioma	26	47	41	48	51	40	51	0.2	0.5	0.4	0.4	0.4	0.3	0.4	

C46	Kaposi's sarcoma	9	8	12	4	10	11	7	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
C47-C49	Soft tissues	168	137	143	163	166	156	152	2.0	1.9	1.7	2.0	1.8	1.6	1.7	1.7	1.7
C48	Retoperitoneum and peritoneum	38	40	42	38	53	47	33	0.4	0.5	0.5	0.4	0.6	0.4	0.4	0.4	0.4
C50	Breast	9,420	9,403	9,506	9,695	9,590	9,604	9,908	109.9	107.2	107.7	108.0	104.9	103.8	106.2	106.2	106.2
C51	Vulva	149	170	170	172	190	192	216	1.3	1.4	1.5	1.5	1.6	1.6	1.6	1.8	1.8
C52	Vagina	53	47	49	47	36	45	43	0.5	0.4	0.4	0.4	0.3	0.4	0.4	0.4	0.4
C53	Cervix uteri	653	655	611	702	640	605	593	8.5	8.7	7.9	9.2	8.2	7.7	7.5	7.5	7.5
C54	Corpus uteri	1,418	1,371	1,344	1,392	1,473	1,456	1,415	13.8	13.1	13.1	13.1	13.4	13.2	12.5	12.5	12.5
C55	Uterus	59	55	24	11	7	10	9	0.6	0.5	0.3	0.1	0.0	0.1	0.1	0.1	0.1
C56	Ovary	915	936	928	925	885	791	865	9.7	9.5	9.5	9.6	8.7	7.6	8.2	8.2	8.2
C57	Female genital organs, NOS	28	33	33	28	52	48	46	0.3	0.3	0.4	0.3	0.5	0.5	0.4	0.4	0.4
C58	Placenta	3	5	1	8	4	4	3	0.0	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1
C64	Kidney	531	538	534	533	548	523	551	5.5	5.5	5.3	5.1	5.3	5.1	5.0	5.0	5.0
C65	Renal pelvis	70	71	73	80	80	83	79	0.6	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.5
C66	Ureter	32	22	33	34	41	45	39	0.2	0.1	0.3	0.2	0.3	0.3	0.3	0.3	0.3
C67	Bladder	398	453	392	416	481	467	477	2.9	3.3	2.9	2.8	3.3	3.1	3.3	3.3	3.3
C68	Urinary organs, NOS	6	6	1	6	8	7	11	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1
C69	Eye and adnexa	50	38	37	46	44	63	56	0.7	0.7	0.5	0.6	0.6	0.6	0.7	0.8	0.8
C70	Meninges	19	11	10	13	10	11	10	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
C71	Brain	325	294	294	309	328	359	322	4.2	4.1	4.1	4.0	4.4	4.8	4.0	4.0	4.0
C72	Spinal cord, cranial nerves and CNS, NOS	21	12	13	12	7	10	18	0.5	0.3	0.3	0.2	0.2	0.2	0.2	0.4	0.4
C73	Thyroid gland	475	503	511	515	551	639	651	6.9	7.0	7.3	7.3	7.6	9.0	8.8	8.8	8.8
C74	Adrenal gland	18	20	24	22	16	15	29	0.4	0.6	0.4	0.3	0.3	0.3	0.5	0.5	0.5
C75	Endocrine glands, NOS	4	3	10	5	8	6	6	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1
C81	Hodgkin's disease	128	122	114	109	128	125	149	2.3	2.4	2.0	2.1	2.2	2.4	2.7	2.7	2.7
C82-C86	Non-Hodgkin-lymphoma	834	780	809	866	876	887	926	8.3	7.6	7.8	8.3	8.2	8.1	8.4	8.4	8.4
C88	Malignant immunoproliferative diseases	82	83	95	97	83	76	111	0.8	0.8	0.9	0.9	0.8	0.6	1.0	1.0	1.0
C90	Multiple myeloma	380	313	317	333	336	348	327	3.3	2.7	2.9	2.9	2.8	2.7	2.6	2.6	2.6
C91	Lymphoid leukaemia	335	277	254	298	270	344	343	4.2	3.5	3.4	3.6	3.1	3.9	3.8	3.8	3.8
C92	Myeloid leukaemia	256	249	220	275	239	223	292	2.9	3.0	2.4	3.1	2.5	2.4	3.1	3.1	3.1
C93	Monocytic leukaemia	22	24	26	34	53	35	40	0.2	0.2	0.2	0.4	0.6	0.3	0.4	0.4	0.4
C94-C95	Leukaemia other	20	17	13	11	15	19	30	0.2	0.2	0.1	0.1	0.1	0.2	0.3	0.3	0.3
C96	Lymphoid, haematopoietic and related tissue, NOS	7	7	8	11	15	17	28	0.1	0.2	0.2	0.1	0.4	0.3	0.7	0.7	0.7
C76	Other and ill-defined sites	24	10	11	2	5	3	3	0.3	0.2	0.1	0.0	0.1	0.0	0.0	0.0	0.0
C80	Unknown primary site	529	483	432	516	541	384	408	4.2	4.0	3.5	4.3	4.2	2.8	3.0	3.0	3.0
MPD	Myeloproliferative Disorders	158	177	195	217	218	235	247	1.3	1.7	1.9	1.9	1.9	2.2	2.1	2.1	2.1
MDS	Myelodysplastic syndromes	197	207	171	188	237	216	212	1.4	1.6	1.4	1.4	1.7	1.5	1.5	1.5	1.5
Total		27,359	27,369	27,462	28,596	29,109	29,475	30,533	285.4	284.0	282.3	288.4	287.5	287.4	295.1	295.1	295.1
Total excl. non-melanoma		26,192	26,141	26,237	27,123	27,546	27,899	28,750	277.4	275.4	274.0	278.5	277.1	277.6	284.0	284.0	284.0
Total excl. non-melanoma and MDS, MPD		25,837	25,757	25,871	26,718	27,091	27,448	28,291	274.6	272.1	270.7	275.2	273.6	273.9	280.4	280.4	280.4

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)

EAPC: Estimated annual percentage change (%)

Primary site	N										WSR				
	2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010	
C00 Lip	-	-	-	4	5	4	3	-	-	-	-	0.5	0.6	0.5	
C01 Base of tongue	6	7	10	7	6	12	8	0.9	1.3	1.7	1.2	1.1	1.7	1.1	
C02 Tongue	14	16	16	17	13	11	17	2.4	2.5	2.5	2.7	2.2	1.7	2.6	
C03 Gum	2	4	5	2	2	1	2	0.4	0.7	0.7	0.2	0.3	0.2	0.3	
C04 Floor of mouth	17	5	13	23	11	8	12	2.8	0.8	2.2	3.6	1.6	1.0	1.9	
C05 Palate	4	6	2	5	3	3	6	0.8	1.0	0.4	0.9	0.4	0.5	0.9	
C06 Mouth, NOS	6	4	3	8	4	8	6	0.8	0.4	0.4	1.3	0.4	1.2	0.9	
C07 Parotid gland	3	3	5	3	3	7	2	0.4	0.5	0.7	0.2	0.4	0.9	0.3	
C08 Salivary glands, NOS	3	3	3	2	-	3	2	0.5	0.4	0.2	0.2	-	0.5	0.2	
C09 Tonsil	13	18	20	25	18	15	12	2.1	2.7	2.8	3.6	2.9	2.1	1.7	
C10 Oropharynx	9	12	9	10	15	16	13	1.5	1.9	1.4	1.7	2.4	2.5	2.1	
C11 Nasopharynx	9	8	14	7	5	8	8	1.5	1.4	2.6	1.2	0.8	1.3	1.1	
C12 Pyriform sinus	13	16	6	13	16	6	11	2.4	2.7	0.9	2.0	2.4	0.9	1.5	
C13 Hypopharynx	5	5	7	5	10	3	5	0.8	0.9	1.2	0.7	1.3	0.3	1.0	
C14 Lip, oral cavity and pharynx, NOS	5	3	1	1	2	-	2	0.7	0.5	0.1	0.1	0.3	-	0.2	
C15 Oesophagus	48	44	51	46	46	53	41	7.2	6.4	7.6	6.8	6.4	7.8	5.3	
C16 Stomach	76	66	75	80	64	66	71	10.4	8.2	9.7	11.0	8.6	8.9	8.6	
C17 Small intestine	6	10	7	8	12	4	11	0.9	1.3	1.0	1.1	1.7	0.6	1.3	
C18 Colon	204	228	207	239	228	187	239	26.6	29.4	24.0	29.4	28.4	23.3	29.4	
C19 Rectosigmoid junction	22	18	16	13	15	9	24	2.9	2.8	2.1	1.6	2.1	1.1	2.9	
C20 Rectum	70	77	85	94	94	85	91	9.7	9.8	11.4	12.0	12.2	11.3	12.9	
C21 Anus and anal canal	5	7	8	6	8	6	7	0.7	0.8	0.9	1.0	0.9	0.8	1.0	
C22 Liver and intrahepatic bile ducts	19	28	35	35	36	52	56	2.8	3.7	4.8	5.4	5.0	7.4	7.5	
C23 Gallbladder	2	1	3	2	5	-	4	0.2	0.2	0.4	0.4	0.6	-	0.6	
C24 Biliary tract, NOS	4	11	11	11	6	7	15	0.5	1.4	1.6	1.2	0.7	0.8	2.1	
C25 Pancreas	51	38	40	61	64	62	65	6.9	4.8	5.3	8.3	8.3	9.0	8.2	
C26 Other ill-defined digestive organs	-	1	1	-	3	1	4	-	0.2	0.2	-	0.5	0.2	0.5	
C30 Nasal cavity and middle ear	1	-	-	3	2	3	4	0.1	-	-	0.4	0.3	0.5	0.5	
C31 Accessory sinuses	1	3	6	3	-	3	6	0.2	0.4	0.7	0.4	-	0.4	1.1	
C32 Larynx	63	47	51	62	53	51	36	10.4	7.3	7.6	9.2	7.9	7.6	5.2	
C33 Trachea	-	1	1	2	-	1	1	-	0.2	0.2	0.3	-	0.2	0.1	
C34 Bronchus and lung	410	393	363	364	375	386	450	58.2	57.3	49.9	51.1	52.7	51.3	60.8	
C37 Thymus	1	2	2	1	1	6	3	0.2	0.2	0.3	0.2	0.2	1.0	0.4	
C38 Heart, mediastinum and pleura	1	1	1	1	-	2	2	0.2	0.1	0.1	0.1	-	0.5	0.3	
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C40 Bone and articular cartilage of limbs	7	3	2	3	5	4	8	1.4	0.8	0.4	0.4	1.1	0.8	1.6	
C41 Bone and articular cartilage, NOS	6	5	3	5	4	2	6	0.8	1.0	0.6	1.0	0.8	0.5	1.2	
C43 Malignant melanoma of skin	59	65	57	72	77	83	80	8.8	8.7	7.8	10.5	10.6	11.9	11.2	

	164	166	154	224	198	191	242	173	18.4	16.7	24.8	20.2	20.4	23.3
C44 Malignant neoplasms of skin	164	166	154	224	198	191	242	173	18.4	16.7	24.8	20.2	20.4	23.3
C45 Mesothelioma	6	9	9	13	6	7	4	0.7	1.1	1.2	1.4	1.0	1.0	0.6
C46 Kaposi's sarcoma	9	9	3	13	13	21	13	1.4	1.4	0.5	2.0	2.1	3.3	1.8
C47-C49 Soft tissues	16	24	26	19	14	20	12	2.5	3.8	3.7	2.9	2.2	3.2	1.9
C48 Retroperitoneum and peritoneum	1	1	4	-	3	-	4	0.1	0.1	0.6	-	0.3	-	0.6
C50 Breast	7	8	8	8	5	7	9	1.1	1.0	1.2	1.1	0.5	1.0	1.2
C60 Penis	6	11	7	7	11	6	7	0.6	1.5	0.9	0.9	1.5	0.9	0.9
C61 Prostate	605	666	604	552	627	579	526	79.0	85.4	81.6	75.8	83.0	76.2	67.9
C62 Testis	18	24	24	24	32	26	32	3.3	4.2	4.4	4.4	5.6	4.4	5.1
C63 Male genital organs, NOS	1	2	-	1	1	1	3	0.1	0.5	-	0.1	0.2	0.1	0.4
C64 Kidney	55	69	42	54	76	57	75	7.9	9.9	6.5	8.2	10.9	7.8	10.7
C65 Renal pelvis	7	8	7	12	14	9	10	1.0	1.1	1.2	2.0	1.9	0.9	1.2
C66 Ureter	5	5	6	6	1	8	6	0.7	0.6	0.7	0.8	0.1	1.2	0.7
C67 Bladder	137	140	123	129	130	131	140	16.1	15.8	14.8	16.5	15.2	15.2	17.2
C68 Urinary organs, NOS	-	6	1	3	2	4	1	-	0.7	0.1	0.3	0.3	0.5	0.2
C69 Eye and adnexa	3	6	5	2	6	3	8	0.6	1.1	0.5	0.3	0.9	0.6	1.5
C70 Meninges	-	1	-	-	-	1	2	-	0.1	-	-	-	0.1	0.3
C71 Brain	24	36	29	27	38	48	44	3.9	6.1	5.0	4.2	6.0	7.5	7.1
C72 Spinal cord, cranial nerves and CNS, NOS	6	2	2	4	-	2	2	0.9	0.3	0.5	0.9	-	0.4	0.3
C73 Thyroid gland	23	15	21	27	33	28	30	3.5	2.5	3.4	4.1	4.9	4.3	4.6
C74 Adrenal gland	3	1	1	1	2	4	3	1.0	0.2	0.2	0.1	0.4	0.9	0.7
C75 Endocrine glands, NOS	1	-	-	1	2	-	-	0.3	-	-	0.2	0.5	-	-
C81 Hodgkin's disease	20	21	26	18	15	26	27	3.4	3.8	4.8	3.5	2.7	4.7	4.1
C82-C86 Non-Hodgkin-lymphoma	86	90	71	81	83	82	86	13.3	12.5	10.0	10.6	11.7	11.3	11.5
C88 Malignant immunoproliferative diseases	8	4	9	8	10	8	8	0.9	0.7	1.3	1.1	1.3	1.0	1.1
C90 Multiple myeloma	36	39	30	34	27	36	41	4.3	5.3	4.4	4.6	3.5	4.6	5.3
C91 Lymphoid leukaemia	31	50	26	31	34	43	37	5.5	9.7	4.7	4.9	5.5	7.2	5.4
C92 Myeloid leukaemia	25	22	27	26	19	32	24	3.8	3.4	4.0	4.2	2.5	4.5	3.8
C93 Monocytic leukaemia	5	3	2	3	9	8	3	0.7	0.4	0.3	0.3	1.0	1.3	0.5
C94-C95 Leukaemia other	1	3	2	2	-	1	1	0.2	0.6	0.5	0.2	-	0.1	0.1
C96 Lymphoid, haematopoietic and related tissue, NOS	1	-	2	1	2	1	2	0.3	-	0.5	0.2	0.6	0.1	0.4
C76 Other and ill-defined sites	1	1	1	-	-	1	-	0.1	0.2	0.1	-	-	0.2	-
C80 Unknown primary site	85	54	54	55	63	37	57	11.4	7.1	7.0	7.3	8.1	4.4	7.2
MPD Myeloproliferative Disorders	13	8	9	6	18	16	16	1.8	1.1	1.3	0.8	2.3	1.9	1.9
MDS Myelodysplastic syndromes	26	22	11	11	21	22	19	2.9	2.7	1.6	1.5	2.1	2.7	2.9
Total	2,600	2,686	2,486	2,648	2,728	2,647	2,830	357.7	366.0	338.5	362.7	365.3	355.4	372.0
Total excl. non-melanoma	2,436	2,520	2,332	2,424	2,530	2,456	2,588	340.4	347.6	321.8	337.9	345.1	335.0	348.8
Total excl. non-melanoma and MDS, MPD	2,397	2,490	2,312	2,407	2,491	2,418	2,553	335.7	343.9	319.0	335.5	340.6	330.4	343.9

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)

EAPC: Estimated annual percentage change (%)

Brussels Capital Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010

Primary site	N										WSR				
	2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010	
C00 Lip	-	-	2	1	2	-	-	-	-	0.2	0.1	0.1	-	-	
C01 Base of tongue	1	1	5	-	1	5	4	0.2	0.1	0.5	-	0.1	0.7	0.6	
C02 Tongue	11	5	13	9	9	9	8	1.5	0.5	1.9	1.4	0.9	0.9	1.0	
C03 Gum	3	3	6	2	2	1	-	0.3	0.3	0.7	0.3	0.3	0.0	-	
C04 Floor of mouth	5	1	3	5	-	6	6	0.7	0.2	0.5	0.8	-	0.9	0.8	
C05 Palate	2	5	7	3	4	3	3	0.3	0.6	0.9	0.4	0.6	0.5	0.5	
C06 Mouth, NOS	4	5	1	-	7	3	4	0.5	0.5	0.2	-	0.5	0.5	0.4	
C07 Parotid gland	4	5	1	2	1	2	1	0.4	0.6	0.1	0.2	0.1	0.3	0.2	
C08 Salivary glands, NOS	1	2	1	1	-	1	2	0.0	0.2	0.1	0.0	-	0.1	0.3	
C09 Tonsil	6	11	6	10	7	12	5	0.6	1.6	0.8	1.3	1.0	1.6	0.7	
C10 Oropharynx	2	3	2	3	6	3	4	0.1	0.4	0.3	0.2	0.9	0.4	0.4	
C11 Nasopharynx	3	2	3	3	3	3	3	0.5	0.2	0.5	0.5	0.5	0.5	0.4	
C12 Pyriform sinus	2	3	5	1	2	3	3	0.3	0.3	0.7	0.2	0.3	0.3	0.4	
C13 Hypopharynx	1	2	1	-	2	1	3	0.0	0.2	0.2	-	0.3	0.1	0.3	
C14 Lip, oral cavity and pharynx, NOS	2	3	-	-	3	1	-	0.2	0.3	-	-	0.4	0.1	-	
C15 Oesophagus	26	21	16	32	32	15	25	3.1	2.2	1.9	3.2	2.9	1.3	2.7	
C16 Stomach	34	40	29	40	60	55	48	2.5	4.0	2.2	3.5	6.6	4.0	4.0	
C17 Small intestine	6	7	10	7	9	3	4	0.5	0.8	1.2	0.4	0.9	0.5	0.5	
C18 Colon	230	260	254	218	230	195	236	17.7	21.0	20.2	19.0	19.0	14.5	19.6	
C19 Rectosigmoid junction	21	9	11	5	17	10	16	2.4	0.9	1.3	0.3	1.5	1.1	1.4	
C20 Rectum	75	64	86	70	59	81	65	6.4	6.0	9.2	6.3	5.4	8.0	7.1	
C21 Anus and anal canal	14	11	13	12	15	12	15	1.5	1.1	1.2	1.3	1.8	1.5	2.0	
C22 Liver and intrahepatic bile ducts	13	23	17	12	21	26	21	1.0	2.6	1.7	1.1	2.1	2.6	2.1	
C23 Gallbladder	4	4	6	6	2	4	9	0.4	0.4	0.7	0.4	0.3	0.5	1.0	
C24 Biliary tract, NOS	8	10	12	7	7	12	17	1.0	0.7	0.8	0.8	0.6	0.9	1.4	
C25 Pancreas	42	35	68	40	64	60	68	4.2	3.5	7.4	3.8	6.1	5.6	6.3	
C26 Other ill-defined digestive organs	2	1	-	-	-	2	-	0.2	0.0	-	-	-	0.1	-	
C30 Nasal cavity and middle ear	-	-	-	3	2	3	2	-	-	-	0.4	0.2	0.3	0.2	
C31 Accessory sinuses	2	1	1	2	-	-	3	0.4	0.0	0.1	0.3	-	-	0.4	
C32 Larynx	11	11	14	5	7	8	12	1.3	1.4	1.4	0.8	1.0	1.0	1.7	
C33 Trachea	1	-	-	1	-	2	-	0.1	-	-	0.0	-	0.3	-	
C34 Bronchus and lung	182	167	188	192	175	204	206	20.5	20.4	22.1	21.7	20.8	23.4	23.3	
C37 Thymus	3	1	-	3	2	2	2	0.3	0.1	-	0.2	0.3	0.2	0.3	
C38 Heart, mediastinum and pleura	1	-	-	2	-	2	2	0.4	-	-	0.2	-	0.2	0.2	
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C40 Bone and articular cartilage of limbs	4	4	5	8	5	2	-	0.5	1.0	1.1	1.3	1.0	0.3	-	
C41 Bone and articular cartilage, NOS	2	6	3	4	5	2	5	0.2	0.9	0.6	0.7	0.7	0.3	0.8	
C43 Malignant melanoma of skin	84	87	90	100	96	113	102	10.8	11.3	11.5	12.7	11.6	13.3	12.6	
C44 Malignant neoplasms of skin	92	117	121	154	134	153	189	6.9	9.3	8.4	11.0	8.8	11.4	11.5	
C45 Mesothelioma	1	3	2	5	-	3	6	0.1	0.4	0.3	0.5	-	0.1	0.5	

	C46	2	2	4	3	5	4	3	5	4	0.3	0.3	0.7	-	0.3	0.6	0.4
C46	Kaposi's sarcoma	13	17	14	17	15	15	12	15	15	1.6	2.6	2.1	2.3	1.5	1.6	2.0
C47-C49	Soft tissues	4	1	3	6	2	3	3	2	3	0.4	0.2	0.4	0.7	0.3	0.2	0.4
C48	Retroperitoneum and peritoneum	929	876	932	921	882	908	882	908	927	122.1	110.7	119.7	116.1	108.6	111.8	112.6
C50	Breast	15	13	13	26	25	17	25	17	19	1.2	1.2	1.3	2.4	2.2	1.7	1.9
C51	Vulva	5	5	3	5	5	7	5	7	3	0.3	0.5	0.5	0.6	0.5	0.7	0.2
C52	Vagina	62	62	85	72	72	81	72	81	57	8.3	8.6	11.7	10.4	9.5	10.4	7.3
C53	Cervix uteri	109	103	104	106	117	121	117	121	115	11.2	10.6	10.6	11.1	11.6	12.8	11.6
C54	Corpus uteri	4	2	1	1	-	2	-	2	1	0.5	0.2	0.1	0.1	-	0.1	0.1
C55	Uterus	73	85	65	74	80	63	80	63	83	9.5	9.5	7.7	8.2	8.9	7.7	8.9
C56	Ovary	2	2	3	2	9	2	9	2	5	0.3	0.2	0.3	0.1	0.9	0.3	0.3
C57	Female genital organs, NOS	-	-	-	-	2	-	2	-	-	-	-	-	-	0.3	-	-
C58	Placenta	28	33	36	27	34	37	34	37	39	3.5	4.3	3.9	3.2	4.2	4.2	3.8
C64	Kidney	5	6	8	9	10	8	9	8	4	0.8	0.5	0.7	0.7	0.9	0.8	0.3
C65	Renal pelvis	3	3	1	3	6	5	3	5	1	0.1	0.1	0.1	0.3	0.5	0.4	0.0
C66	Ureter	36	47	39	37	32	38	32	38	43	2.9	4.0	3.3	2.5	2.6	2.9	3.1
C67	Bladder	-	1	-	2	2	-	2	-	2	-	0.2	-	0.1	0.2	-	0.2
C68	Urinary organs, NOS	6	8	1	4	3	4	3	4	7	0.8	2.0	0.3	0.5	0.6	0.5	1.1
C69	Eye and adnexa	2	-	-	-	2	-	2	-	2	0.2	-	-	-	0.1	-	0.3
C70	Meninges	27	22	34	18	33	35	33	35	28	4.0	3.8	5.6	2.4	4.5	5.4	4.2
C71	Brain	1	1	-	-	1	-	1	-	1	0.1	0.1	-	-	0.2	-	0.3
C72	Spinal cord, cranial nerves and CNS, NOS	80	54	62	86	66	97	66	97	88	12.7	8.1	9.6	13.3	10.3	14.5	12.3
C73	Thyroid gland	1	2	4	3	2	-	2	-	3	0.2	0.5	0.9	0.4	0.3	-	0.5
C74	Adrenal gland	-	-	1	-	2	-	2	-	-	-	-	0.2	-	0.5	-	-
C75	Endocrine glands, NOS	18	7	9	10	15	12	15	12	13	2.8	1.3	1.6	2.0	3.0	1.9	1.8
C81	Hodgkin's disease	84	92	71	88	86	98	86	98	95	9.3	9.6	8.6	8.6	7.6	9.8	10.2
C82-C86	Non-Hodgkin-lymphoma	3	9	12	15	11	4	11	4	13	0.3	0.8	1.4	1.9	1.5	0.4	1.3
C88	Malignant immunoproliferative diseases	46	31	28	29	23	32	29	32	29	4.6	3.4	3.2	2.8	1.8	3.2	2.7
C90	Multiple myeloma	30	23	18	33	26	21	29	21	29	4.2	3.7	2.9	4.7	2.9	2.5	3.3
C91	Lymphoid leukaemia	31	31	20	30	28	23	34	23	34	4.2	4.6	2.2	3.7	3.3	2.8	3.8
C92	Myeloid leukaemia	1	-	2	5	8	4	8	4	3	0.0	-	0.2	0.3	1.1	0.5	0.3
C93	Monocytic leukaemia	1	2	2	2	-	1	-	1	1	0.0	0.1	0.2	0.1	-	0.1	0.1
C94-C95	Leukaemia other	2	-	1	-	5	3	5	3	5	0.2	-	0.3	-	1.0	0.8	1.2
C96	Lymphoid, haematopoietic and related tissue, NOS	2	2	1	-	1	1	-	1	-	0.2	0.2	0.1	-	0.2	0.2	-
C76	Other and ill-defined sites	63	44	60	53	62	47	62	47	42	5.1	4.0	5.0	4.4	5.3	4.2	3.3
C80	Unknown primary site	9	16	11	14	19	10	19	10	15	0.8	1.6	1.5	1.6	1.4	1.1	1.3
MPD	Myeloproliferative Disorders	15	17	10	17	17	10	17	10	9	1.4	1.1	0.7	1.3	1.2	0.9	0.3
MDS	Myelodysplastic syndromes	2,617	2,552	2,660	2,683	2,695	2,735	2,683	2,735	2,837	302.6	292.8	308.1	302.6	297.6	303.4	307.5
Total excl. non-melanoma		2,525	2,435	2,539	2,529	2,561	2,582	2,529	2,582	2,648	295.7	283.4	299.7	291.6	288.7	292.0	296.0
Total excl. non-melanoma and MDS, MPD		2,501	2,402	2,518	2,498	2,525	2,562	2,498	2,562	2,624	293.5	280.6	297.6	288.7	286.2	290.0	294.4

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)

EAPC: Estimated annual percentage change (%)

Walloon Region: Males, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010

Primary site	N										WSR				
	2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010	
C00 Lip	15	17	15	11	15	16	6	0.6	0.6	0.6	0.4	0.5	0.5	0.2	
C01 Base of tongue	21	27	30	32	43	38	31	0.9	1.1	1.2	1.3	1.7	1.4	1.2	
C02 Tongue	78	63	71	63	68	81	55	3.2	2.5	3.0	2.6	2.6	3.1	2.1	
C03 Gum	16	20	16	21	16	14	12	0.7	0.9	0.6	0.8	0.6	0.4	0.5	
C04 Floor of mouth	58	70	46	68	57	69	66	2.4	3.0	1.8	2.8	2.3	2.7	2.6	
C05 Palate	23	34	30	26	28	24	25	1.0	1.4	1.3	1.1	1.0	1.0	1.0	
C06 Mouth, NOS	33	19	13	20	25	16	24	1.3	0.8	0.5	0.8	0.9	0.6	0.9	
C07 Parotid gland	13	15	20	23	18	12	26	0.5	0.6	0.8	0.8	0.7	0.4	0.9	
C08 Salivary glands, NOS	8	9	-	10	3	5	5	0.3	0.4	-	0.4	0.1	0.2	0.1	
C09 Tonsil	67	63	45	83	78	69	54	2.9	2.6	1.9	3.4	3.2	2.7	2.1	
C10 Oropharynx	46	53	43	45	60	47	47	2.0	2.2	1.8	1.8	2.4	1.8	1.8	
C11 Nasopharynx	13	12	10	13	12	16	13	0.6	0.5	0.4	0.5	0.6	0.7	0.5	
C12 Pyriform sinus	57	56	71	77	64	74	59	2.5	2.2	2.9	3.2	2.6	3.0	2.3	
C13 Hypopharynx	14	16	18	27	25	35	23	0.6	0.7	0.8	1.1	1.0	1.2	0.9	
C14 Lip, oral cavity and pharynx, NOS	28	27	16	8	7	12	10	1.2	1.1	0.7	0.4	0.3	0.5	0.3	
C15 Oesophagus	216	225	218	210	227	218	231	8.4	8.6	8.4	7.9	8.2	7.9	7.8	
C16 Stomach	275	285	275	269	220	237	234	9.7	10.2	9.3	9.0	7.3	7.7	7.5	
C17 Small intestine	27	34	29	30	34	42	34	1.0	1.3	1.1	1.1	1.2	1.5	1.2	
C18 Colon	768	779	772	797	794	814	854	26.5	26.0	26.2	25.7	25.8	26.8	26.8	
C19 Rectosigmoid junction	76	67	40	44	40	37	50	2.6	2.3	1.3	1.5	1.4	1.2	1.6	
C20 Rectum	358	353	395	378	409	408	404	12.9	11.9	13.6	13.4	13.7	14.0	13.4	
C21 Anus and anal canal	13	13	16	17	12	20	19	0.4	0.5	0.6	0.6	0.4	0.8	0.7	
C22 Liver and intrahepatic bile ducts	99	105	143	155	165	151	173	3.5	3.8	5.5	5.9	6.1	5.5	6.0	
C23 Gallbladder	14	8	4	4	9	3	10	0.3	0.3	0.1	0.1	0.2	0.1	0.3	
C24 Biliary tract, NOS	44	35	31	51	43	46	47	1.8	1.2	1.0	1.8	1.6	1.5	1.5	
C25 Pancreas	190	180	215	235	171	245	274	6.7	6.4	7.6	8.3	5.9	8.4	9.0	
C26 Other ill-defined digestive organs	10	6	7	4	7	8	9	0.3	0.2	0.3	0.1	0.2	0.3	0.3	
C30 Nasal cavity and middle ear	12	5	6	10	8	14	6	0.5	0.2	0.2	0.4	0.3	0.5	0.2	
C31 Accessory sinuses	10	23	11	14	19	9	14	0.4	0.8	0.5	0.5	0.7	0.3	0.5	
C32 Larynx	216	198	168	219	226	200	195	8.9	7.8	6.6	8.2	8.6	7.4	7.0	
C33 Trachea	4	5	2	3	2	2	4	0.1	0.1	0.1	0.1	0.1	0.1	0.2	
C34 Bronchus and lung	1,846	1,843	1,771	1,810	1,830	1,877	1,818	66.6	65.9	63.5	63.8	62.8	64.2	59.9	
C37 Thymus	4	5	6	6	4	2	12	0.2	0.2	0.2	0.3	0.1	0.1	0.5	
C38 Heart, mediastinum and pleura	2	1	3	7	2	5	5	0.1	0.0	0.2	0.3	0.0	0.2	0.2	
C39 Respiratory system and intrathoracic organs, NOS	1	-	-	-	-	1	3	0.0	-	-	-	-	0.0	0.1	
C40 Bone and articular cartilage of limbs	13	8	11	14	11	12	6	0.8	0.5	0.6	0.9	0.6	0.7	0.5	
C41 Bone and articular cartilage, NOS	11	9	10	10	6	9	11	0.6	0.7	0.4	0.5	0.4	0.5	0.6	
C43 Malignant melanoma of skin	205	196	186	219	261	245	323	8.8	7.9	7.8	9.2	10.4	9.8	13.1	

C44	Malignant neoplasms of skin	548	526	548	637	653	692	771	16.5	16.9	18.8	18.3	18.4	19.6
C45	Mesothelioma	66	60	47	54	52	52	2.4	2.0	1.4	1.6	1.8	1.6	1.6
C46	Kaposi's sarcoma	5	5	5	7	3	6	0.2	0.2	0.1	0.2	0.3	0.1	0.2
C47-C49	Soft tissues	48	54	43	61	38	49	1.8	2.2	1.9	2.3	2.7	1.6	2.3
C48	Retroperitoneum and peritoneum	7	3	3	6	1	6	0.3	0.1	0.1	0.3	0.5	0.0	0.2
C50	Breast	24	25	20	29	38	27	1.0	0.8	0.7	0.7	1.0	1.3	0.9
C60	Penis	22	20	16	23	25	27	0.8	0.8	0.6	0.9	0.7	0.9	0.9
C61	Prostate	3,206	2,926	2,734	2,399	2,377	2,486	113.1	102.8	96.7	86.1	82.5	80.3	82.7
C62	Testis	105	102	101	115	107	121	6.2	5.9	5.8	6.6	6.6	5.9	6.8
C63	Male genital organs, NOS	3	4	3	4	2	1	0.1	0.2	0.1	0.2	0.1	0.1	0.0
C64	Kidney	259	256	274	293	299	255	10.4	9.8	10.8	9.8	10.8	11.3	9.2
C65	Renal pelvis	32	33	29	35	25	43	1.0	1.1	0.9	1.2	1.2	0.7	1.4
C66	Ureter	33	24	18	25	40	25	1.2	0.9	0.6	0.8	0.7	1.2	0.8
C67	Bladder	573	515	462	524	537	536	19.1	17.2	15.0	16.3	16.3	16.5	16.1
C68	Urinary organs, NOS	4	13	11	7	7	14	0.1	0.4	0.4	0.3	0.2	0.2	0.4
C69	Eye and adnexa	7	13	17	14	12	20	0.4	1.0	0.7	0.8	0.7	0.9	0.8
C70	Meninges	4	3	-	2	-	3	0.2	0.2	-	-	0.1	-	0.1
C71	Brain	143	136	133	129	128	147	7.0	6.4	6.1	5.7	6.1	6.1	6.7
C72	Spinal cord, cranial nerves and CNS, NOS	12	-	4	3	1	1	0.6	-	0.3	0.3	0.2	0.0	0.0
C73	Thyroid gland	70	86	75	87	121	82	3.1	4.1	3.3	3.7	3.7	5.4	3.3
C74	Adrenal gland	4	5	3	6	9	6	0.3	0.4	0.1	0.8	0.5	0.6	0.3
C75	Endocrine glands, NOS	-	1	4	1	2	-	-	0.1	0.2	-	0.0	0.2	-
C81	Hodgkin's disease	57	51	60	64	51	46	3.2	3.0	3.2	3.0	3.2	2.8	2.4
C82-C86	Non-Hodgkin-lymphoma	86	91	72	85	85	89	13.3	12.6	10.2	10.9	12.0	11.7	12.0
C88	Malignant immunoproliferative diseases	32	26	25	36	27	36	1.3	1.0	1.0	1.4	1.3	1.0	1.2
C90	Multiple myeloma	105	101	124	91	108	131	3.6	3.5	4.2	4.4	3.0	3.5	3.9
C91	Lymphoid leukaemia	121	120	111	131	145	134	6.1	5.5	4.7	4.8	5.6	6.6	5.2
C92	Myeloid leukaemia	83	98	71	98	106	97	3.5	4.3	3.1	4.0	3.5	4.0	3.4
C93	Monocytic leukaemia	9	7	12	12	19	24	0.3	0.3	0.5	0.8	0.4	0.6	0.8
C94-C95	Leukaemia other	7	12	8	9	4	8	0.2	0.5	0.3	0.3	0.3	0.2	0.3
C96	Lymphoid, haematopoietic and related tissue, NOS	6	2	5	2	3	7	0.4	0.2	0.4	0.2	0.2	0.1	0.5
C76	Other and ill-defined sites	3	7	10	2	-	-	0.1	0.3	0.5	0.0	-	-	-
C80	Unknown primary site	232	220	220	194	208	139	8.3	7.9	7.5	6.8	7.2	6.2	4.5
MPD	Myeloproliferative Disorders	37	36	36	45	52	60	1.6	1.3	1.4	1.5	1.8	2.0	2.0
MDS	Myelodysplastic syndromes	79	60	53	41	79	116	2.8	1.8	1.6	1.2	2.2	3.0	3.4
Total		11,174	10,768	10,340	10,573	10,597	10,913	412.0	392.4	375.9	370.1	373.7	374.2	370.0
Total excl. non-melanoma		10,626	10,242	9,792	9,919	9,960	10,221	394.9	375.9	359.0	360.3	355.3	355.8	350.4
Total excl. non-melanoma and MDS, MPD		10,510	10,146	9,703	9,833	9,829	10,045	390.6	372.9	356.0	357.6	351.3	350.8	345.0

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)

EAPC: Estimated annual percentage change (%)

Walloon Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010

Primary site	N										WSR				
	2004	2005	2006	2007	2008	2009	2010	2004	2005	2006	2007	2008	2009	2010	
C00 Lip	4	9	7	5	1	-	4	0.1	0.2	0.2	0.1	0.0	-	0.1	
C01 Base of tongue	6	6	8	13	12	18	11	0.3	0.3	0.3	0.5	0.5	0.6	0.4	
C02 Tongue	28	22	26	23	21	24	34	1.0	0.8	1.0	0.9	0.6	0.9	1.1	
C03 Gum	15	11	8	13	14	20	15	0.5	0.3	0.3	0.4	0.5	0.5	0.4	
C04 Floor of mouth	12	10	7	23	16	21	21	0.4	0.4	0.3	0.9	0.5	0.8	0.7	
C05 Palate	13	8	12	8	15	8	12	0.6	0.4	0.4	0.3	0.5	0.3	0.4	
C06 Mouth, NOS	15	11	9	12	6	14	16	0.4	0.4	0.3	0.4	0.2	0.4	0.5	
C07 Parotid gland	13	15	15	24	14	16	18	0.4	0.4	0.5	0.9	0.5	0.6	0.6	
C08 Salivary glands, NOS	8	3	7	2	4	4	1	0.3	0.2	0.2	0.1	0.1	0.2	0.0	
C09 Tonsil	29	22	23	37	37	21	28	1.1	0.9	0.9	1.3	1.3	0.8	0.9	
C10 Oropharynx	11	14	15	16	14	17	13	0.3	0.5	0.5	0.6	0.5	0.6	0.5	
C11 Nasopharynx	3	4	1	4	5	8	4	0.1	0.1	0.0	0.2	0.2	0.4	0.2	
C12 Pyriform sinus	6	5	12	8	10	18	15	0.2	0.2	0.5	0.3	0.3	0.6	0.5	
C13 Hypopharynx	6	9	4	5	12	5	3	0.2	0.3	0.2	0.2	0.5	0.2	0.1	
C14 Lip, oral cavity and pharynx, NOS	5	9	7	3	2	4	1	0.2	0.3	0.3	0.1	0.1	0.1	0.0	
C15 Oesophagus	85	80	73	83	81	85	91	2.3	2.3	2.2	2.3	2.3	2.2	2.5	
C16 Stomach	150	147	165	141	155	126	165	3.9	3.5	4.1	3.6	3.7	3.1	3.8	
C17 Small intestine	35	33	37	36	30	41	34	1.0	0.9	1.3	1.0	0.8	1.1	0.9	
C18 Colon	778	769	787	797	783	802	716	18.5	18.9	18.8	18.5	17.8	18.5	16.2	
C19 Rectosigmoid junction	76	55	45	32	29	49	50	2.0	1.4	1.0	0.9	0.7	1.3	1.2	
C20 Rectum	279	314	269	311	303	259	301	7.4	8.8	6.5	8.2	7.8	6.9	7.7	
C21 Anus and anal canal	27	27	29	26	26	27	40	0.9	0.8	0.8	0.7	0.9	0.8	1.2	
C22 Liver and intrahepatic bile ducts	28	54	50	50	69	67	71	0.8	1.8	1.3	1.3	1.8	1.8	1.9	
C23 Gallbladder	20	13	21	15	22	14	33	0.4	0.3	0.5	0.4	0.5	0.3	0.7	
C24 Biliary tract, NOS	33	28	14	40	33	45	46	0.8	0.7	0.4	0.9	0.7	1.1	1.0	
C25 Pancreas	175	187	207	185	203	217	248	4.8	5.3	5.2	5.1	5.2	5.9	6.2	
C26 Other ill-defined digestive organs	6	8	6	6	6	5	6	0.2	0.2	0.1	0.1	0.2	0.1	0.1	
C30 Nasal cavity and middle ear	5	3	6	2	7	8	4	0.1	0.1	0.3	0.0	0.2	0.2	0.2	
C31 Accessory sinuses	7	9	5	7	4	5	2	0.2	0.3	0.3	0.3	0.2	0.1	0.0	
C32 Larynx	44	39	39	22	40	50	34	1.5	1.4	1.3	0.8	1.5	1.9	1.2	
C33 Trachea	1	1	-	3	1	3	2	0.0	0.0	-	0.1	0.0	0.1	0.1	
C34 Bronchus and lung	554	567	641	699	667	805	814	18.8	19.2	21.0	23.1	21.6	26.2	25.2	
C37 Thymus	6	3	3	5	5	3	9	0.2	0.1	0.1	0.1	0.2	0.1	0.3	
C38 Heart, mediastinum and pleura	-	6	3	1	7	3	1	-	0.3	0.1	0.0	0.3	0.2	0.0	
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C40 Bone and articular cartilage of limbs	9	7	9	7	12	8	7	0.5	0.4	0.5	0.3	0.8	0.5	0.4	
C41 Bone and articular cartilage, NOS	13	9	16	9	11	5	7	0.7	0.5	0.8	0.4	0.6	0.2	0.3	
C43 Malignant melanoma of skin	312	327	282	311	381	362	459	13.2	13.5	11.5	12.7	15.3	14.7	19.5	
C44 Malignant neoplasms of skin	385	410	357	459	480	468	478	7.6	9.0	7.1	9.2	9.6	8.6	9.6	
C45 Mesothelioma	6	10	15	11	14	9	10	0.2	0.3	0.4	0.3	0.4	0.2	0.3	

C46	Kaposi's sarcoma	3	4	4	1	3	4	1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0
C47-C49	Soft tissues	55	28	45	50	53	41	41	2.2	1.1	1.7	1.8	1.8	1.8	1.3	1.4
C48	Retroperitoneum and peritoneum	7	14	18	14	17	15	12	0.3	0.5	0.6	0.5	0.5	0.5	0.5	0.4
C50	Breast	3,179	3,061	3,079	3,098	3,233	3,156	3,250	115.0	107.9	109.2	107.7	109.1	107.7	106.1	108.5
C51	Vulva	49	55	55	66	52	60	69	1.3	1.5	1.4	1.6	1.3	1.6	1.7	2.0
C52	Vagina	21	14	19	16	11	12	12	0.5	0.4	0.4	0.5	0.2	0.5	0.3	0.4
C53	Cervix uteri	219	190	166	229	211	169	206	8.9	7.8	6.6	9.2	8.6	9.2	6.6	8.1
C54	Corpus uteri	451	441	406	430	437	445	474	13.5	13.3	12.3	12.3	12.3	12.3	12.2	12.7
C55	Uterus	35	25	7	6	1	4	4	1.1	0.8	0.2	0.2	0.0	0.2	0.1	0.1
C56	Ovary	276	288	280	304	270	246	272	9.0	9.3	8.9	9.6	8.6	9.6	7.3	8.2
C57	Female genital organs, NOS	10	12	16	4	19	16	15	0.4	0.4	0.5	0.2	0.5	0.2	0.6	0.4
C58	Placenta	1	2	-	2	-	1	-	0.0	0.1	-	0.1	-	0.1	-	-
C64	Kidney	150	168	161	147	162	147	144	5.1	5.6	4.8	4.3	5.2	4.3	4.4	4.5
C65	Renal pelvis	21	21	22	26	23	24	23	0.5	0.4	0.5	0.6	0.4	0.6	0.4	0.5
C66	Ureter	12	7	14	4	8	14	13	0.4	0.1	0.4	0.0	0.2	0.0	0.3	0.3
C67	Bladder	116	136	99	124	157	156	142	2.6	3.0	2.6	2.5	3.4	2.5	3.2	3.0
C68	Urinary organs, NOS	2	1	1	-	-	3	4	0.0	0.0	0.0	-	-	-	0.1	0.1
C69	Eye and adnexa	16	9	20	12	14	20	14	0.8	0.5	0.8	0.5	0.5	0.5	0.8	0.6
C70	Meninges	6	4	4	3	2	2	2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1
C71	Brain	93	109	102	101	100	117	102	4.2	5.0	3.8	4.1	4.5	4.1	5.2	4.3
C72	Spinal cord, cranial nerves and CNS, NOS	9	4	3	5	-	2	3	0.4	0.3	0.2	0.3	-	0.3	-	0.3
C73	Thyroid gland	229	221	229	220	262	279	277	10.0	9.7	10.2	10.0	11.3	10.0	12.2	12.0
C74	Adrenal gland	5	10	9	8	2	5	6	0.3	0.8	0.4	0.4	0.1	0.4	0.4	0.4
C75	Endocrine glands, NOS	-	-	2	3	2	4	2	-	-	0.1	0.2	0.2	0.2	0.2	0.1
C81	Hodgkin's disease	36	38	37	42	42	42	53	1.9	2.4	1.8	2.4	2.4	2.4	2.6	3.1
C82-C86	Non-Hodgkin-lymphoma	288	248	256	289	291	280	286	8.8	7.7	7.2	8.7	8.9	8.7	8.0	7.8
C88	Malignant immunoproliferative diseases	32	18	38	40	25	30	36	1.0	0.6	1.1	1.2	0.9	1.2	0.7	0.9
C90	Multiple myeloma	114	82	99	93	90	114	92	3.2	2.2	2.7	2.6	2.4	2.6	2.6	2.3
C91	Lymphoid leukaemia	88	66	67	75	82	116	127	3.6	2.7	2.6	2.5	3.2	2.5	4.2	4.5
C92	Myeloid leukaemia	71	68	75	83	80	80	82	2.6	2.5	2.6	3.1	2.6	3.1	2.3	2.7
C93	Monocytic leukaemia	8	8	8	7	10	10	15	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.5
C94-C95	Leukaemia other	9	4	3	4	5	7	6	0.2	0.1	0.1	0.2	0.1	0.2	0.2	0.2
C96	Lymphoid, haematopoietic and related tissue, NOS	2	2	4	5	5	5	4	0.1	0.2	0.1	0.2	0.4	0.2	0.3	0.2
C76	Other and ill-defined sites	7	5	3	-	2	1	2	0.2	0.3	0.1	-	0.1	-	0.0	0.0
C80	Unknown primary site	195	183	163	191	203	140	147	4.8	4.9	4.5	5.0	5.0	5.0	3.4	3.7
MPD	Myeloproliferative Disorders	40	38	46	43	61	72	61	1.0	1.0	1.6	1.2	1.5	1.2	2.1	1.7
MDS	Myelodysplastic syndromes	61	53	68	40	66	68	83	1.4	1.5	2.0	0.9	1.5	0.9	1.4	2.0
Total		9,124	8,901	8,868	9,239	9,553	9,571	9,906	298.0	290.6	283.9	292.1	297.5	292.1	294.8	304.8
Total excl. non-melanoma		8,739	8,491	8,511	8,780	9,073	9,103	9,428	290.4	281.7	276.9	282.9	287.9	282.9	286.3	295.2
Total excl. non-melanoma and MDS, MPD		8,638	8,400	8,397	8,697	8,946	8,963	9,284	287.9	279.2	273.3	280.8	284.9	280.8	282.8	291.6

WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)



Belgian Cancer Registry

Koningsstraat 215 / Rue Royale 215

1210 Brussel / Bruxelles

T +32 2 250 10 10

F +32 2 250 10 11

www.kankerregister.org
www.registreducancer.org